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Abstract 
 
Stroke accounts for 9% of all deaths worldwide and is a major cause of severe disability 
(Donnan et al, 2008). Following ischaemic stroke, the penumbra represents tissue which is 
hypoperfused and functionally impaired but is not yet irreversibly damaged. However, the 
penumbra has a finite lifespan and will proceed to infarction in the absence of swift 
reperfusion. Therefore, the identification and potential salvage of penumbral tissue in acute 
ischaemic stroke is the ultimate goal for both clinicians and experimental stroke 
researchers. Positron emission tomography (PET) is the „gold standard‟ imaging modality 
for identifying the penumbra, but the complex logistics of PET limit its widespread use.  
Magnetic Resonance Imaging (MRI) is widely used for penumbra imaging in both clinical 
and pre-clinical research. The MRI perfusion-diffusion mismatch model provides an 
approximation of the penumbra, where diffusion weighted imaging (DWI) identifies the 
core of ischaemic injury and perfusion weighted imaging (PWI) reveals the perfusion 
deficit. The mismatch between the DWI and PWI provides a measure of penumbral tissue. 
However, there is no consensus on the perfusion and diffusion thresholds used to identify 
mismatch tissue in clinical and preclinical stroke research. Furthermore, in rodent stroke 
models differences in the evolution of ischaemic injury between strains may limit the use 
of a single set of threshold values. Therefore, the first aim of this thesis was to establish 
strain specific perfusion and diffusion thresholds to compare penumbra volume in the 
clinically relevant spontaneously hypertensive stroke-prone rat (SHRSP) and the 
normotensive control strain, Wistar-Kyoto (WKY) using 3 different methods. The SHRSP 
strain is characterised by the progressive development of severe hypertension which is 
followed by a tendency to spontaneous stroke and an increased sensitivity to experimental 
stroke.  
Experimental stroke was induced by permanent middle cerebral artery occlusion (MCAO) 
by the intraluminal filament method. DWI and PWI were obtained every hour from 1-4 
hours post-MCAO. Strain-specific diffusion and perfusion thresholds were established 
from final infarct at 24 hours post-MCAO, as defined by T2 weighted imaging. The 
calculated ADC thresholds were comparable between the strains but the absolute perfusion 
threshold was significantly higher in SHRSP compared to WKY. This may be indicative of 
an increased sensitivity to ischaemia in the hypertensive strain. Furthermore, application of 
these thresholds to the acute MRI data revealed that the volume of ischaemic injury and the 
perfusion deficit were significantly larger in SHRSP compared to WKY and this was also 
reflected in the significantly larger infarct volume observed in SHRSP at 24 hours post-
MCAO. Interestingly, there was evidence of a temporal increase in the volume of the 
 xx 
perfusion deficit in SHRSP and WKY. This may indicate that there is a progressive failure 
of collateral blood supply in both strains following stroke.  
Penumbra volume was then assessed in SHRSP and WKY rats using the mismatch method 
and also indirectly by examining the growth of the volume of ADC derived ischaemic 
injury. Mismatch volume was determined by arithmetic subtraction of the volume of 
ischaemic injury from the volume of perfusion deficit (volumetric method) and also by 
manual delineation of mismatch on each of 6 coronal slices (spatial method). There was a 
limited volume of mismatch tissue in either strain from as early as 1 hour post-MCAO and 
the volumetric method generated smaller mismatch volumes than the spatial mismatch 
method. Mismatch volume was comparable in SHRSP and WKY from 1-4 hours post-
MCAO. Penumbra was also determined retrospectively by subtracting the volume of 
ischaemic injury at each time point from final infarct volume. Using this method, 
penumbra volume was significantly larger in WKY compared to SHRSP at 30 minutes 
post-MCAO but penumbra volume was comparable at all later time points. This suggests 
that there is reduced potential for tissue salvage in SHRSP compared to WKY within the 
first hour following MCAO but from 1 hour onwards, there is limited potential for 
penumbra salvage in both strains.  
In addition, there was evidence of „negative‟ mismatch tissue in SHRSP and WKY rats, 
where the ADC derived lesion expanded beyond the boundary of the perfusion deficit. The 
volume of negative mismatch tissue was comparable between the strains and was persistent 
over the 4 hour time course. This phenomenon may arise from the spread of toxic 
mediators from the ischaemic core.  
Oxidative stress is a major mediator of cellular injury following ischaemic stroke and 
reactive oxygen species, like superoxide, have multiple deleterious effects on the 
components of the neurovascular unit. It is well established that NADPH oxidase is the 
principal source of superoxide in acute ischaemic stroke and is therefore a target for 
potential neuroprotective strategies (Moskowitz et al, 2010). Consequently, the second aim 
of this thesis was to evaluate the potential neuroprotective effect of NADPH oxidase 
inhibition with low and high dose apocynin following permanent or transient ischaemia. 
Rats were administered apocynin at a dose of 5mg/kg or 30mg/kg or vehicle, at 5 minutes 
post-MCAO. Apocynin treatment had no significant effect on infarct volume or functional 
outcome at 24 hours following permanent MCAO in WKY rats. However, both low and 
high dose apocynin treatment significantly reduced infarct volume at 72 hours post-MCAO 
by 60% following 1 hour of ischaemia in Sprague-Dawley rats. Furthermore, functional 
outcome was improved in the low dose apocynin treated group, although this did not reach 
the level of statistical significance. On the basis of these results, low dose apocynin 
 xxi 
treatment was evaluated in SHRSP rats following 1 hour of ischaemia. However, apocynin 
treatment had no effect on the acute evolution of ischaemic injury and failed to improve 
stroke outcome, where the mortality rate was high in both the apocynin treated and the 
vehicle treated group. The conflicting effects of apocynin may be attributable to a 
differential expression of NADPH oxidase subunits in normotensive and hypertensive rat 
strains. These findings may also explain the failure of neuroprotective drugs to translate 
from bench to bedside, as therapies which are neuroprotective in young healthy animals 
may not demonstrate the same efficacy in animal models with stroke co-morbidities. 
Therefore, potential therapeutic strategies should be extensively evaluated in animal 
models with stroke risk factors before proceeding to clinical trial.  
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1.1 Stroke 
 
1.1.1 Types of Stroke and Major Risk Factors 
 
Stroke is a common multifactorial neurological disorder, which arises as a result of a 
severe reduction in cerebral blood flow. The brain accounts for around 2-3% of body 
weight yet receives approximately 15% of the total cardiac output. Furthermore, it has high 
metabolic requirements; accounting for around 20% of total body oxygen consumption and 
25% of total body glucose consumption. The brain has a very limited capacity to store 
energy and therefore requires a constant supply of substrates for normal metabolic 
function. This great demand for substrates helps to illustrate how damaging even a 
transient reduction in blood flow could potentially be to brain tissue. 
 
Stroke is the third leading cause of death in the Western hemisphere, after heart disease 
and cancer. Every year in the UK approximately 150,000 people have a stroke, which 
equates to a stroke occurring in the population every 5 minutes (Office of National 
Statistics). In Scotland, there are 13,000 new strokes every year with 3,000 of these new 
cases occurring in people who are under 65 years of age (Chest, Heart & Stroke 
Scotland,www.chss.org.uk/stroke/index.php). Increasing age is a major stroke risk factor 
as most strokes occur in the elderly population, with 75% of first strokes occurring in the 
over 75 age group (Sudlow & Warlow, 1997). In addition to increasing age, hypertension 
is also a powerful determinant of risk for stroke, where the lifetime risk of stroke is 
doubled in hypertensive patients (Lloyd-Jones et al, 2010). Other factors which contribute 
to the incidence of stroke are diabetes mellitus and dyslipidemia, in addition to lifestyle 
factors including being overweight, cigarette smoking and excessive alcohol consumption. 
 
It has been proposed that the incidence of stroke will rise in future years due to the world‟s 
ageing population, thereby further increasing the healthcare burden on the economy. 
Stroke patients occupy around 20% of all acute hospital beds and 25% of long term beds 
(Department of Health, 2005). The direct cost to the National Health Service is estimated 
to be £2.8 billion per year. This burden is increased further since 50% of stroke patients are 
rendered severely disabled and require day to day care, while 30% of patients die within a 
year of the first stroke onset (Warlow et al, 2003).   
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Figure 1-1. An example of a poster produced by The Stroke Association to promote the FAST 
campaign which aims to raise public awareness of the common visible symptoms of stroke and 
highlights the need for early diagnosis and treatment to limit brain injury. 
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A recent campaign by The Stroke Association in the UK has sought to raise public 
awareness of the symptoms of stroke and highlights the importance of getting the stroke  
patient to hospital as quickly as possible in order to limit brain damage and functional 
impairment. This highly successful campaign is called FAST and focuses on recognising 
the common stroke symptoms of Facial weakness, Arm weakness, Speech problems and 
Time to call 999 (Figure 1-1). The FAST campaign has been supported by UK wide 
television commercials, billboard posters and leaflets in hospitals, GPs surgeries and health 
centres. 
 
The reduction in cerebral blood flow observed in stroke can arise from haemorrhage or 
from occlusion of a cerebral blood vessel. These are termed haemorrhagic and ischaemic, 
or occlusive strokes, respectively. Haemorrhagic strokes are less common than ischaemic 
strokes (Figure 1-2), accounting for approximately 20% of all strokes (Warlow et al, 2003).  
 
Haemorrhagic Stroke 
 
Hypertension is a major stroke risk factor and is closely correlated with the incidence of 
haemorrhagic stroke. Excessive alcohol consumption and cigarette smoking have also been 
identified as risk factors for haemorrhagic stroke (Feigin et al, 2005). This type of stroke 
can arise from a subarachnoid haemorrhage or primary intracerebral haemorrhage, where 
the latter is more common, accounting for 75% of all haemorrhagic strokes (Warlow et al, 
2003). 
Subarachnoid haemorrhage results from the rupture of an intracranial aneurysm, leading to 
a build up of blood in the subarachnoid space, which is situated between the arachnoid and 
pia mater meningeal layers. The mortality rate is high and most deaths occur as a result of 
the period of initial bleeding, with over 40% of patients dying within one month following 
aneurysmal rupture (Kissela et al, 2002). In approximately one third of aneurysmal 
subarachnoid haemorrhage patients the haemorrhage extends into the parenchyma. These 
patients have a higher mortality rate and a reduced functional recovery (van Gijn et al, 
2007). Recently, it has been reported that patients with aneurysms located in the middle 
cerebral artery are at greater risk of intraparenchymal extension (Liu & Rinkel, 2011). 
 
Primary intracerebral haemorrhage may result from rupture of microaneurysms of 1-2mm 
in diameter, which are most often located deep within the cerebral hemispheres 
(Standgaard & Paulson, 1990) and are predominantly found in hypertensive patients. Other 
risk factors include long-term alcohol abuse, male sex and increasing age (Ariesen et al,  
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Figure 1-2. Approximate frequency of the three main causes of stroke in Caucasian 
populations and of the main subtypes of ischaemic stroke. Reproduced from Warlow et al 
(2003). 
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Figure 1-3. Ischaemic stroke arising from a cardiac embolus. The embolus ascends from the 
heart to the cerebral circulation via the aorta and the common carotid artery. It can travel through 
the cerebrovasculature to occlude a cerebral artery. Adapted from Go (2009). 
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2003; Zia et al, 2007). Mortality rates following intracerebral or subarachnoid 
haemorrhage are high, with 50% of patients dying within 1 month of stroke onset (Donnan 
et al, 2008). 
 
Ischaemic Stroke 
 
Occlusive or ischaemic stroke is the most common type and accounts for 80% of all 
strokes (Figure 1-2). In Western countries, stroke causes 10-12% of all deaths (Brouns & 
De Deyn, 2009). In the Developing World these statistics are likely to be much higher but 
there are difficulties obtaining accurate figures in countries where death certificates are not 
routinely available or where death certificates feature unreliable details (Warlow et al, 
2003). 
 
Cerebral artery occlusion most often arises from the production of an atherosclerotic 
plaque, or thrombus, or from an embolism, which has travelled through the circulation 
from its origin in the heart (Figure 1-3). The reduction in blood flow can be transient or 
permanent and the territory of the occluded cerebral artery determines the brain area 
affected by the stroke and the symptoms exhibited by the patient. Fifty percent of 
ischaemic strokes are as a direct result of atherothrombotic disease of the extra or 
intracranial vessels, although the large intracranial vessels are less commonly the source of 
the thrombus (Warlow et al, 2003). The site of the occlusion is often at bifurcation points 
of the arterial system due to a combination of turbulent flow and weakened vessel walls at 
these regions. 
 
Emboli which arise from the heart account for 20% of occlusive strokes. There are various 
sources of cardiac embolism, the most common being atrial fibrillation and this link has 
been well established (Warlow et al, 2003). Other sources include cardiac valve disease 
and patent foramen ovale, although there has been some difficulty in establishing a causal 
relationship between recurrent ischaemic events and the latter condition (Almekhlafi et al, 
2009). 
 
A quarter of all ischaemic strokes arise from occlusion of small intracranial vessels and 
lacunar stroke, which affects small arterioles, which become tortuous, often as a result of 
chronic hypertension. These vessels are small (≤ 400µm) and are deeply penetrating and 
the resulting tortuosity makes the vessel susceptible to occlusion from micro-thrombi and 
fibrin deposition which can result in lipohyalinosis (Ogata et al, 2011). 
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1.1.2 Clinical Treatments for Stroke 
 
On admission to hospital following stroke, patients are assessed in order to establish if the 
clinical diagnosis of stroke is correct and to establish if the stroke is haemorrhagic or 
ischaemic in origin. This is achieved by the use of the brain imaging techniques, such as 
computed tomography (CT) and magnetic resonance imaging (MRI). If the stroke is 
ischaemic in origin, then recanalisation of the occluded vessel will allow restoration of 
blood supply to the affected brain region and potential salvage of penumbral tissue. Rapid 
reperfusion of the occluded artery with thrombolysis has been shown to result in 
favourable clinical outcomes (NINDS, 1995). The only licensed therapy currently available 
for acute ischaemic stroke is the administration of recombinant tissue plasminogen 
activator (rtPA). Endogenous tPA is a serine protease which is found in vascular 
endothelial cells and it catalyzes the activation of plasmin from plasminogen by cleavage 
of the peptide bond between Arg-560 and Val-561. Activated plasmin has a fibrinolytic 
function and dissolves fibrin rich blood clots, leading to recanalisation of the occluded 
blood vessel. 
 
In 1995, the National Institute of Neurological Disorders and Stroke (NINDS) study group 
evaluated the use of thrombolytic therapy with rtPA in ischaemic stroke patients. 
Intravenous rtPA (0.9mg/kg) was administered up to 3 hours following stroke onset and 
the authors reported that patients who received rtPA were at least 30% more likely to have 
minimal or no disability at 3 months following stroke, compared to those patients who 
received placebo (NINDS, 1995). However, these authors also reported that there was an 
increased incidence of intracerebral haemorrhage following thrombolysis.  
The European Cooperative Acute Stroke Study (ECASS) examined the effects on 
neurological outcome when rtPA was administered within 6 hours of stroke onset. This 
study group reported that thrombolytic therapy effectively improved functional outcome in 
patients who demonstrated moderate to severe neurological impairment. However, the 
mortality rate at 30 days following stroke onset was higher than that observed in the 
placebo treated group and there was also an increased incidence of parenchymal 
haemorrhage. These findings led the ECASS group to conclude that rtPA should not be 
administered to an unselected population of acute ischaemic stroke patients due to the 
increased risk of mortality and haemorrhage asscociated with administration up to 6 hours 
following stroke onset (Hacke et al, 1995). The second ECASS trial (Hacke et al, 1998) 
failed to show a significant improvement in patient outcome following administration of 
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rtPA up to 6 hours following stroke onset. Similarly to the original ECASS trial, the 
authors reported an increased risk of haemorrhage following thrombolysis.  
Thrombolytic therapy with rtPA was therefore recommend for acute ischaemic stroke 
patients up to 3 hours following stroke onset as it was believed that the risk of 
haemorrhage following administration at later time points outweighed the clinical benefits. 
Despite this recommendation, thrombolytic therapy with rtPA is relatively underused with 
less than 5% of stroke patients receiving treatment to restore cerebral blood flow 
(Weinberger, 2006). As a consequence, clinical trials continued to explore the effects of 
administering rtPA outwith the narrow 3 hour time window to increase the number of 
patients who can potentially benefit from thrombolysis. 
 
 The Desmoteplase in Acute Ischemic Stroke Trial (DIAS) evaluated the potential benefit 
of extending the therapeutic time window to 9 hours following stroke onset. The DIAS 
trials differed from those discussed previously in that it used desmoteplase as a 
thrombolytic, not alteplase, which was evaluated in the other thrombolysis trials. The 
DIAS authors reported that patients who received intravenous desmoteplase within 9 hours 
of stroke onset demonstrated a higher rate of reperfusion and improved clinical outcome 
compared to placebo treated patients (DIAS, 2005). The potential benefits of extending the 
thrombolysis treatment window were also examined in the third ECASS trial. ECASS III 
reported that intravenous rtPA administered between 3 to 4.5 hours following stroke onset, 
significantly improved clinical outcome in ischaemic stroke patients (Hacke et al, 2008). 
As a result of these findings, the Stroke Therapy Academic Industry Roundtable (Saver et 
al, 2009) recommended that the therapeutic time window should be extended to 4.5 hours 
following stroke onset and this has recently been put into place. This will allow greater 
numbers of stroke patients to benefit from thrombolytic therapy. Despite this extension to 
the thrombolytic time window, the development of new stroke therapies is still urgently 
required, to ensure that a greater proportion of patients can obtain treatment and experience 
an improved outcome following stroke.  
 
It is estimated that up to 30% of first stroke patients are likely to experience another stroke 
within 1 month of stroke onset (Donnan et al, 2008). Therefore, patients may be prescribed 
a daily dose of aspirin to reduce the likelihood of secondary stroke. Aspirin can lower the 
risk of stroke by around 20% due to its antiplatelet actions, which are mediated via 
inhibition of the cyclo-oxygenase (COX) pathway (Deb et al, 2010). Furthermore, if the 
patient is hypertensive, their anti-hypertensive medication may be reassessed to reduce the 
risk of stroke reoccurrence.   
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Following diagnosis and administration of thrombolytic therapy, if appropriate, stroke 
patients may be referred to a specialised stroke unit, if the facilities are available. Stroke 
patients who are admitted to a specialist stroke unit have a better outcome than those 
patients who are admitted to a general hospital ward (Donnan et al, 2008). Stroke patient 
mortality is 14-25% higher in general wards compared to stroke units (Clinical Audit 
Report, Royal College of Physicians, 2001).  
 
1.1.3 Stroke Pathophysiology and the Ischaemic Cascade 
 
The ischaemic cascade describes the complex series of events which contribute to cellular 
injury following ischaemic stroke (Figure 1-4). Occlusion of a cerebral vessel results in the 
initiation of multiple deleterious pathways which converge to mediate irreversible 
ischaemic injury.  
 
Anoxic Depolarisation 
 
Reduced blood flow results in complete absence or a severe reduction in oxygen and 
glucose delivery to all cell types which comprise the neurovascular unit in the territory 
served by the occluded vessel. The neurovascular unit consists of neuronal, glial and 
vascular cell types which contribute to normal brain function. Lack of nutritive delivery 
renders cells of the neurovascular unit unable to meet their required energy demands via 
oxidative phosphorylation. This in turn reduces ATP levels and decreases cell pH as lactic 
acid accumulates as a result of anaerobic glycolysis. Lack of ATP results in neurons being 
unable to maintain their normal resting membrane potential (-65 to -90mV), since ATP is 
required to power the Na
+
/K
+
 ATPase. Under normal conditions, this pump acts to 
maintain the resting membrane potential by extruding 3Na
+
 ions out of the cell and allows 
entry of 2K
+
 ions for every molecule of ATP utilised. This preserves a high intracellular 
concentration of potassium and a low intracellular concentration of sodium ions. 
 
Inactivity of the pump due to ATP depletion allows intracellular sodium levels to rise 
leading to depolarisation of the membrane potential. Membrane depolarisation triggers 
opening of voltage-gated calcium channels with subsequent influx of calcium down the 
electrochemical gradient. Further calcium entry may occur due to reversal of the sodium-
calcium exchanger, NCX, which is widely expressed in the brain. This transmembrane 
protein uses the sodium gradient generated by the Na
+
/K
+
 ATPase to catalyze the extrusion 
of one calcium ion and influx of three sodium ions in each reaction cycle, under normal  
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Figure 1-4. The Ischaemic Cascade. A wide spectrum of neurochemical alterations are triggered 
following occlusion of a cerebral blood vessel. Multiple pathways converge to contribute to 
irreversible cellular injury and cytotoxic oedema. The ischaemic cascade presents multiple targets 
for neuroprotection following ischaemia. Reproduced from Chavez et al. (2009). 
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resting conditions (Besancon et al, 2008). In severe ischaemia, where ATP levels are low 
and Na
+
/K
+
 pump activity is compromised, intracellular overloading of sodium causes 
NCX to operate in the reverse mode, leading to entry of 3 calcium ions per cycle. The 
combined influx of calcium via NCX reversal and through voltage gated calcium channels 
can trigger spontaneous release of neurotransmitters from the active zone of the 
presynaptic neuronal element via calcium-mediated exocytosis. Glutamate is the major 
excitatory neurotransmitter of the central nervous system and when its release and re-
uptake are not under physiological control, is largely responsible for initiating a cascade of 
excitotoxic events. 
 
Glutamate Excitotoxicity 
 
The mechanism of presynaptic glutamate release may occur via spontaneous exocytosis, by 
reverse operation of the sodium dependent glutamate uptake system, or by standard 
calcium-mediated exocytosis. However, the excessive extracellular glutamate levels 
observed in ischaemia are likely to be attributable to all three modes of release. 
The excess glutamate release into the extracellular space allows for an increased activation 
of postsynaptic glutamate receptors, of which there are four classes: Ionotropic kainate, 
AMPA and NMDA receptors and metabotropic glutamate receptors (mGluR). Kainate 
receptors are found in specific brain regions only, and along with AMPA receptors, they 
mediate basal synaptic transmission. Ligand binding triggers channel opening, allowing 
entry of sodium and chloride ions and extrusion of potassium ions along their 
electrochemical gradients. Water enters the cell passively as a result of high Na
+
 and Cl
-
 
entry, leading to cytotoxic oedema. This may have an effect on the perfusion of regions of 
brain tissue surrounding the infarct and may also cause a slight rise in intracranial pressure, 
vascular compression and herniation. These are major determinants of whether a patient 
survives beyond the first few hours following a stroke (Dirnagl et al, 1999).  
 
Excessive and prolonged membrane depolarization occurs as a result of AMPA receptor 
stimulation and this in turn results in activation of the NMDA receptor. The NMDA 
receptor is unique in that it requires both ligand binding and a voltage change to induce 
channel opening. Local depolarisation displaces the voltage-dependent magnesium block 
from the channel to allow entry of sodium and calcium and extrusion of potassium ions. 
 
Additionally, glutamate activation of mGluRs leads to activation of Phospholipase C. This 
enzyme catalyzes the hydrolysis of the membrane protein, phosphatidylinositol 4,5-  
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Figure 1-5. A representation of the temporal profile of the pathophysiological mechanisms 
underlying acute focal ischaemia and their contribution to cerebral ischaemic injury. In the 
absence of reperfusion, the ischaemic penumbra (shown in grey) will proceed to infarction as the 
ischaemic core expands to encompass the perfusion deficit (shown in black). Reproduced from 
Brouns & De Deyn (2009). 
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bisphosphate (PIP2) to release the 2
nd
 messengers diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). DAG activates protein kinase C, which further stimulates voltage-gated 
calcium channels. IP3 mediates the release of calcium from intracellular stores by binding 
to an IP3  sensitive channel located in the membrane of the endoplasmic reticulum (ER). 
The ER is a major source of calcium since under normal conditions, 99% of total cell 
calcium (1000µmol/l) is bound or stored, with only 0.1µmol/l free in the cytosol. 
Furthermore, resequestration of calcium into the ER is mediated via a calcium ATPase, so 
re-uptake of calcium into the ER lumen is reduced as a result of decreased ATP levels. 
This further contributes to the increase in intracellular calcium and it is evident that the rise 
in cytosolic calcium associated with ischaemia is derived from multiple pathways (Kristian 
& Siesjo, 1998). 
 
Calcium Activation of the Ischaemic Cascade 
 
Calcium is the major mediator of ischaemic cell damage and death, by triggering a cascade 
of reactions within the cell. It activates a variety of enzymes including endonucleases, 
which result in DNA and RNA damage, as well as proteases and lipases, along with other 
factors, which mediate further cell dysfunction and damage. The calcium-mediated cascade 
also involves the production of free radicals including nitric oxide, which have numerous 
effects on cell function and viability. The temporal profiles of the components of the 
ischaemic cascade are illustrated by Figure 1-5. 
 
Free Radical Generation 
 
Calcium mediated activation of the enzyme phospholipase A2 triggers the breakdown of 
membrane phospholipids to form arachidonic acid, which then undergoes oxidative 
metabolism via the COX or lipoxygenase pathways, resulting in the synthesis of 
eicosanoids. Superoxide or hydroxyl free radicals are also released during this process. 
This pathway involves a positive feedback cycle, as free radical production further 
stimulates phospholipase A2 activity and consequently enhances the generation of free 
radicals. Free radicals may also be generated as a result of hypoxanthine oxidation. 
Hypoxanthine accumulates under hypoxic conditions due to the breakdown of adenine 
nucleotides. Superoxide radicals are released as xanthine dehydrogenase is converted to 
xanthine oxidase during the metabolism of hypoxanthine. 
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Nitric oxide (NO) production increases in ischaemia as a result of increased intracellular 
calcium levels. Calcium activates calcineurin, which in turn activates neuronal nitric oxide 
synthase (nNOS). This enzyme catalyzes the synthesis of NO from its precursor,              
L-arginine. Under normal physiological conditions, NO functions as a neurotransmitter and 
has a role in synaptic plasticity (Pacher et al, 2007) as well as in the control of cerebral 
blood flow, where it acts as a vasodilator. Under ischaemic conditions, NO combines with 
superoxide to form peroxynitrite, which is a highly reactive oxidant. In ischaemia, where 
L-arginine levels may become rate limiting, nNOS may generate peroxynitrite directly by 
producing both NO and superoxide. Peroxynitrite is extremely potent and causes extensive 
tissue damage via inhibition of DNA synthesis and nucleic acid damage, lipid 
peroxidation, leading to membrane breakdown. This oxidant also mediates mitochondrial 
dysfunction and activation of poly (ADP-ribose) polymerase (PARP). PARP is a nuclear 
enzyme, which is strongly activated by single stranded breaks in DNA caused by the 
actions of peroxynitrite and free radicals (as reviewed by Lipton, 1999). PARP upregulates 
the transcription factors activator protein 1 (AP1) and nuclear factor kappa B (NFκB), 
which enhance post-ischaemic brain inflammation. PARP toxicity also involves depletion 
of ATP and stimulates release of apoptosis inducing factor (AIF) from mitochondria which 
activates caspase independent apoptosis (as reviewed by Beckman & Koppenol, 1996). 
Therefore PARP neurotoxicity is multifactorial and influences multiple pathways. 
NO may also have an indirect neuroprotective effect by inducing vasodilatation to increase 
local blood flow and enhance collateral circulation. NO also inhibits platelet aggregation 
and leukocyte adhesion, thereby preventing microvascular plugging and occlusion. 
Furthermore, vascular NO may inhibit the ischaemic cascade by preventing inflammation, 
oxidative injury and neuronal apoptosis (as reviewed by Pacher et al, 2007). 
 
Free radicals have extremely destructive effects on cells and under ischaemic conditions 
their high production levels completely overwhelm endogenous free radical scavengers, 
like uric acid and glutathione. The brain is particularly susceptible to free radical mediated 
cellular injury due to its limited antioxidant responses (Adibhatla & Hatcher, 2010). Free 
radicals have a range of detrimental cellular effects including enzyme inactivation, release 
of calcium ions from intracellular stores, protein denaturation, lipid peroxidation and 
damage to DNA and RNA, in addition to cytoskeletal component breakdown (Brouns & 
De Deyn, 2009). Free radicals also act as signalling molecules to induce an inflammatory 
response and trigger apoptosis (Brouns & De Deyn, 2009). Free radicals have detrimental 
effects on mitochondria, where they disrupt the inner mitochondrial membrane via lipid 
peroxidation. In addition, free radicals impair mitochondrial function further by oxidising 
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the proteins, which are involved in the electron transport chain to mediate ATP production 
and H
+ 
extrusion (Dugan & Choi, 1994). Overall, free radicals result in severe 
mitochondrial dysfunction and mediate cellular damage via various actions within the cell. 
 
Peri-infarct Spreading Depolarisations 
 
In the ischaemic core, cells undergo anoxic depolarisation and are unable to repolarise. 
However, in less severely hypoperfused penumbral tissue located at the boundary of the 
ischaemic core, cells retain the ability to repolarise but they do so at the expense of further 
energy consumption and oxygen extraction levels are increased to compensate for the 
reduced cerebral blood flow. Once repolarised, these cells can then again depolarize in 
response to high glutamate and potassium ion levels, which accumulate in the extracellular 
space. This cycle can continue and repetitive depolarisations are called peri-infarct 
depolarisations. Peri-infarct depolarisations occur spontaneously over several days 
following stroke onset and this has been demonstrated both in pre-clinical (Hartings et al, 
2003) and clinical stroke research (Dohmen et al, 2008). This phenomenon has been 
particularly well documented in rodent models of stroke and as the frequency of these 
events increases, greater numbers of cells in the penumbra become incorporated into the 
ischaemic core (Mies et al, 1993). This has also been demonstrated in human stroke 
patients, where delayed ischaemic brain damage was associated with spreading 
depolarisations (Drier et al, 2006). 
 
Inflammatory Responses to Ischaemia 
 
An inflammatory response is triggered by various factors in ischaemic conditions, 
including increasing free radical levels, calcium activated second messenger systems and 
by the state of hypoxia itself. This results in the synthesis of transcription factors, like 
NFκB and hypoxia inducible factor 1 (HIF1), which promote expression of pro-
inflammatory genes to produce inflammatory mediators like tumour necrosis factor α 
(TNFα), interleukin1β (IL-1β) and platelet activating factor (PAF), to name but a few. 
Production of these mediators induces surface expression of adhesion molecules like 
intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) 
and E-selectin. These molecules interact with complementary receptors located on the 
surface of neutrophils, allowing their passage across the blood-brain barrier (BBB). 
Macrophages and monocytes follow suit, migrating into the ischaemic brain, guided by 
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chemokine signals produced by cells at the site of the lesion (as reviewed by Dirnagl et al, 
1999). 
Four to six hours following cerebral ischaemia, microglia become activated and attracted 
to the site of injury by monocyte chemoattractant protein 1 (MCP-1) (Brouns & De Deyn, 
2009). MCP-1 is activated by plasmin following opening of the BBB due to death of 
endothelial cells in response to ischaemia. Once activated, microglia assume an ambeoid 
appearance and retract their processes (Dirnagl et al, 1999), allowing proliferation to occur. 
They then secrete a variety of neurotoxic and neuroprotective compounds. The 
neuroprotective factors include plasminogen, thrombospondin and tumour growth factor b1 
(TGFb1), which has a role in angiogenesis and extracellular matrix formation. However, 
there is increasing evidence that post-ischaemic inflammation actually contributes to brain 
injury via microvascular obstruction by neutrophils (Del Zoppo, 1991). Activated 
microglia secrete neurotoxins, such as TNFα, which may exacerbate ischaemic neuronal 
damage. Furthermore, TNFα is also released by ischaemic neurons (Barone et al, 1997). In 
addition, the ischaemic inflammatory response may also be linked to the initiation of 
apoptotic pathways, since it has been described that the use of antibodies against cell 
surface adhesion molecules, reduced ischaemic cell damage and apoptotic cell death 
(Chopp et al, 1996). Therefore, the inflammatory response observed following ischaemia 
appears to have a dual role in both neuroprotection and neurotoxicity, although its principal 
role is not yet clear. 
 
Astrocyte Response to Ischaemia 
 
Within the neurovascular unit, astrocytes provide trophic, metabolic and antioxidant 
support to neurons and also react to ischaemic conditions in the brain (Pastor et al, 2009).  
Within minutes of reduced cerebral blood flow, astrocytes swell and the cytoplasm 
becomes lucent. This particularly occurs in perivascular foot processes surrounding 
capillaries. In irreversible ischaemic injury, swelling leads to a doubling of cell volume 
with a reduction in cell organelle content and complete loss of glial fibrillary acidic protein 
(GFAP). Reactive astrocytes are stimulated by the release of TGFb1 by activated microglia 
and they can be distinguished morphologically by the large quantity of GFAP and vimentin 
intermediate filaments in the cytosol (Li et al, 2008). These astrocytes produce a variety of 
neurotrophic factors, including basic fibroblast growth factor (bFGF) and insulin-like 
growth factor 1 (IGF-1), to potentiate recovery of damaged neurons (Ridet et al, 1997). 
However, the precise molecular mechanisms involved in the astrocyte response to 
ischaemia are not yet clear. 
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Figure 1-6. Apoptosis cascades mediated by TNFα and mitochondrial pathways. The 
activation of TNF receptors can induce apoptosis directly by activating caspase cascades and 
indirectly by stimulating mitochondrial mediated apoptosis. Cytochrome c released from the 
mitochondrion mediates formation of the apotosome complex and subsequent activation of 
caspases 9 and 3, leading to induction of apoptosis. Ischaemia induced release of AIF from the 
mitochondrion promotes apoptosis independently of caspase activation. Reproduced from 
Weinberger (2006). 
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Mechanisms of Cell Death 
 
Under ischaemic conditions, cells of the neurovascular unit may die either by necrosis or 
by apoptotic pathways which are highly conserved biochemical pathways which signal and 
execute cell death. The mechanism of cell death employed depends on the nature of the 
excitotoxic stimulus, cell type and the stage in development or life cycle (Leist & Nicotera, 
1998). 
Necrosis appears to be the predominant mechanism of neuronal cell death following acute, 
permanent vascular occlusion (Dirnagl et al, 1999). Therefore, necrotic cell death occurs in 
the ischaemic core, where perfusion is most severely reduced and cells are irreversibly 
damaged, since necrosis only occurs following an exogenous insult and is not involved in 
normal physiological processes. If a cell dies through the necrotic pathway, it releases 
more glutamate and toxic mediators into the environment, affecting surrounding cells 
(Brouns & De Deyn, 2009).  
 
Apoptosis 
 
Apoptosis is a programmed cell death mechanism, which appears to occur in cells that are 
affected by milder injury and particularly occurs in the ischaemic penumbra (Dirnagl et al, 
1999). Characterization of programmed cell death processes in Caenorhabditis elegans 
lead to much greater understanding of the mechanisms involved in apoptosis in 
mammalian systems. 
 
Apoptotic pathways can either be caspase dependent or independent (Figure 1-6), although 
neurons are particularly susceptible to caspase mediated cell death programmes following  
focal cerebral ischaemia. Caspase dependent apoptosis involves the release of cytochrome 
c from the mitochondrial intermembrane space as a result of free radical induced 
mitochondrial dysfunction. Cytochrome c enters the cytosol and activates apoptosis 
activating factor 1 (Apaf-1) and procaspase 9, which combine to form an apoptosome 
complex. This complex then activates an apoptosis effector system, which involves a 
cascade of endonucleases and caspases.  Caspases are cysteine proteases, which cleave 
proteins of the nuclear lamina and cytoskeleton, including PARP and gelsolin, 
Caspase 3 activation has been shown to be one of the most critical steps in apoptosis 
induction and occurs hours before cell death occurs. Following transient middle cerebral 
artery occlusion in the mouse, cytochrome c release was detected after 6 hours, caspase 
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processing occurred at 9 hours and prominent cell death was not evident until 24 hours 
following occlusion (Endres et al, 1998). 
 
Caspase independent apoptosis is mainly driven by apoptosis inducing factor (AIF). AIF is 
a mitochondrial inner membrane flavoprotein oxioreductase, which acts as a pro-survival 
factor. It is essential for long time mitochondrial function and is important in maintaining 
complex 1 integrity and H2O2 scavenging capability. However, when AIF is released from 
the mitochondrion into the cytosol, it reaches the nucleus, where it has an anti-survival role 
by triggering DNA degradation and cell death. 
 
1.2 Animal Models of Cerebral Ischaemia 
 
1.2.1 Rodent Stroke Models 
 
The main features of human ischaemic stroke can be modelled in animal models of focal 
cerebral ischaemia. Primate and higher mammal models of stroke are of greatest relevance 
to the human condition but such models present a variety of problems. Primate models in 
particular are most relevant when examining the behavioural effects of stroke, especially 
with regards to manual dexterity, which is lacking in lower mammals. However, there are 
many disadvantages to using such models, namely cost of maintenance and the need for 
specialist animal facilities. There are also many ethical considerations as there are lower 
levels of social acceptance with the use of these models (Carmichael, 2005).  
However, there are many advantages in the use of rodent stroke models. Mice are the most 
suitable species when examining the molecular pathophysiology of stroke, since genetic 
modifications can be easily introduced (Fujimura et al, 1999). Rat models are the most 
appropriate to model focal cerebral ischaemia due to their size, which allows physiological 
parameters to be easily monitored and brain tissue can also be easily examined by 
neuroimaging techniques or histological staining methods. Furthermore, reproducible 
studies can be conducted with ease due to the relative homogeneity within strains of rat 
(Durukan & Tatlismak, 2007). However, by far the most convincing argument for the 
relevance of rat models of stroke, is the similarity between the cerebrovascular systems of 
humans and rats, both on an anatomical and functional level (Macrae, 1992), with both 
species possessing a circle of Willis (Figure 1-7). 
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Figure 1-7. The cerebrovascular systems of rat (left) and man (right). Both species possess a 
circle of Willis which makes the rat a suitable species for modelling human stroke. In humans the 
middle cerebral artery is commonly occluded and therefore most rat models of focal cerebral 
ischaemia involve occlusion of this artery. This procedure is most often performed using the 
intraluminal thread model where a nylon suture (shown in black) is introduced into the internal 
carotid artery and progressed until it blocks the origin of the middle cerebral artery. 
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The middle cerebral artery is the vessel which is most commonly occluded in human stroke 
(Mohr et al, 1986) and therefore, rat models involving middle cerebral artery occlusion 
(MCAO) are of particular relevance to the clinical situation. The intraluminal filament  
model of MCAO was first described by Koizumi et al (1986) and this technique has since 
been refined by various study groups (Belayev et al, 1996; Schmid-Elsaesser et al, 1998). 
This technique involves introducing and passing a filament of a specified diameter along 
the internal carotid artery until the filament reaches the bifurcation point and is lodged at 
the junction of the anterior and middle cerebral arteries, blocking off the proximal origin of 
the middle cerebral artery. This model can induce either transient or permanent ischaemia, 
since the filament can be retracted after a defined time period. There are various factors 
which can influence the reproducibility of this model, including filament diameter, 
insertion length and filament coating. Filaments coated with silicon have been shown to 
reduce the risk of haemorrhage and premature reperfusion (Belayev et al, 1996; Schmid-
Elsesser et al, 1998) and the size of the filament correlates well with infarct volume 
(Durukan & Tatlisumak, 2007). However, intraluminal thread MCAO models present their 
own problems, primarily from the risk of blood vessel rupture and haemorrhage. 
Furthermore, artery occlusion may be incomplete, allowing some perfusion of the territory 
served by the middle cerebral artery (MCA). Additionally, blood vessels outside of the 
territory of the MCA may also be occluded by the filament. 
 
Although the intraluminal filament model is the most commonly used stroke model, the 
middle cerebral artery can be occluded by other means. For example, the MCA can be 
permanently occluded by electrocoagulating the proximal region of the artery (Tamura et 
al, 1981). This model requires a craniectomy, which reduces the mortality associated with 
ischaemia induced acute brain swelling and produces a highly reproducible infarct, which 
is smaller than that produced by the intraluminal filament model (Macrae, 1992). 
Experimental stroke can also be induced by stereotaxic injection of the potent 
vasoconstrictor, endothelin-1 which can produce selective grey or white matter ischaemia 
depending on the location of the injection. This allows small white matter infarcts to be 
produced (Frost et al, 2006) and can also be used to occlude the middle cerebral artery by 
injecting endothelin-1 into the adjacent grey matter (Sharkey et al, 1993). Embolic stroke 
can also be induced experimentally where an embolus is introduced into the 
cerebrovasculature to occlude a cerebral artery. The embolic model is of particular 
relevance when examining the effect of thrombolytic therapy (Henninger et al, 2009; Zhu 
et al, 2010). However, infarcts produced by embolic models are generally less reproducible 
than those produced by the intraluminal filament and electrocoagulation models of MCAO. 
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This is likely to arise from variations in clot stability and the final lodgement of the 
embolus within the cerebrovasculature (DiNapoli et al, 2006). 
 
There are many who question the validity of rat stroke models and their relevance to the 
human condition due to the lack of research using aged animals with stroke risk factors and 
poor study design. In addition, experimental strokes are highly reproducible in rodent 
models but in the human stroke patients the size and location of the stroke is highly 
variable. The intraluminal filament model of MCAO in particular, produces very large 
infarcts which may not model the most treatable and common human strokes (Carmichael, 
2005). In addition, many of the anaesthetics commonly used during stroke surgery, have 
been demonstrated to have neuroprotective effects, which will influence stroke outcome. 
Therefore, the choice of anaesthetic used during the experiment, must be carefully 
considered. 
 
1.2.2 Neuroprotection in Animal Models of Stroke 
 
In animal models of stroke, pharmacological targeting of the pathways involved in the 
ischaemic cascade have been successful in reducing infarct size and the extent of neuronal 
damage as well as improving functional outcome. However, when these treatments were 
introduced into human clinical trials, their efficacy was lost and in some cases, even led to 
exacerbation of ischaemic damage (Internet Stroke Centre:www.strokecenter.org/trials/). 
There are many hundreds of published pre-clinical articles reporting the neuroprotective 
effects of drugs which target the mechanisms involved in stroke pathophysiology but to 
date, none of these therapeutic strategies have translated to human stroke patients. There 
are many reasons why this may occur, including the increased age of clinical trial patients 
compared to the use of young adult animals, as well as anatomical and physiological 
differences between the brains of humans and animals, poor study design and lack of 
penumbral imaging for patient recruitment in clinical trials (Dirnagl et al, 1999; Röther, 
2008; Chavez et al, 2009). Despite these disappointing results, the pathophysiological 
pathways involved in stroke remain a prime target for the development of future stroke 
therapies. Therefore understanding the pathophysiological mechanisms underlying stroke 
can identify targets for possible pharmacological intervention to allow development of 
stroke therapies, which will reduce the high mortality rates and the degree of disability 
associated with this disorder. 
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1.2.3 The Spontaneously Hypertensive Stroke-Prone Rat (SHRSP) 
 
The spontaneously hypertensive stroke-prone rat (SHRSP) is commonly utilised in models 
of malignant hypertension and cerebrovascular disease, including stroke. This strain 
develops progressive hypertension at a young age and is prone to spontaneous stroke, 
which is similar to the human condition. Hypertension is well established as a major risk 
factor for human stroke and contributes to the development of stroke in the SHRSP.  
 
The SHRSP was developed in 1974 by Okamoto and colleagues, by selective inbreeding of 
spontaneously hypertensive rats (SHR). The offspring produced, where at least one of the 
breeding pair experienced spontaneous stroke, were maintained over successive 
generations. The SHR strain had been previously developed from selective inbreeding of 
normotensive Wistar-Kyoto (WKY) rats which exhibited elevated blood pressure 
(Okamoto & Aoki, 1963). 
 
Both SHR and SHRSP show increased sensitivity to experimental stroke compared to 
normotensive rat strains (Duverger & MacKenzie, 1988). However, the SHRSP strain 
demonstrates more severe hypertension and an increased susceptibility to spontaneous 
stroke. There are many factors implicated in the increased stroke sensitivity observed in the 
SHRSP, including an enhanced inflammatory response, impaired collateral flow and a 
variety of other anatomical and physiological abnormalities, in addition to genetic 
hypertension.  
 
Furthermore, the SHRSP can also be used as a model of metabolic syndrome, which is a 
complex multifactorial disease linked to insulin resistance. Hypertension is a known risk 
factor for metabolic syndrome and feeding SHRSPs a 60% fructose diet induces impaired 
glucose tolerance, dyslipidaemia and increased adiposity compared to WKY rats (Strahorn 
et al, 2005).  
 
1.2.4 Genetic Background of SHRSP 
 
The structural and physiological differences that are demonstrated by the SHRSP, 
compared to SHR and WKY, are determined by their genetic background. At least three 
major genes are known to influence the development of severe hypertension and the gene  
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Figure 1-8. Hypothetical genetic make-up of SHR and SHRSP. SHRSP possess additional 
genes which contribute to increased sensitivity to experimental stroke which are independent of 
blood pressure since larger infarcts are observed in SHRSP before the development of 
hypertension. Reproduced from Nabika et al (2004). 
 
 
 
 
 
 
 
 
 
 26 
loci which contribute to the development and maintenance of hypertension are different 
depending on the age of the animal (Mashimo et al, 1999). In young animals, quantitative 
trait loci (QTLs) on chromosomes 1, 3 and 4 contribute to the elevated basal blood 
pressure observed in the stroke-prone strain. However, the rise in blood pressure observed 
following salt-loading can be linked to a QTL on chromosome 10. In addition, there are 
other genes which are involved in stroke which are independent of blood pressure since 
SHRSP show increased stroke sensitivity before the onset of hypertension, indicating other 
genetic factors (Figure 1-8). 
 
The increased stroke sensitivity demonstrated by the stroke-prone strain has been shown to 
be inherited as a dominant trait. Gratton et al (1998) reported that the offspring of a 
SHRSP/WKY cross (WKY father) exhibited infarcts following experimental stroke which 
were directly comparable with that observed in the SHRSP strain, indicating a dominant 
mode of inheritance for increased stroke sensitivity. Furthermore, Carswell et al (1999) 
reported that male offspring from a WKY/SHRSP cross, where the father was of the 
stroke-prone strain, demonstrated reduced sensitivity to experimental stroke than those 
with a WKY father. The authors proposed that this effect may be attributed to the increased 
blood pressure exhibited by males with a Y chromosome inherited from SHRSP, since they 
demonstrated that there was a significant negative correlation between high blood pressure 
and small infarct volume following permanent MCA occlusion. 
 
 Jeffs et al (1997) proposed that increased sensitivity to experimental stroke in the SHRSP 
was linked to a QTL on chromosome 5, which co-localises with the genes which encode 
atrial natriuretic factor (ANF) and brain natriuretic factor (BNF). Both of these proteins are 
vasoactive and may play a role in the control of vasoreactivity, growth and remodelling of 
cerebral blood vessels (Jeffs et al, 1997). However, in a later study by the same group, the 
genes encoding ANF and BNF were excluded as candidates for the increased stroke 
sensitivity demonstrated by SHRSP as they were unable to identify any differences in the 
coding regions of these genes between the stroke-prone and the normotensive reference 
strain. In addition, there was no difference in the expression of ANF and BNF between 
strains, even following MCA occlusion (Brosnan et al, 1999).  
 
Rubbatu and colleagues (1999) examined the genes involved in stroke proneness and these 
authors did identify strain differences in the sequence coding atrial natriuretic peptide, 
resulting in altered structure of the gene product in the stroke-prone strain. The conflicting 
findings of these studies show that the genes involved in the risk of spontaneous stroke  
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Figure 1-9.  The range of systolic pressures of the SHRSP and normotensive WKY strain, 
measured using the tail cuff method at weeks 8, 12 and 16. Both sexes of the stroke-prone 
strain display higher pressures than the normotensive reference strain WKY. However, female 
SHRSP develop hypertension which is not as severe as that observed in male SHRSP. Adapted 
from Davidson et al (1995). 
 
 
 
Age in weeks 
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differ from those genes which predispose SHRSP to increased sensitivity to experimental 
stroke although both QTLs are localised on chromosome 5. 
1.2.5 Development of Hypertension in SHRSP 
 
Immature SHRSP are normotensive, with blood pressure values which are comparable to 
that of the reference strain WKY (Davidson et al, 1995). When the animals reach around 8 
weeks of age, systolic blood pressure begins to rise progressively from approximately 
140mmHg to 175mmHg by 16 weeks. Blood pressure of the normotensive WKY remains 
at around 135mmHg. However, Okamoto et al (1974) reported frequent severe 
hypertension in the SHRSP of up to 250mmHg by 20 weeks of age, while maximal blood 
pressure observed in the stroke-resistant SHR strain did not rise above 200mmHg.  
Therefore, the increased susceptibility to stroke demonstrated by the SHRSP may be 
attributed to the increased blood pressure observed in this strain since induction of severe 
hypertension (>225mmHg) in normotensive rats using a kidney clip procedure, resulted in 
spontaneous stroke and infarct sizes comparable to that observed in SHRSP (Zeng et al, 
1998). Despite this, other genetic factors must contribute to stroke susceptibility in the  
SHRSP, since experimental stroke produces significantly larger infarcts in this strain 
compared to WKY, even before hypertension develops (Coyle & Jokelainen, 1983). 
Interestingly, females develop hypertension much more slowly and to a much lesser degree 
than their male counterparts (Figure 1-9). In immature SHRSP females, systolic blood 
pressure is comparable with that of the male and also begins to rise at around 8 weeks. By 
week 12, female systolic blood pressure has reached a peak of around 150mmHg (Ibrahim 
et al, 2005). Chronic hypertension is associated with growth and remodelling of the 
cerebral vasculature, where the lumen diameter of vessels is reduced and the vascular wall 
is thickened in response to increased pressure. This results in an increased wall to lumen 
ratio and increased vascular resistance. Thickening of the vascular wall is an adaptation to 
the increased intraluminal pressure and serves to counteract the increased wall tension and 
protect the vessel against high pressure changes (Izzard et al, 2003). The autoregulation 
curve is shifted to the right as the resistance vessels act to regulate diameter at a higher 
pressure range and the vasodilatory response to lower pressures is impaired as a 
consequence of reduced lumen diameter (Izzard et al, 2003). This means that cerebral 
blood flow will be compromised at blood pressure values which are capable of maintaining 
cerebral blood flow (CBF) in normotensive rats. 
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1.2.6 Spontaneous Stroke 
 
Okamoto and colleagues (1974) reported a high incidence of spontaneous stroke in both 
sexes of adult SHRSP, although the likelihood of stroke in males was markedly greater 
than that observed in females, where incidence of spontaneous stroke was 80% in males 
aged over 100 days and 60% in females over 150 days old.   
 
Common symptoms of spontaneous stroke in the SHRSP include hyperirritability, 
aggression, and motion disturbances, comprising of episodes of repetitive paw lifting, 
ataxia and paralysis (Okamoto et al, 1974). Following the appearance of these symptoms, 
the rats typically survived from a couple of days to 24 weeks. Just prior to death, many  
animals displayed additional symptoms of apathy and urinary incontinence and a small 
group of animals also demonstrated self-biting behaviours. 
 
Examination of brains following death revealed cerebral lesions resulting from fresh 
intracerebral haemorrhage or infarction. In some cases, infarcts were accompanied by 
evidence of previous haemorrhage (Okamoto et al, 1974). Most lesions were located in the 
cortex or subcortical region of the left occipital area but around 15% of animals which had 
experienced spontaneous stroke demonstrated lesions in the basal ganglia. Occasionally, 
lesions were observed in the frontal cortex. Okamoto et al (1974) recognised that cerebral 
lesions correspond to the boundary areas between the three major cerebral arteries and that 
anastomoses between these vessels were scarcely observed. This suggests a vascular 
abnormality in this strain of rat and it has been widely reported that spontaneous stroke in 
the SHRSP occurs as a result of pathological changes in small perforating arteries, leading 
to fibrinoid necrosis and brain oedema. This mirrors the clinical situation of malignant 
hypertension in humans (Ogata et al, 1980). In addition, the onset of spontaneous stroke 
can be accelerated by feeding the animals a salt-loaded diet or by administration of 1% 
sodium chloride in their drinking water (Okamoto et al, 1974). 
 
Furthermore, the incidence of stroke is highly correlated with a rapid increase in blood 
pressure and also with the severity of hypertension. This may give some explanation why 
the incidence of stroke in higher in male SHRSP than females, as hypertension progresses 
more quickly in males and increases to a greater level, as previously discussed. This means 
that females may die of another condition, like pneumonia, before spontaneous stroke 
occurs (Okamoto et al, 1974), since this strain is particularly susceptible to respiratory 
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infections, as a result of an impaired immune system and may die before there is evidence 
of hypertensive vascular changes (Ogata et al, 1982). 
 
1.2.7 Increased Sensitivity to Experimental Stroke 
 
It is well established that SHRSP are more sensitive to experimental stroke than the 
normotensive control strain, WKY (Coyle & Jokelainen, 1983; Carswell et al, 1999; Marks 
et al, 2001). Following permanent middle cerebral artery occlusion  via electrocoagulation 
of the distal portion of the artery, infarct volume was significantly greater in the ipsilateral 
hemisphere of the SHRSP compared to that observed in the WKY (36.6% of the 
hemisphere vs. 14.0% respectively – see Figure 1-10), as reported by Carswell et al (1999). 
Similarly, Marks and colleagues also reported significant differences in infarct volume  
following permanent distal MCAO, between the two strains. Twenty four hours post 
occlusion, infarct volume in the SHRSP was recorded as 135mm
3
. In comparison, infarct 
volume in the ipsilateral hemisphere of the WKY was measured as 102mm
3 
(Marks et al, 
2001). However, a more accurate representation of infarct volume is given by the 
percentage of the hemisphere, rather than actual volume, since there are differences in 
overall brain volume between the two strains and this method does not take brain oedema 
into account and therefore may overestimate infarct size. 
 
There are many factors which may account for the increased sensitivity to stroke exhibited 
by the SHRSP. It has been demonstrated that the stroke-prone strain display increased 
release of glutamate during cerebral ischaemia, compared to normotensive WKY and 
stroke-resistant SHR (Gemba et al, 1992). This may contribute to increased excitotoxicity 
and neuronal damage contributing to the increased infarct volume observed in SHRSP. 
There are many additional anatomical and physiological factors which may contribute to 
the increased sensitivity to experimental stroke in this strain and these shall now be 
discussed. 
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Figure 1-10. The topography of the infarct observed in WKY and SHRSP across 8 coronal 
levels following distal middle cerebral artery occlusion. The shaded bar (scale 0 to 4) indicates 
the infarct areas observed, where 4 represents areas which were infarcted in 100% of animals; 3- 
areas infarcted in 75% of animals; 2- areas infarcted in 50% of animals and 1- areas infarcted in 
25% of animals. Note the greater infarct density in SHRSP compared to WKY. Reproduced from 
Marks et al (2001). 
 
 
 
 
 
 
 
 32 
1.2.8 Anatomical and Physiological Characteristics of SHRSP 
 
Vascular Abnormalities 
 
Many studies have reported impaired collateral flow and other anatomical vascular 
abnormalities in the SHRSP. Coyle and Jokelainen (1983) observed that the collateral 
circulation of the SHRSP was inadequate compared to that of the WKY and proposed that  
this may contribute to the increased infarct size following experimental stroke. A later 
study examined collateral flow a month after MCA occlusion and reported that the number 
of collateral vessels to the territory of the middle cerebral artery was the same in both the 
SHRSP and the normotensive WKY strain. However, the internal diameter of anastomoses 
was reduced in the SHRSP, 33μm compared to 50μm in the WKY (Coyle & Heistad, 
1987). These authors also reported that some collateral vessels had an internal diameter 
which was often less than half the diameter of the upstream arteriole, creating a 
“bottleneck effect” leading to increased resistance to flow. The reverse was observed in 
WKY rats, where the collateral vessels were larger in diameter than the cortical penetrating 
arterioles (Figure 1-11). In addition, large diameter branches of the anterior and middle  
cerebral arteries were significantly smaller in aged SHRSP (40-69 weeks old) compared to 
age matched WKY. However, there was no difference between the strains in the young 
animal groups (5-10 weeks old). This illustrates the vascular effects of progressive 
hypertension in the aged SHRSP. Since the internal diameter of ACA-MCA anastomoses  
was smaller in SHRSP in both age groups, this study suggests that the vascular resistance 
in fully relaxed collaterals is greater in the SHRSP, which compromises dorsal collateral 
flow even before the onset of hypertension (Coyle, 1987). This may partly explain why 
SHRSP demonstrate larger infarcts, compared to WKY, even before hypertension 
develops. 
 
Vascular function also appears to be impaired in the SHRSP strain. Volpe and colleagues 
(1996) demonstrated that in the thoracic aorta and the basilar artery of the SHRSP, 
endothelium-dependent vasodilatation was strikingly reduced compared to the vessels of 
the SHR. This is particularly interesting since the SHRSP and SHR strains show similar 
development of hypertension and therefore this observation must be independent of blood 
pressure. This may contribute to the reduced regional cerebral blood flow and increased 
infarct size observed in the SHRSP following experimental stroke, relative to that of the 
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Figure 1-11. End-to-end anastomosing branches of the anterior and middle cerebral artery in 
young WKY and SHRSP. (A) In 8 week old WKY, the anastomoses are larger in internal diameter 
than cortical penetrating branches (green arrows) (B) in 5 week old SHRSP, the anastomoses 
(denoted by  yellow arrows) are often less than 50% of the internal diameter of the supply vessels 
and the collaterals are smaller in diameter than cortical penetrating arterioles. Adapted from Coyle 
(1987). 
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SHR (Volpe et al, 1996). Therefore, impaired endothelium dependent vasodilation may 
account for part of the increased stroke sensitivity demonstrated by the stroke-prone strain.  
With greater relevance to experimental stroke, Izzard et al (2003) examined the 
vasoreactivity of the middle cerebral arteries of both hypertensive strains and discovered 
that the ability to autoregulate was reduced in the vessels of the SHRSP. Furthermore, they 
reported that the diameter of these arteries progressively increased as a linear function with 
increasing hypertension, presumably as a result of increased growth in response to 
increased wall stress. Therefore the impaired autoregulatory ability of SHRSP vessels 
compared to that of SHR may play a role in the increased stroke susceptibility observed in 
the stroke-prone strain (Izzard et al, 2003). 
 
Dysfunction of the Blood-Brain Barrier 
 
Dysfunction of the BBB has also been reported in SHRSP. The BBB is characterized by 
the presence of tight-junctions between endothelial cells and decreased levels of vesicular 
transport, which serves to limit passage of materials between the cerebral circulation and 
the brain parenchyma (Yamagata et al, 1997).  There are many reports of an increased 
permeability of the BBB in SHRSP, although the underlying mechanisms involved are not 
clear. The functions of the BBB are supported by astrocytes and it has been demonstrated 
by Yamagata and colleagues (1997) that in vitro, the astrocytes of SHRSP show a reduced 
ability to support the BBB, compared to WKY astrocytes.  
There is also evidence of differences in the structure of tight junctions of SHRSP, in 
addition to an alteration in the polarity of endothelial cells of the BBB prior to stroke onset.  
This may predispose the SHRSP to stroke-induced BBB breakdown rather than contribute 
to stroke onset per se (Lippoldt et al, 2000).   
Although there are reports of structural differences and increased BBB permeability in the 
SHRSP, the contribution to stroke pathogenesis is not yet clear, however BBB dysfunction 
is likely to enhance cerebral oedema formation following stroke.  
 
Oxidative Stress 
 
Increased levels of oxidative stress are also thought to contribute to increased sensitivity to 
experimental stroke in SHRSP. In both SHR and SHRSP, production levels of superoxide 
anions have been shown to be higher than that observed in normotensive rats in the 
vasculature and the brain (Suzuki et al, 1995; Kerr et al, 1999; Kishi et al, 2004) 
Furthermore, reactive oxygen species (ROS), such as superoxide anions and hydroxyl 
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radicals have been implicated in the pathogenesis of hypertension (Kerr et al, 1999). In 
addition, superoxide dismutase (SOD) activity is reduced in SHRSP in comparison to 
WKY (Kishi et al, 2004). This enzyme is an endogenous antioxidant and catalyzes the 
formation of oxygen and hydrogen peroxide from superoxide anions. Therefore, reduced 
SOD activity will result in increased superoxide levels, contributing to increased oxidative 
stress. 
 
Increased superoxide levels may result in increased damage following stroke by disrupting 
the blood-brain barrier, leading to brain oedema and also by lipid peroxidation of cell 
membranes, increasing cellular damage. Kim-Mitsuyama and colleagues (2005) 
demonstrated that superoxide production in the cortex and hippocampus was increased in 
SHRSP. Furthermore, they identified that NADPH oxidase was the source of the increase 
in superoxide anions, since inhibition of NADPH oxidase significantly reduced the 
elevation in superoxide levels.  
 
It has also been reported that levels of the eicosanoid 20-hydroxyeicosatetraenoic acid (20-
HETE) are twice as high in SHRSP as that observed in WKY. 20-HETE is a potent 
vasoconstrictor and has been reported to contribute to the enhanced stroke sensitivity of 
SHRSP.  It mediates endothelial dysfunction and increased oxidative stress by stimulating 
superoxide production via interactions with NADPH oxidase and uncoupling of NOS 
(Cheng et al, 2008). Inhibition of 20-HETE with N-hydroxy-N‟ –(4-butyl-2-
methylphenyl)-formamidine (HET0016) significantly reduced infarct volume in SHRSP 
following transient MCA occlusion but had no effect on the WKY infarct size (Dunn et al, 
2008).  
 
Heightened Inflammatory Response 
 
In addition to increased levels of oxidative stress, it has been reported that SHRSP 
demonstrate an increased inflammatory response to focal cerebral ischaemia compared to 
the reference strain WKY. Following permanent MCA occlusion, SHRSP showed 
significantly greater numbers of activated microglia. In the ischaemic core region, 183 
activated microglia were identified per mm
2
, compared to 156/mm
2 
in WKY rats (Marks et 
al, 2001). It has been proposed that the increased level of microglial activation may 
contribute to the increased infarct volume observed in SHRSP, since activated microglia 
release neurotoxins including oxygen radicals, nitric oxide and glutamate, leading to lipid 
peroxidation, oedema and necrosis. Rather interestingly, this team of investigators also  
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Figure 1-12. Reduced functional recovery in the SHRSP 2 days following experimental 
stroke. Note the asymmetrical placement of the forepaw and the hindpaw location for the SHRSP 
(red arrows). Adapted from Coyle & Jokelainen (1983). 
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observed that levels of resting and activated microglia in control SHRSP were increased 
relative to control WKY rats. This may account for the increased inflammatory response in 
the stroke-prone strain. 
 
1.2.9 Reduced Functional Recovery in SHRSP 
 
SHRSP display a poorer functional recovery following experimental stroke when 
compared to their normotensive control, the WKY (Figure 1-12), even when the focal 
ischaemic insult has been manipulated to produce comparable infarct volumes (McGill et 
al, 2005). Despite similar neurological deficits in both strains 2 hours post occlusion, 
SHRSP rats scored significantly lower on the 33 point neurological test at days 3, 7 and 28 
post surgery. Long-term impairment of contralateral limb use in the SHRSP was also 
accompanied by a decline in general health, with a reduction in body weight and 
dishevelled coat appearance. A similar study examined functional deficits in SHRSP in 
comparison to SHR following permanent MCAO (Maguire et al, 2004). This team reported 
prolonged behavioural deficits in SHRSP despite almost identical infarct size to that 
observed in SHR. This suggests that there is a genetic basis for the reduced recovery 
shown by the stroke-prone strain, since the degree of brain damage was comparable in both 
strains. The authors of both behavioural studies have suggested that this phenomenon may 
be indicative of impaired brain plasticity but the possible mechanisms involved have yet to 
be examined. 
 
1.3 Imaging the Ischaemic Penumbra 
 
1.3.1 Ischaemic Core and Penumbra 
 
The observed haemodynamic, metabolic and ionic changes observed following stroke do 
not occur in a homogenous manner across the ischaemic territory. In the severely 
hypoperfused core, cells are irreversibly damaged as permanent anoxic depolarization 
begins to develop within minutes of the onset of ischaemia. Cell damage occurs as a result 
of ionic homeostatic breakdown, and activation of multiple cellular pathways which 
converge to initiate the irreversible degradation of cellular components, as previously 
described in this chapter.  
 
The concept of the ischaemic penumbra arose from a series of seminal experiments 
performed in the 1970s which measured the effects of progressive reductions in cerebral 
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blood flow on the baboon cortex (Branston et al, 1974; Branston et al, 1977; Astrup et al, 
1977).  These studies examined cortical-evoked responses to determine the reduction in 
CBF required to abolish electrical activity and established the principle that there are two 
ischaemic thresholds which exist in the pathogenesis for cerebral infarction; one threshold 
for morphological damage and a less severe threshold for functional impairment.  The 
concept of two separate blood flow thresholds for the disruption of functional and 
structural integrity was refined by Symon and colleagues (1977). This team of 
investigators used a primate model to identify that cerebral blood flow below 
12ml/100g/min rendered neurons non-functional. In brain areas where cerebral flow was 
above 20ml/100g/min, neurons were fully functional and evoked somatosensory responses. 
At a flow rate of 15ml/100g/min the evoked somatosensory response sharply declined and 
therefore marks the threshold for disruption of function (Symon et al, 1977). 
These experiments led to the definition of the ischaemic penumbra as a region of brain 
tissue which is functionally impaired but structurally intact surrounding a severely 
hypoperfused central core where both functional and structural damage is evident (Astrup 
et al, 1981, Figure 1-13). Over the past 30 years, the definition of the ischaemic penumbra 
has evolved as a result of advances in neuroimaging and in light of both clinical and pre-
clinical studies which have examined the characteristics and lifespan of the penumbra. A 
revised definition of the penumbra defines it as  
“ischaemic tissue which is functionally impaired and is at risk of infarction and has the 
potential to be salvaged by reperfusion and/or other strategies. If it is not salvaged this  
tissue is progressively recruited into the infarct core which will expand with time into the 
maximal volume originally at risk” (Donnan et al, 2007). 
 
Furthermore, a set of criteria have been established to define the ischaemic penumbra 
(Donnan et al, 2007):  
 
(1) The penumbra is a region of hypoperfused, abnormal tissue with physiological and 
biochemical characteristics consistent with cellular dysfunction but not cellular 
death. 
(2) The tissue is located within the same ischaemic territory as the infarct core. 
(3) The tissue can either survive or progress to necrosis. 
(4) Salvage of the tissue is associated with better clinical outcome. 
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Figure 1-13. The Ischaemic Core and Penumbra.  Following occusion of a cerebral vessel, most 
commonly the middle cerebral artery, a core of severely hypoperfused injured tissue is found within 
the territory of the occluded vessel. Outwith the ischaemic core, there is a region of less severely 
hypoperfused tissue which is still metabolically active. This is the ischaemic penumbra and 
represents tissue which may be salvaged following stroke but has a finite lifespan and will proceed 
to infarction in the absence of reperfusion. Reproduced from Allan & Rothwell (2001). 
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Characteristics of the Ischaemic Penumbra 
 
Advances in neuroimaging have allowed the biochemical and metabolic characteristics of 
the ischaemic penumbra to be defined. Positron emission tomography (PET) has allowed 
measurement of regional CBF (rCBF), cerebral metabolic rate of oxygen (CMRO2), 
regional cerebral metabolic rate of glucose (rCMRglc) and oxygen extraction fraction 
(OEF). In humans, regional CBF below 12ml/100g/min and rCMRO2 below 
65µmol/100g/min corresponds to the infarct core (Ackerman et al, 1981). The penumbra 
has been defined as rCBF decreased to 12-22ml/100g/min with the rCMRO2 above 
65µmol/100g/min. This relative preservation of CMRO2 is an indicator of maintained 
neuronal metabolism. Hypoperfused tissue where rCBF is greater than 22mL/100g/min 
represents benign oligaemic tissue which will not proceed to infarction (as reviewed by del 
Zoppo et al, 2011). In addition, the penumbra displays an increased OEF compared to 
normal brain tissue in an attempt to compensate for the reduction in blood flow. In the 
penumbra OEF is increased to 50-90% (Heiss, 2000) compared to an OEF of 
approximately 40% in normal tissue (del Zoppo et al, 2011). 
 
In addition to biochemical and metabolic alterations, the ischaemic penumbra has also 
been characterised at the molecular level. As regional CBF decreases to approximately 
30% to 50% of baseline CBF, a reduction in protein synthesis is observed. In the severely 
hypoperfused infarct core, the ability to synthesise proteins is lost relatively early 
following ischaemia and is associated with ATP depletion. However, in the penumbra, 
ATP levels are maintained and protein synthesis is initially depressed but recovers over 
time (Hossman, 1994). It has been suggested that the loss of protein synthesis in the 
ischaemic core is a protective function to prevent the formation of partially denatured or 
incorrectly processed proteins. It is not yet understood why protein synthesis resumes in 
penumbral tissue but this area is currently under study (del Zoppo et al, 2011). 
 
There is also compelling evidence that heat shock protein 70 (Hsp70) is upregulated in 
penumbral tissue. Under normal conditions, Hsp70 is expressed in brain cells at levels 
which are almost undetectable. However, in ischaemic conditions, Hsp70 is massively 
induced and it can promote cell survival by refolding denatured proteins or alternatively, it 
can allow protein degradation and progression to cell death (Hohfeld et al, 2001). 
Following MCA occlusion, Hsp70 mRNA has been shown to be expressed throughout the 
MCA territory. However, in the ischaemic core, Hsp70 mRNA is not translated into the 
Hsp70 protein (Kinouchi et al, 1993). Conversely, in the ischaemic penumbra both 
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transcription and translation of Hsp70 occur, allowing refolding of proteins to occur and 
promoting cell survival.  
 
The ischaemic penumbra is of great interest to both clinicians and stroke researchers as it 
represents tissue which may be potentially salvaged following stroke. However, the 
penumbra has a finite lifespan and as time passes without reperfusion, the penumbra can 
progress to become part of the ischaemic core as a result of ongoing excitotoxicity, 
spreading depolarization, post ischaemic inflammation and apoptosis. This illustrates that 
the penumbra is not a fixed structure; it is highly dynamic and changes its boundaries over 
time. The existence of the penumbra is well established in rat models of focal cerebral 
ischaemia but in human stroke patients the extent, location and the lifespan of the 
penumbra is highly variable. 
 
1.3.2 Multi-Modal Identification of the Penumbra 
 
Identification of potentially salvageable penumbra, a region of hypoperfused but viable 
tissue which is at risk of infarction, is of the utmost importance to clinicians and 
experimental stroke researchers. Clinically, the presence of a significant volume of 
penumbral tissue can be used to identify those patients who are most likely to benefit from 
thrombolytic therapy. Furthermore, penumbra imaging can be potentially utilised to group 
stroke patients together in clinical trials, where the extent and location of the penumbra is  
similar. This will allow potential therapeutic strategies to be assessed in comparable groups 
of patients. In experimental stroke, identification of the penumbra can allow the efficacy of 
neuroprotective agents to be assessed. In this setting, the use of magnetic resonance 
imaging (MRI) is favoured. Although, positron emission tomography (PET) is considered 
to be the „gold standard‟ imaging modality for penumbra imaging and is still used as a 
clinical research tool, MRI is now becoming the modality of choice for identifying 
potentially salvageable tissue in clinical research. In addition, the use of computed 
tomography (CT perfusion) to identify the penumbra is being increasingly used in the 
clinical setting due to its cost effectiveness and availability (Heiss & Sorensen, 2009). 
 
1.3.3 Positron Emission Tomography 
 
PET is widely regarded as the „gold-standard‟ imaging modality for clinical identification 
of the ischaemic penumbra as it provides quantitative assessment of cerebral blood flow 
and oxygen metabolism. This technique involves intravenous administration of a positron 
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emitting radioisotope bound to a ligand.  The radioactivity emitted is then reconstructed to 
produce a tomographic image. Multi-tracer PET, using the ligands H2 
15 
O and 
15 
O, has  
been used to quantitatively measure cerebral blood flow (CBF), cerebral metabolism of 
oxygen (CMRO2 ) and oxygen extraction fraction (OEF) (Ebinger et al, 2009, Figure 1-14). 
The penumbra can therefore be identified as a hypoperfused region, where oxygen 
metabolism is preserved and oxygen extraction is increased, to compensate for the 
reduction in cerebral blood flow. This phenomenon was described as „misery-perfusion‟ by 
Baron et al (1981). Clinical studies have defined irreversibly damaged tissue using 
thresholds of oxygen metabolism and cerebral blood flow of 65µmol/100g/min and 
12ml/100g/min respectively and defined penumbra as tissue where regional CBF decreased 
to 12-22ml/100g/min, with a CMRO2 above 65µmol/100g/min and OEF increased to 50-
90% (Heiss, 2000).  
 
Modern PET tracers like 
18 
F-fluromisonidazole (FMISO) and 
11 
C-flumazenil (FMZ) can 
also be used to identify potentially salvageable tissue post-stroke. FMZ is a central 
benzodiazepine receptor ligand, a marker of neuronal integrity and has been used to detect 
neuronal damage within the first few hours of the onset of cerebral ischaemia. FMISO is a 
tracer of hypoxic viable tissue and can therefore be used to identify the ischaemic 
penumbra in the acute phase of stroke, where increased areas of tracer uptake are detected 
(Heiss, 2003).  
 
In experimental stroke, serial multi-tracer PET studies in the baboon (Touzani et al, 1995) 
and the cat (Heiss et al, 1994) have demonstrated the spatial and temporal evolution of the 
ischaemic penumbra following occlusion of the middle cerebral artery. Both studies have 
demonstrated the progressive incorporation of the penumbra into infarct core and that this 
process is complete at 24 hours or later post-MCAO. This aids to reinforce the dynamic 
nature of the penumbra and that the life-span of this tissue is finite. 
 
Despite the ability of PET to provide quantitative measurements of cerebral blood flow and 
oxygen metabolism, there are a variety of factors which limit its use, both clinically and 
experimentally. Primarily, the availability of PET has been hampered by its expense and 
the fact that it requires experienced chemists to synthesise short half-life radioisotopes, in 
addition to physicists and radiographers who run the scans. Furthermore, it is limited in the 
clinical setting due to the necessity to cannulate arteries for arterial blood sampling to 
allow quantitative measurements of cerebral blood flow. This invasive procedure and the 
need for exposure to radioisotopes therefore limits the clinical use of this imaging  
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Figure 1-14. Identification of the ischaemic penumbra using positron emission tomography. 
18 
F-fluromisonidazole (FMISO) PET scan was performed 7 hours after stroke onset, where a 
significant volume of penumbral tissue surrounds the infarct core. The yellow outline denotes the 
final infarct as defined by CT 7 days post stroke onset, indicating penumbral tissue which has been 
incorporated into the infarct. Adapted from Ebinger et al (2009). 
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modality.  The cost of PET is also a major limiting factor in experimental stroke research 
in addition to the poor resolution in small rodent brains and as a consequence, MRI is more 
widely utilised to image the penumbra in this setting.  
 
1.3.4 Perfusion Computed Tomography 
 
Computed tomography (CT) is one of the most readily available imaging modalities and is 
becoming increasingly utilised in the clinical identification of the penumbra in acute stroke 
patients. Perfusion CT in particular can help to predict the fate of ischaemic tissue (Ebinger 
et al, 2009). This technique involves the intravenous injection of an iodinated contrast 
agent and the bolus is tracked through the cerebral circulation. Parametric maps of cerebral 
blood volume (CBV), cerebral blood flow (CBF) and mean transit time (MTT) can be 
generated and quantified using post-processing software (Figure 1-15). However, there can 
be qualitative differences in the software used and currently there is a lack of agreement 
with regards to quantification of the perfusion CT parameters (Ebinger et al, 2009). 
In the ischaemic penumbra, tissue perfusion is reduced leading to vasodilatation and 
recruitment of collaterals in an attempt to restore cerebral blood flow. This results in an 
increased cerebral blood volume in the penumbra, compared to the infarct core, where 
severe hypoperfusion induces loss of the ability to autoregulate and as a consequence, 
cerebral blood volume falls. Following a systematic evaluation of 130 acute stroke 
patients, Wintermark et al (2006) reported that the infarct core is most accurately described 
by absolute CBV, with an optimal threshold of ≤2ml/100g. The parameter which optimally 
defines the penumbra is the relative MTT, where the threshold for this parameter is ≥145% 
of the contralateral tissue MTT (Wintermark et al, 2006).  
 
Earlier clinical perfusion CT studies used absolute CBF thresholds or combined CBF and 
CBV thresholds to identify the ischaemic penumbra. However, as discussed by 
Wintermark et al (2006), these were small pilot studies, each with less than 23 acute stroke 
patients. Furthermore, these studies defined the penumbra using parameters where the 
thresholds were arbitrarily selected. 
 
In addition, the ability of this technique to define the ischaemic penumbra has been 
assessed against MR measurements of perfusion-diffusion mismatch, with a significant 
correlation (r
2 
=0.81, P<0.001) between the two imaging modalities (Schaefer et al, 2008). 
Despite these results, perfusion CT has yet to be sufficiently validated for the identification 
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Figure 1-15. Identification of the penumbra by perfusion CT. The patient was imaged with 
multimodal CT at 3.5 hours after stroke onset with National Institute of Health Stroke Scale 
(NIHSS) of 14. Vessel occlusion was demonstrated by CT angiography (CTA, bottom left). A small 
area of reduced cerebral blood volume (CBV) was apparent in the lentiform nucleus and deep 
white matter but surrounded by much larger areas of reduced cerebral blood flow (CBF)/prolonged 
mean transit time (MTT) consistent with the ischaemic penumbra. Minimal change was detected by 
non-contrast CT (NCCT). The patient was treated with intravenous thrombolysis and had major 
early improvement of neurological symptoms. Magnetic resonance angiography (MRA) indicated 
complete recanalization (lower right) and only a small volume of tissue infarction on the follow-up 
diffusion weighted images (DWI). Reproduced from Ebinger et al (2009). 
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of the ischaemic penumbra and standardisation of the perfusion CT definitions for core and 
penumbral tissue has not yet been performed. However, when this technique has been 
extensively validated it is likely to become one of the most widely used imaging modalities 
to approximate the ischaemic penumbra and identify those acute stroke patients who are 
most likely to benefit from tissue salvage therapies. At present, some stroke centres are 
using a multi-modal CT approach to identify patients who are potentially eligible for 
thrombolytic therapy, using perfusion CT in combination with CT angiography and non-
contrast CT, which detects isolated focal swelling associated with tissue at risk of 
infarction (Wintermark et al, 2006). 
 
1.3.5 Magnetic Resonance Imaging 
 
Nuclear magnetic resonance analysis is used to determine the presence and concentration 
of certain atomic nuclei within a sample. In MRI, hydrogen atoms are the nuclei of choice 
in medical imaging since they are the most abundant nuclei in the body. Each hydrogen 
nucleus consists of a single positively charged proton. The proton behaves like a small 
magnet since it continually spins and has an electrical charge. This also means that protons 
can be influenced by external magnetic fields. Under normal conditions, these protons spin 
with their axes pointing in random directions. However, in the presence of an external 
magnetic field, a proportion of hydrogen nuclei will align in parallel to the external 
magnetic field. In order to record the magnetic resonance signal, protons are excited from a 
low to a high energy state, by exposure to electromagnetic radiation of radio frequency 
(RF). Excitation of protons causes them to spin with their axes pointing in the opposite 
direction. This alters their magnetic effect and the resulting deflection in the angle of the 
magnetization vector can be recorded. In MRI, the magnetization vector is deflected by 90
o 
or 180
o 
by exposure to precise radio frequencies, called the 90
o 
RF pulse and 180
o 
RF 
pulse, respectively. 
 
Following excitation of protons and subsequent deflection of the magnetization vector, the 
time taken for the magnetic resonance (MR) signal to fade is measured, as the protons 
return to a low energy state and magnetic equilibrium is regained. This parameter is termed 
the relaxation time. The return to equilibrium results from two independent processes 
called spin-lattice interaction and spin-spin interaction. Spin-lattice relaxation, or T1 
relaxation as it is otherwise known, involves the dissipation of energy from the excited 
nuclei to their surroundings in order to return to steady state. This time constant, T1, is 
dependent on the strength of the external magnetic field, where the greater the magnetic 
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field strength, the longer it takes for excited nuclei to return to steady state. Spin-spin 
interaction results in transverse relaxation. This process involves the interaction of adjacent 
nuclear spins. The MR signal fades as the magnetic fields of adjacent nuclei interfere with 
each other. The time constant for transverse relaxation is known as T2. Unlike T1 
relaxation, T2 relaxation time is independent of magnetic field strength. Furthermore, 
despite T1 and T2 relaxation being completely independent processes, they occur almost 
simultaneously. 
 
The MR image is constructed from the MR signal and there are three factors which 
influence the contrast of the image by determining how bright the image appears. Firstly, 
the proton density of the biological tissue determines the maximum signal which can be 
obtained. MR images in which contrast is determined mainly by proton density are called 
proton density-weighted images. The T1 relaxation time of the tissue also has an affect on 
image contrast and those images where contrast is determined mainly by T1 are called T1-
weighted images. Similarly, T2-weighted images are produced when T2 relaxation time is 
used to determine image contrast. 
 
Magnetic resonance imaging techniques have also allowed the penumbra to be identified, 
by the use of diffusion and perfusion weighted imaging. The logistics of magnetic 
resonance imaging are less complex than PET and are therefore more widely available in 
both the clinic and the laboratory. 
 
Diffusion Weighted Imaging (DWI) 
 
The production of diffusion-weighted images display signal changes which are dependent 
on the diffusion of water protons in biological tissues. The diffusion of water protons is 
quantified by the diffusion constant, which varies with the direction of movement. In an 
isotropic medium, water molecules move randomly in all directions, according to 
Brownian motion. However, in biological tissues, diffusion may be impeded by natural 
barriers like cell membranes and protein structures, resulting in anisotropic diffusion. For 
example, in axons, protons will tend to travel along the axis of the fibre due to the barrier 
presented by the myelin sheath. This results in a greater diffusion constant along the 
longitudinal axis of the axon, compared to that of the perpendicular axis, across the myelin 
sheath. The degree of signal loss on the diffusion-weighted image increases with the 
diffusion constant. Therefore tissue areas with restricted diffusion will have greater signal 
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intensity than those tissues where diffusion is normal and signal loss is greater. DWI can 
therefore be used to obtain a quantitative measure relating to diffusion within a voxel.    
In biological tissues, the diffusion constants can be measured and are represented by the 
apparent diffusion coefficient (ADC), which can then be used to construct ADC maps. 
Tissue areas where diffusion is restricted will appear dark on an ADC map due to the 
reduced value of the diffusion constant. Compare this to the diffusion-weighted image, 
where the same area of tissue will appear bright due to increased signal intensity, resulting 
from reduced mobility of water protons. 
In acute stroke, diffusion of water molecules becomes restricted as a result of cytotoxic 
oedema following ischaemic injury (Moseley et al, 1990a). Diffusion of water molecules is 
reduced by the redistribution of water from the extracellular to the intracellular space and 
increased tortuosity or viscosity as failure of the Na
+
/K
+
 pump ensues (Abe et al, 2003). 
The reduction in ADC produces a hyperintense signal on diffusion-weighted images, 
identifying the bright region of ischaemic tissue damage within the first 6 hours of stroke 
onset (Moseley at al, 1990a). This timescale gives DWI a great advantage over 
conventional MRI techniques. 
 
In animal models of stroke, DWI can be used to identify ischaemic damage within minutes 
of MCA occlusion (Moseley et al, 1990b; Hoehn-Berlage et al, 1995). Similarly, in human 
stroke patients, this imaging technique has been used to detect ischaemic lesions less than 
40min following stroke onset (Yoneda et al, 1999). If the stroke patient is untreated, the 
diffusion lesion will expand over time and follows a relatively consistent pattern of growth  
during the first 3 days after stroke onset and will then decrease in size up to day 7 (Baird et 
al, 1997; Beaulieu et al, 1999; Lansberg et al, 2001). This is reflected in the changes in 
ADC which occur following stroke. As the ischaemic lesion evolves over the first 24h 
post-stroke, the ADC will decrease further and the lesion will appear brighter on diffusion 
weighted images. In the subacute and chronic phases of stroke, the ADC will start to return 
to normal. However, since the tissue is infarcted and can never recover, this process is 
termed „pseudonormalization‟. Later in the chronic phase (>7 days from stroke onset), 
ADC will further increase (Warach et al, 1995). This allows acute and chronic stroke to be 
confidently distinguished using DWI. This is in contrast to T2 weighted imaging, where 
similar signal intensity is displayed by the infarct in both the subacute and chronic stages 
of stroke. 
 
However, areas of hyperintense signalling on DWI are not always associated with low 
ADC values, since T2 also has an effect on signal intensity and in some cases the effect of  
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Figure 1-16. MR images produced 3 hours following stroke onset in a 75 year old female 
patient. In the acute phase of stroke, there is no evidence of abnormal signal intensity in the T2-
weighted image (A). However, examination of the diffusion weighted image (B) reveals a 
hyperintense lesion in the left caudate body and corona radiata (red arrow). Adapted from Abe  
et al (2003). 
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an elongated T2 can result in hyperintense signalling, even when diffusion is normal or 
increased. This effect is called T2 shine-through and can be reduced by increasing the 
amount of diffusion-weighting. Furthermore, hyperintense signalling on diffusion-
weighted images may also be attributable to a previous stroke or susceptibility artefacts 
(Baird & Warach, 1998). Therefore, DWI should always be examined alongside the 
appropriate T2 image and/or the calculated ADC map to assess the extent and severity of 
ischaemic injury and identify brain tissue which is likely to proceed to infarction (Figure 1-
16). 
 
Perfusion Imaging 
 
 
Brain blood flow can be evaluated by MR perfusion imaging techniques. These techniques 
can provide quantitative assessment of tissue perfusion regardless of whether the blood is 
delivered by the main artery supplying the brain territory, or by collaterals. This type of 
imaging is dependent on signal changes that are induced by an exogenous or endogenous 
tracer and there are two techniques which are commonly utilised in clinical and preclinical 
research: contrast agent bolus tracking and arterial spin labelling. 
 
Contrast Agent Bolus Tracking 
 
Contrast agent bolus tracking is the most commonly utilised perfusion imaging technique 
and it involves the intravenous introduction of gadolinium-based contrast agents into the 
circulation. These contrast agents are paramagnetic and therefore result in magnetic 
inhomogeneity when administered into the bloodstream. This increases magnetic 
susceptibility and reduces T2 relaxation time, resulting in decreased signal intensity as the 
agent passes through blood vessels. Homogeneity of the magnetic field is restored as the 
contrast disappears from the detection plane and the intensity of the signal returns to 
normal. This allows the contrast agent to be tracked throughout the cerebral circulation. 
This type of imaging is commonly performed using T2
*
-weighted 2D or 3D echo planar 
sequences, which allow fast image acquisition, where a new image can be produced every 
second (Weishaupt et al, 2006). 
 
A time-intensity curve can be constructed from the changes in signal intensity as the 
contrast agent passes through the circulation. The amount of signal loss is proportional to 
the concentration of the contrast agent and in healthy brain tissue, is directly proportional 
to cerebral blood volume (CBV) (Belliveau et al, 1990). From the curve, the time to peak 
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(TTP) is the time from the start of the scan to the point where signal intensity is maximal. 
The mean transit time (MTT) is the time taken for the contrast bolus to pass from the 
arterial cerebral circulation to the venous side. 
 
 In healthy humans, to calculate CBF and MTT, an estimate of arterial input function is 
required. Where the blood-brain barrier is disrupted, both cerebral blood volume and blood 
flow are represented by changes in signal intensity (Edelman et al, 1990) and the latter part 
of the time-intensity curve can be examined to estimate the permeability of the blood-brain 
barrier. However, in acute stroke patients, blood-brain barrier permeability is likely to be 
small, since disruption of the BBB does not predominantly occur until 24 hours following 
stroke onset (Baird & Warach, 1998). Following acute ischaemic stroke, this technique 
reveals well demarcated reductions in cerebral blood flow (Fisher et al, 1995). 
 
Arterial Spin Labelling 
 
Cerebral blood flow can also be assessed using perfusion imaging techniques which use 
blood itself as a tracer, rather than gadolinium based contrast agents, as previously 
described. This technique allows MR imaging of blood flow by spin labelling of water 
protons in an artery supplying the anatomical area of interest. It involves inversion of the 
longitudinal magnetization of the arterial blood and a decrease in signal is produced as the 
labelled blood reaches its target anatomy before relaxation of its magnetization. However, 
the decrease in signal is too small to be viewed directly and therefore in order to view the 
contrast, two image sets are used to highlight the contrast by image subtraction, where one 
image set shows inversion of inflowing water protons in the blood and the other does not 
(Weishaupt et al, 2006).  
 
Arterial spin labelling has been widely used in animal models to quantify the perfusion 
deficit following experimental stroke in rodent models (Shen et al, 2003; McCabe et al, 
2009; Foley et al, 2010) and is advantageous over other perfusion imaging techniques in 
that it is non-invasive, can be repeated to assess temporal changes in CBF and does not 
require administration of an exogenous tracer into the circulation. It also provides a more 
direct assessment of cerebral blood flow and can generate absolute blood flow 
quantification (Baird & Warach, 1998). However, this technique is less widely used than 
contrast agent bolus tracking because it is relatively more difficult to perform (Duong & 
Fisher, 2007) 
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1.3.6 MRI Perfusion-Diffusion Mismatch 
 
The use of DWI and PWI in stroke neuroimaging led to the emergence of a new concept 
for defining the ischaemic penumbra using MRI. The perfusion-diffusion mismatch model 
was constructed to identify potentially salvageable penumbral tissue following stroke. The 
mismatch model arose from observations that diffusion lesions expand over t ime to 
encompass the region of PWI defined perfusion deficit in the absence of early reperfusion 
(Baird et al, 1997). According to the model, the DWI lesion represents the ischaemic core, 
where severely hypoperfused brain tissue is experiencing bioenergetic failure and becomes 
irreversibly damaged. PWI reveals hypoperfused tissue and the mismatch between the PWI 
and the DWI lesions provides an approximation of the ischaemic penumbra, which 
represents tissue which is hypoperfused but is not yet experiencing bioenergetic failure 
(Schlaug et al, 1999, Figure 1-17). As time progresses, mismatch tissue will reduce as the 
diffusion lesion expands and penumbral tissue becomes incorporated into the ischaemic 
core. 
 
Clinical Use of Perfusion-Diffusion Mismatch 
 
The perfusion-diffusion mismatch model has been widely used in clinical research to 
define the ischaemic penumbra (Figure 1-18). Darby and colleagues demonstrated that 
despite the presence and volume of mismatch decreasing over time, up to 70% of patients  
will display substantial regions of mismatch up to 24 hours following stroke onset (Darby 
et al, 1999).  
 
The mismatch model has been used in clinical trials to assess the efficacy of thrombolytic 
therapy. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS) was the first phase II  
clinical trial which employed the perfusion-diffusion mismatch model as a criterion for 
selecting patients suitable for thrombolytic therapy. All stroke patients recruited into the 
trial showed evidence of a perfusion-diffusion mismatch of ≥20% of perfusion deficit and 
those patients who received intravenous desmoteplase within 9 hours of stroke onset 
demonstrated a higher rate of reperfusion and improved clinical outcome compared to 
placebo treated patients (Hacke et al, 2005). A phase III trial was then undertaken to 
confirm the findings of DIAS but unfortunately the results were negative (Hacke et al, 
2009). The DIAS-2 study reported no improvement in clinical outcome with administration 
of desmoteplase 3-9 hours following stroke onset. In this trial however, patients were  
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Figure 1-17. The Perfusion-Diffusion Mismatch Model.  The diffusion abnormality represents 
the irreversibly damaged ischaemic core and the perfusion abnormality represents hypoperfused 
tissue. The mismatch between the diffusion and perfusion abnormalities provides an approximation 
of the ischaemic penumbra. Reproduced from Kidwell et al (2003). 
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Figure 1-18. Identification of the penumbra in a stroke patient by magnetic resonance 
imaging. The arrow denotes the acute diffusion weighted imaging (DWI) lesion (left image). The 
area in red signifies the perfusion deficit (centre) and the penumbra as defined by diffusion-
perfusion mismatch (right). Reproduced from Ebinger et al (2009). 
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selected by the presence of penumbra as determined by perfusion-diffusion mismatch or by 
perfusion CT and the pooling of these data may not be appropriate since the authors 
reported inconsistencies between MRI and CT. 
 
The DIAS trial was followed by the Diffusion and Perfusion Imaging Evaluation for 
Understanding Stroke Evolution (DEFUSE) Study, which sought to validate the use of 
perfusion-diffusion mismatch to identify those patients who were likely to benefit from 
thrombolytic therapy administered 3-6 hours following stroke onset (Albers et al, 2006). 
Patients were categorised into „mismatch‟ and „no mismatch‟ groups, where the mismatch 
profile was defined as a PWI lesion which was greater than 10ml and at least 120% of the 
DWI lesion. In cases where the PWI lesion was less than 120% of the DWI lesion patients 
were assigned to the „no mismatch‟ group. Patients with the „no mismatch‟ profile did not 
appear to benefit from early reperfusion with rtPA. However, patients who were identified 
as having the target mismatch profile demonstrated a significantly improved clinical 
outcome following early reperfusion. This study indicates that the perfusion-diffusion 
mismatch model is a useful tool for identifying potentially salvageable tissue in acute 
stroke.  
 
Similar observations were reported from the Echoplanar Imaging Thrombolytic Evaluation 
Trial (EPITHET), where patients who received thrombolytic therapy within 3-6 hours of 
stroke onset demonstrated reduced infarct growth and increased reperfusion when there 
was evidence of mismatch tissue. Increased reperfusion was also associated with an 
improved functional outcome (Davis et al, 2008). However, this study differs from the 
earlier DEFUSE study as the presence of mismatch was not used for patient selection as 
the sample size was small and the authors were keen  to include patients who did not show 
evidence of mismatch tissue for the purpose of exploratory analysis.  
 
The DIAS, DEFUSE, and EPITHET trials have demonstrated that the perfusion-diffusion 
mismatch model can be successfully used to identify patients who are likely to benefit 
from thrombolytic therapy and demonstrate an improved clinical outcome following  
stroke. The mismatch model can be used to identify groups of stroke patients with similar 
lesion size and location to improve the characterization of therapeutic efficacy (or 
inefficacy) in clinical trials (Baird & Warach, 1998). 
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Perfusion-Diffusion Mismatch in Experimental Stroke Models 
 
The perfusion-diffusion mismatch model has been used in animal stroke models to assess 
the temporal evolution of the ischaemic penumbra but the use of the mismatch model to 
assess potential neuroprotective strategies in experimental stroke models is notably 
lacking. In animal models, the mismatch model could be used to evaluate the potential 
therapeutic window of interventions to salvage penumbra following stroke. 
 
Meng and colleagues (2004) defined the temporal evolution of the penumbra in Sprague-
Dawley rats following permanent or transient MCAO using perfusion-diffusion mismatch. 
These authors reported that following permanent MCAO, the diffusion lesion expands to 
encompass the larger perfusion deficit and as a consequence, the volume of penumbra, as 
defined by the mismatch model, decreases over time. By 2-3 hours post-MCAO the 
diffusion lesion has fully evolved and no penumbral tissue remains. This suggests that in 
Sprague-Dawley rats, there may be a narrow time window for penumbra salvage.  
 
In a transient stroke model, perfusion-diffusion mismatch was used to evaluate the effect of 
reperfusion following 60 minutes of ischaemia in Sprague-Dawley rats (Meng et al, 2004). 
The authors observed that the diffusion lesion at 3 hours post-MCAO and 2,3,5-
triphenyltetrazolium chloride (TTC) infarct volume at 24 hours post-MCAO were 
significantly smaller than those observed following permanent MCAO, indicating that 
early reperfusion had successfully salvaged penumbral tissue. 
The same study group also used perfusion-diffusion mismatch to assess the temporal 
evolution of ischaemic injury in Wistar rats following permanent MCAO (Bardutzky et al, 
2005a). It was reported that 90 minutes post-MCAO, Wistar rats demonstrated a mismatch 
volume which was significantly larger than that observed in Sprague-Dawley rats at the 
same time point. Recently, Foley and colleagues (2010) defined quantitative temporal 
profiles of penumbra in Sprague-Dawley rats using dual parameter voxel analysis. All 
voxels which had normal ADC values but an abnormal CBF value were defined as 
penumbra. This method revealed that penumbra persisted even after 4 hours following 
MCAO, which conflicts with previous reports in the Sprague-Dawley strain (Shen et al, 
2003; Meng et al, 2004). 
 
The perfusion-diffusion mismatch model has also been used to assess penumbral tissue in 
rat models with genetic stroke risk factors. McCabe and colleagues reported that mismatch 
area was reduced in the spontaneously hypertensive stroke-prone rat (SHRSP) compared to 
 57 
the normotensive control, Wistar-Kyoto (WKY) (McCabe et al, 2009). Similarly, 
Letourneur and colleagues reported a reduced perfusion-diffusion mismatch in 
spontaneously hypertensive rats (SHR) compared to WKY rats following permanent focal 
ischaemia (Letourneur et al, 2011). These studies illustrate how the mismatch model can 
be used to assess differences in the temporal evolution of perfusion-diffusion mismatch 
between rat strains. 
 
The potential use of the mismatch model to assess neuroprotective strategies has not been 
widely investigated in experimental stroke. Bardutzky and colleagues (2005b) evaluated 
the neuroprotective effects of dimethylsulphoxide (DMSO) in a rodent permanent stroke 
model and reported that administration of 33% DMSO at 60 minutes post-MCAO 
preserved the mismatch region and therefore salvaged penumbra and prevented it from 
proceeding to infarction. The efficacy of normobaric hyperoxia has also been evaluated in 
rat stroke models using perfusion-diffusion mismatch as an outcome measure. Kim and 
colleagues (2005) reported that normobaric hyperoxia initiated at 30 minutes following 
permanent MCAO, reduced the growth of the diffusion lesion and therefore preserved the 
lifespan of the penumbra. However, the treatment effect was only observed during 
treatment and the neuroprotective effect is lost when treatment stops.  
 
Preservation of the perfusion-diffusion mismatch has also been examined in rodent models 
with genetic risk factors. It has been reported that Sprague-Dawley rats display a 
significant mismatch which is maintained until 150 minutes post-MCAO and 
administration of a selective endothelin receptor antagonist successfully reduced 
progression to infarction (Legos et al, 2008). However, the authors reported that there was 
little evidence of mismatch in SHR rats from as early as 60 minutes post-MCAO and 
consequently, administration of endothelin receptor antagonist had no protective effect and 
did not reduce infarct volume. These studies illustrate how perfusion-diffusion mismatch 
can be used in animal models of stroke to evaluate potential neuroprotective strategies but 
at present, there is a notable lack of such investigations in the pre-clinical literature.  
 
1.3.7 Challenges to the Mismatch Model 
 
Despite the widespread use of the diffusion-perfusion mismatch model in both 
experimental and clinical stroke studies, its definition of the penumbra has been widely 
challenged by various study groups. The first challenge to the model is the inability of 
perfusion imaging to distinguish between the penumbra and tissue which is experiencing 
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benign oligaemia. Although this region of tissue displays a perfusion deficit, it functions 
normally and is not at risk of infarction. Therefore perfusion weighted images are likely to 
overestimate the outer boundary of the penumbra. This problem has been addressed by 
several groups by studying the evolution of the diffusion and perfusion abnormalities in 
untreated patients. This allows identification of the penumbra, as tissue which proceeds to 
infarction and areas of benign oligaemia, which does not become part of the infarct. These 
studies allowed a range of ADC and perfusion thresholds to be identified, designed to 
differentiate between penumbra and benign oligaemia (Kidwell et al, 2003). 
 
In addition, the mismatch model has been challenged for the apparently clear distinction 
between the penumbra and ischaemic core tissue. The model assumes that the initial 
diffusion abnormality represents tissue which is irreversibly damaged and cannot be 
salvaged even if reperfused. However, animal models have shown that the diffusion lesion 
can be partially or fully reversed if reperfused within 3 hours (Kidwell et al, 2003). This 
has also been demonstrated to occur in human stroke patients following intra-arterial 
thrombolytic therapy, although some tissue redevelops diffusion abnormalities as late  
secondary injury (Kidwell et al, 2002). These findings are significant as they demonstrate 
that patients who do not show evidence of diffusion-perfusion mismatch may still benefit 
from thrombolytic therapy. These findings have led to the construction of a modified 
perfusion-diffusion mismatch model (Figure 1-19). 
 
Furthermore, it has recently been reported that penumbra as defined by perfusion-diffusion 
mismatch does not reliably reflect the PET defined penumbra (Zaro-Weber et al, 2009). 
Areas of mismatch were compared with areas of increased OEF. All of the 13 stroke 
patients examined in the study demonstrated areas of mismatch but only 8 of those patients 
showed evidence of penumbra as defined by OEF elevation using PET. However, the 
mismatch model could potentially be improved by refining the perfusion and diffusion 
thresholds which are used to define tissue at risk of infarction by distinguishing the 
penumbra from the ischaemic core and benign oligaemic tissue. 
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Figure 1-19. The current concept of the ischaemic penumbra.  This model recognises that 
tissue within the diffusion abnormality is not necessarily irreversibly damaged and may recover with 
early reperfusion. It also recognises the perfusion abnormality may include benign oligaemic tissue 
which is not at risk of infarction. The arrow shows penumbral tissue which is at risk of infarction but 
is potentially salvageable with adequate reperfusion. In this model the penumbra includes a 
component of the diffusion abnormality in addition to the perfusion abnormality, with the exclusion 
of benign oligaemic tissue. Reproduced from Davis & Donnan (2004). 
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1.4 Aims of the Thesis 
 
The aims of the first study were to define strain-specific MRI perfusion and diffusion 
thresholds in the SHRSP and WKY rat. These thresholds would then be applied to 
quantitative perfusion and diffusion MRI data acquired in the acute phase following 
experimental stroke to allow the temporal evolution of ischaemic injury and perfusion 
deficit to be assessed and compared between the strains. The acute MRI data would then be 
used to assess and compare three different methods of calculating penumbra volume to 
evaluate the strengths and limitations of each method. Each calculation method would be 
used to compare the extent and lifespan of the ischaemic penumbra following permanent 
MCAO in SHRSP and WKY rats.  
 
The aim of the second study was to evaluate the neuroprotective efficacy of the NADPH 
oxidase inhibitor, apocynin, in rodent stroke models. First, the effects of apocynin 
treatment on stroke outcome following permanent MCAO would be assessed. Apocynin 
treatment would then be evaluated in a model of transient ischaemia. Finally, the effect of 
apocynin treatment on the acute evolution of the ischaemic penumbra would be assessed in 
a rat model with stroke co-morbidities (SHRSP) using the MRI perfusion-diffusion 
mismatch model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 2. 
Methods 
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2.1 Animal and Surgical Procedures 
 
2.1.1 Animal Preparation 
 
All animal procedures were performed under licence from the UK Home Office (Personal 
Licence number 60/11949, working under Project Licence numbers 60/3759 and 60/3618) 
and in accordance with the Animals (Scientific Procedures) Act, 1986. Prior to surgery, all 
animals were housed in groups with water and food freely available and were kept on a 12 
hour light/dark cycle. All surgical procedures were performed by Emma Reid. 
 
On the day of surgery, rats were weighed following transfer from the animal housing unit 
to the operating theatre. Anaesthesia was initially induced in an anaesthestic gas chamber, 
where 5% isofluorane (Baxter Healthcare Ltd, UK) was administered in a 30%/70% 
mixture of oxygen and nitrous oxide, respectively. Depth of anaesthesia was assessed by 
means of the withdrawal reflex, where the footpad of the hindlimb is tightly squeezed to 
evoke a reflex withdrawal of the foot. If this reflex absent then the animal is deep enough 
to proceed with surgery. This reflex was assessed at regular intervals during surgical 
procedures to establish if the anaesthetic dose needed to be adjusted.  
 
Once deeply anaesthetised the rat was removed from the chamber and was artificially 
ventilated following tracheal intubation or tracheotomy. In experiments where animals 
were not allowed to recover following surgery, a surgical tracheotomy was performed. 
Following removal from the anaesthetic chamber, the rat was transferred to a face mask 
where the dose of isofluorane was reduced to between 2% and 3% in the same gas mixture 
stated previously, to maintain surgical anaesthesia. The animal was positioned on its back 
and hair was shaved from the neck using an electrical shaver (Wahl, UK). A tracheotomy 
was then performed to allow artificial ventilation of the animal and removal of the face 
mask. An incision was made in the neck using large scissors and the underlying 
musculature was split by blunt dissection to expose the trachea. Two ligatures of 2-0 thread 
(Davis & Geck, UK) were loosely tied around the proximal and distal ends of the trachea, 
approximately 1-1.5cm apart. A small incision was then made in a ring of tracheal muscle 
equidistant between the ties using microscissors. The ventilation tube (Linton Instruments, 
UK) was then quickly inserted into the incision and advanced down the trachea towards the 
bronchi. Particular care was taken not to advance the tube more than 2cm distal to the 
incision site to prevent the tube from blocking off one of the bronchi. The ventilation tube 
was then connected to the ventilator (Ugo Basile, Linton Instuments, UK) where the stroke 
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volume was set to ~3ml at a frequency of 45 strokes per minute to maintain surgical 
anaesthesia and was secured by tightening the ligatures and tying them around the tube. 
The neck of the rat was stitched using 4-0 silk suture (Covidien, UK). 
 
 In experiments where the animal was allowed to recover following surgery, artificial 
ventilation was maintained by intubation, where the tube can be removed without trauma 
to the trachea. Following removal from the anaesthetic chamber, the rat was placed in an 
upright position against a cork board by hooking a loop of 2-0 thread, which was pinned to 
the top of the cork board, around the upper incisors to secure the position of the rat. The 
mouth was opened and the tongue was pulled to the side of the mouth using small forceps 
to allow the trachea to be observed. A fibre optic light (Meiji Techno) was shone onto the 
neck to gain a clear view of the vocal cords and trachea and a 16 gauge catheter 
(MillPledge Veterinary, UK) was then swiftly inserted. The intubation tube was then 
connected to the ventilator and anaesthetic dose was adjusted until breathing was steady 
and in time with the ventilator, where the stroke volume was set to 2.5-3ml with a stroke 
frequency of 60 strokes per minute. The anaesthetic dose was maintained via this method 
and the intubation tube was secured by stitching it to the side of the mouth using 4-0 silk 
suture to prevent it being pulled out during transfer of the rat to the MRI scanner. 
 
In all experiments, with the exception of the permanent stroke model in Chapter 5, 
cannulation of the right femoral artery was performed to allow continual monitoring of 
blood pressure. The right hindlimb and groin were shaved and an incision was made using 
large scissors. Blunt dissection of the underlying musculature was performed to expose the 
right femoral artery. The artery was then isolated from the femoral vein by blunt dissection 
using small curved and straight-edged forceps. Two ligatures (4-0 silk suture) were loosely 
tied at the proximal and distal ends of the artery, approximately 2cm apart. The ligatures 
were pulled tightly by using sticky tape to secure the ends of the ties to the cork board and 
a small incision was made into the artery using microscissors, equidistant between the two 
ligatures. The artery was then cannulated using a length (25cm) of PE-50 tubing (Portex, 
UK) which was advanced approximately 2-3cm along the vessel. The cannula was secured 
in place by tying 4-0 silk suture around the tubing and the artery. The cannula was then 
connected to a transducer which was linked to a computer, where physiological parameters 
including heart rate and mean arterial blood pressure were recorded (Biopac, 
Acqknowledge). Mean arterial blood pressure was maintained within the range of 85-
95mmHg in normotensive rats and was maintained within the range of 105-115mmHg in 
hypertensive rats. Body temperature was monitored with a rectal themal probe (Physitemp, 
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New Jersey, USA) and was maintained at 37±0.5
o 
C using an angle poise heat lamp. Care 
was taken to avoid burning the skin of the animal by placing a layer of gauze (Vernon-
Carus Ltd, UK) over the body.   
 
2.1.2 Focal Cerebral Ischaemia 
 
Permanent MCAO 
 
Occlusion of the middle cerebral artery was then performed according to the model first 
described by Koizumi et al (1986) with subsequent modifications (Longa et al, 1989). All 
surgery was performed under a light microscope (Zeiss, Germany). First, blunt dissection 
of the shaved tissue of the neck revealed the tracheal strap musculature, which was 
retracted to expose the common carotid artery. The surrounding connective tissue was 
dissected and the vessel was tied off using 4-0 silk thread. The external carotid artery was 
then identified and securely tied at an intermediate position between the ascending 
pharyngeal artery and the lingual and maxillary branches. The three branches of the 
external carotid where then subjected to cauterisation using diathermy forceps (Eschmann 
Equipment, UK). The external carotid artery itself was then cauterised above the tie and 
the three branches of this vessel were cut when it had been established that the vessels had 
been sealed off to prevent any bleeding. At this point the occipital artery, which runs 
alongside the internal carotid, was identified, cauterised and cut in the same manner as 
described previously. Any excess connective tissue was removed from the internal carotid 
artery and the vessel was subsequently tied loosely with 4-0 thread. Following this, the 
pterygopalatine artery was securely tied off to prevent the intraluminal thread from 
entering this vessel instead of following the course of the internal carotid artery (Figure 2-
1). 
 
In the stroke reproducibility study, described later in this chapter, the intraluminal thread 
was constructed from a length of 3-0 nylon monofilament (Covidien, UK) where a small 
diameter bulb was created using a cauterising pen (Aaron Medical, FL, USA). In all other 
experiments, a nylon filament with a silicon tip of length 5-6mm and of diameter 0.31-
0.35mm (Doccol Corporation, CA, USA) was used. The length of filament was then  
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Figure 2-1. A schematic diagram of the intraluminal thread model of middle cerebral artery 
occlusion. The external carotid artery is ligated and all branches are transected to allow the artery 
to be manipulated for ease of passage of the nylon monofilament. The pterygopalatine artery is 
ligated and the monofilament is introduced into the internal carotid artery by arteriotomy. The 
filament is advanced along the internal carotid until it lodges in the narrow proximal anterior 
cerebral artery, where it blocks the origin of the middle cerebral artery. This method of middle 
cerebral artery occlusion can be transient or permanent. Image reproduced from Hunter et al 
(1995). 
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measured and at the point of 22mm, a bend was introduced. This ensured that the filament 
would block the vessel at the proximal origin of the middle cerebral artery. 
 
The external carotid artery was then cut using microscissors resulting in an arterial stump 
which can be then be manipulated to aid the passage of the filament. The internal carotid 
tie can then be pulled tightly to limit blood loss as a small incision is made at the 
bifurcation point of the common carotid artery. The filament was then carefully advanced 
along the internal carotid artery until some resistance is felt, which should correspond to 
the point where only the bend of the filament is visible outwith the vessel. The internal 
carotid tie was then be tightened to secure the filament firmly in place. Furthermore, in 
permanent occlusion models the entry point of the filament was sealed using the diathermy 
forceps to further secure its position. The tissue of the animal was then sutured using 4-0 
thread to prevent infection and dehydration. 
 
Transient MCAO 
 
In the transient MCAO models, a modified version of the occlusion method was used 
instead of the technique described in detail previously. Animal recovery following surgery 
may be impinged as a result of difficultly in eating and drinking, as transection of the 
external carotid artery renders the muscles of mastication and swallowing ischaemic. This 
may lead to weight loss and increased mortality following surgery. In the transient stroke 
experiments, animals were allowed to recover for 72 hours following stroke and it was 
decided that to aid eating and improve recovery, a modified filament model would be used. 
This model preserves the integrity of the external carotid artery and its branches. Two 4-0 
thread ligatures were tied round the common carotid artery, one tied loosely at the carotid 
bifurcation and the other tied tightly approximately 1mm below the bifurcation. Loose 
ligatures were also tied around the external carotid, internal carotid and the pterygopalatine 
artery. A small incision was made between the two ligatures on the common carotid artery 
to allow insertion of the filament. All ligatures were pulled tightly at this point to limit 
blood loss. Once the filament had been advanced to block the origin of the middle cerebral 
artery, the pterygopalatine artery tie was removed and the other ties were secured to 
prevent blood loss and to secure the filament in place until it is removed after a fixed time 
period. In all transient MCAO experiments the filament was removed after 1 hour of 
ischemia. This was achieved by releasing the ligature around the internal carotid artery and 
the ligature at the common carotid artery bifurcation was also loosened. This allowed the 
filament to be retracted and subsequently removed. The incision point was then cauterised 
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using diathermy forceps and the external carotid ligature was removed, leaving only the 
common carotid tie in place. The wound was then flushed with sterile saline and stitched 
using 4-0 silk suture. 
 
2.1.3 Perfusion Fixation 
 
Animals were transcardially perfused with fixative to allow histological examination of the 
brain following stroke. Firstly, animals were deeply anaesthetised using 4-5% isofluorane 
delivered in a 30%/70% mixture of oxygen and nitrous oxide administered via a face mask 
to ensure the animal was deeply anaesthetised prior to opening up the chest cavity. An 
incision was made below the sternum and the skin overlying the chest was cut to expose 
the underlying musculature and the diaphragm, which were also incised. The ribcage was 
cut on both sides to allow the tissue of the chest to be retracted and clipped securely to 
expose the viscera of the chest cavity. The beating heart was then gently pulled down to 
allow detection of the aorta. A large needle which is connected to a flask of 0.9% saline 
containing heparin (10ml/Litre) and a flask containing 4% paraformaldehyde (PAM) was 
inserted into the left ventricle and advanced into the aorta. The heart was then clamped to 
secure the position of the needle and the right atrium was cut to allow blood to drain out of 
the heart. At this point, around 200-250 ml of heparinised saline was pumped through the 
circulation at a pressure of around 100mmHg to flush all of the blood out from the animal. 
Once the perfusate ran clear, indicating that all of the animal‟s blood had been flushed out, 
200ml of 4% PAM was then pumped through the circulatory system at the same pressure 
to fix the animal. Spontaneous limb movement was observed as the fixative travelled 
through the circulation, indicating successful fixation. 
 
2.2 Assessment of Final Infarct and Stroke Reproducibility 
 
2.2.1 Haematoxylin and Eosin Staining 
 
Following successful fixation, the animal was immediately decapitated and the entire head 
was stored in 4% PAM for 24 hours. The brain was then removed and post-fixed in 4% 
PAM for a further 24 hours before being embedded in paraffin wax. The embedding 
procedure was carried out in a paraffin processor (Miles Scientific) which undergoes many 
cycles of tissue dehydration and clearance, using alcohols and xylene respectively, before 
the brain is embedded in paraffin wax (Table 2-1). The entire procedure takes a total of 59 
hours to complete. The embedded brain was then cut into 6 micron thick sections of the 8  
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Stage Process Time Period (Hours) 
1 70% Alcohol 2 
2 80% Alcohol 3 
3 95% Alcohol 4 
4 Absolute Alcohol 1 4 
5 Absolute Alcohol 2 5 
6 Absolute Alcohol 3 5 
7 Absolute Alcohol 4 6 
8 50% Alcohol/50% Xylene 4 
9 Xylene 1 5 
10 Xylene 2 5 
11 Paraffin Wax 1 5 
12 Paraffin Wax 2 5 
13 Paraffin Wax 3 6 
 
 
Table 2-1. Paraffin wax processing schedule for rat brains. Following an extensive period of 
dehydration by alcohol immersion and tissue clearance using xylene, the brains are immersed in 
paraffin wax at 60
o 
C for a period of 16 hours. 
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Stage Process Time Period (minutes) 
1 Histoclear 1 4-5 
2 Histoclear 2 4-5 
3 Histoclear 3 4-5 
4 Absolute Alcohol 1 3 
5 Absolute Alcohol 2 3 
6 90% Alcohol 3 
7 70% Alcohol 3 
8 Wash in running water 4 
9 Haematoxylin Staining 4-5 
10 Wash in running water 1-2 
11 Differentiate in Acid Alcohol A few dips only 
12 Wash in running water 3 
13 Scott’s Tap Water Substitute 2 
14 Wash in running water 2 
15 70% Alcohol 2 
16 90% Alcohol 2 
17 Alcoholic Eosin (95%) Staining 4 
18 Absolute Alcohol 1 4 
19 Absolute Alcohol 2 4 
20 Absolute Alcohol 3 4 
21 Histoclear 1 4 
22 Histoclear 2 4 
23 Histoclear 3 4 
 
 
Table 2-2. Haematoxylin and eosin staining procedure for paraffin embedded sections. 
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coronal levels (Osborne et al, 1987) using a microtome (Leica, UK) to allow determination 
of infarct volume following haematoxylin and eosin (H & E) staining. The sections were 
placed on poly-L- lysine coated slides and were left to dry overnight.  
 
The paraffin wax was removed from the sections by immersing them in histoclear 
(National Diagnostics, UK) and the sections were then immersed in a series of graded 
alcohols before haematoxylin (Surgipath, UK) staining was performed. Following a period 
of washing and differentiation in acid alcohol, the sections were again dehydrated before 
eosin (Surgipath, UK) staining took place (Table 2-2). Further dehydration was followed 
by immersion in histoclear prior to mounting the slides using DPX mounting medium 
(Raymond Lamb Laboratory Supplies). H & E staining can be used to detect 
histopathological changes following focal cerebral ischaemia. Haematoxylin stains 
basophilic structures blue and eosin stains eosinophilic structures bright pink. Thus, under 
the light microscope, the neuronal nuclei are stained blue and the surrounding cytoplasm 
and extracellular components appear pink. However ischaemic damage can be readily 
detected as ischaemic neuronal cell bodies become dark and shrunken and can be easily 
distinguished from healthy neurons. There are other clear signs of ischaemic damage 
including pallor of eosin staining and vacuolation of the neuropil. 
 
In order to assess infarct volume, 8 coronal levels spanning the territory of the middle 
cerebral artery (Osborne et al, 1987) were examined under a light microscope (Leica, UK) 
at a range of magnifications (x5, x10, and x20) to identify ischaemic neuronal damage.  
The cell soma of normal healthy neurons appears rounded with a clearly visible nucleus. 
However, ischaemic neurons become pyknotic in appearance, where they appear dark and 
shrunken into a triangular shape.  The surrounding neuropil also becomes sponge-like in 
appearance and demonstrates pallor of eosin staining (Figure 2-2). These attributes can be 
identified under the microscope and the areas of ischaemic damage can then be transcribed 
by hand onto line diagrams at pre-determined coronal levels (Osborne et al, 1987) (Figures 
2-3 & 2-4). This process is repeated 3 times for each animal on separate occasions to 
ensure reproducibility. The line diagrams are then scanned onto a computer and analysed 
using image analysis software, ImageJ (http://rsb.info.nih.gov/ij/). The area of ischaemic 
damage is directly measured on each coronal level. The total volume of damage is 
calculated by the integration of the areas and the distance between each level using the 
stereotaxic co-ordinates (Paxinos & Watson, 1998).  
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Figure 2-2.  Light microscopic images (x20) depicting representative H & E staining of the 
ipsilateral hemisphere of a rat following 4 hours permanent MCAO.  Image A shows normal, 
unaffected cortical tissue, where healthy neurons appear round and uniform. Image B depicts 
ischaemic tissue. Note the pallor of eosin staining of the neuropil and pyknotic neurons. Image C 
shows the border zone, where normal neurons appear alongside ischaemic neurons. Scale 
bars=25µm. 
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         Level 1: Bregma = 3.20mm                   Level 5: Bregma = -1.80mm 
                                            
 
         Level 2: Bregma = 1.20mm                    Level 6: Bregma = -3.14mm 
                                    
                        
         Level 3: Bregma = -0.26mm                   Level 7: Bregma = -4.80mm 
 
                                  
  
         Level 4: Bregma = -0.80mm                   Level 8: Bregma = -6.30mm 
 
                                 
 
 
 
Figure 2-3. The eight coronal levels defined by Osborne et al (1987). The figures are 
reproduced from the stereotaxic atlas of Paxinos & Watson (1998) with the distance from bregma 
defined at each level, where levels 1 and 2 are anterior to bregma and the remaining levels are 
found posteriorly. 
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                                    Level 1                         Level 5 
               
 
                                    Level 2                                               Level 6 
                                         
 
                                    Level 3                                              Level 7 
                                      
 
                                     Level 4                                            Level 8 
                                    
    
Figure 2-4. Line diagrams of the 8 coronal levels defined by Osborne et al (1987) with the 
area of ischaemic damage, as observed by light microscopic examination of H & E stained 
sections, manually traced onto the images (Paxinos & Watson, 1998). The images represent 
the ischaemic damage observed in the median animal of the H & E staining group in the stroke 
reproducibility study. 
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2.2.2 2,3,5-triphenyltetrazolium chloride (TTC) Staining 
 
TTC has been utilised for over 50 years to identify areas of ischaemic tissue damage. It is a 
water-soluble salt which in normal brain tissue is reduced by mitochondrial dehydrogenase 
enzymes to form a deep red, fat soluble compound called formazan. However, in ischaemic 
tissue, these mitochondrial enzyme systems are incapacitated and consequently, these 
tissue areas remain unstained (Figure 2-5). It is therefore, a rather crude yet reliable 
method used to delineate areas of ischaemic damage following middle cerebral artery 
occlusion. 
 
For TTC processing of the brain, the animal was deeply anaesthetised by using 5% 
isofluorane delivered in a 30%/70% mixture of oxygen and nitrous oxide before 
decapitation. The brain was then immediately removed from the skull and bathed in ice-
cold 0.9% saline. The brain was then placed in a rat brain matrix (World Precision 
Instruments, UK) and microtome blades (Feather, Japan) were positioned 2mm apart to cut 
6 coronal brain slices simultaneously. The slices were then incubated in a pre-warmed 
40ml solution of 1% TTC (Sigma, Switzerland) in phosphate buffered saline, for 15 
minutes at 37
o 
C. The brain sections were then removed from the TTC solution and 
allowed to incubate in PAM overnight. Following fixation, both faces of each brain slice 
were photographed using a digital video camera (Canon, UK) which was secured onto a 
stand (Kaiser, Germany) to keep the camera at the same height for all photographs. A 
graticule (Imaging Research Inc.) was used to determine scale for subsequent calibration. 
This allowed the infarct area of each slice to be determined by manually tracing the area of 
ischaemic damage using ImageJ software. The infarct area on both faces of each slice were 
added together and divided by 2 to give the mean infarct area for each slice. The total 
infarct volume was calculated by multiplying the sum of the infarct areas of each slice by 
the slice thickness (2mm). 
 
A stroke reproducibility study was undertaken to assess surgical ability to induce MCAO 
and also to compare final infarct volume at 4 hours post-MCAO using both haematoxylin 
& eosin and TTC staining methods. Permanent stroke was induced in 12 Sprague-Dawley 
rats (300-350g, Harlan, UK) by the intraluminal filament model, as described earlier in this 
chapter. Following 4 hours of MCAO, 6 animals were sacrificed by perfusion fixation to 
allow H & E staining of brain tissue and 6 animals were sacrificed for TTC staining. 
Infarct volumes were determined for both techniques and compared between the groups. 
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Figure 2-5. TTC staining of coronal brain slices following middle cerebral artery occlusion 
identifies area of ischaemic injury. The image on the left depicts the level of contrast observed 
when the staining is performed 4 hours post occlusion. Note that the delineation of the infarcted 
tissue is not as great as that observed when TTC staining is performed 24 hours following middle 
cerebral artery occlusion (right image). Both images depict coronal level three as defined by 
Osborne et al (1987). 
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Infarct volume as derived by TTC staining was significantly greater than infarct volume 
defined by histopathological examination of brain sections stained with H & E (Figure 2-
6). Despite this, within each staining group the calculated infarct volumes were consistent, 
indicating stroke reproducibility. However, one rat was excluded from the H & E staining 
group as microscopic examination revealed no evidence of ischaemic damage. The median 
infarct volume in the TTC staining group was 268mm
3
 compared to a median infarct 
volume of 121mm
3
 in the H & E group. The data were analysed using non-parametric 
statistical tests due to the skewed data in the TTC group, where two rats displayed 
particularly large infarcts. Statistical analysis using the non-parametric Mann-Whitney test, 
revealed that the two groups were significantly different at the 95% level of significance 
(P=0.0043). 
 
The ability of TTC staining to accurately identify cerebral infarction was examined by 
Bederson and colleagues (1986a). These authors reported that when the infarct was 
allowed to develop for 24 hours, there was no significant difference between the infarct 
volume determined by TTC staining or by H & E staining. However, when animals were 
sacrificed less than 6 hours post occlusion, it became more difficult to assess infarct 
volume via the TTC method, as the lesions are stained pink and it can be extremely 
difficult to delineate the borders of the lesion, since the contrast with the surrounding 
normal brain tissue is often very poor (Figure 2-5). By contrast, at the 24 hour time point, 
the infarct can be very clearly distinguished from brightly stained normal tissue. This was 
clearly evident in the stroke reproducibilty study, as there was no clear differentiation 
between normal and infarcted tissue after four hours of MCAO, thereby making it 
extremely difficult to demarcate the borders of ischaemic damage.  
 
The difficulty in distinguishing ischaemic from normal tissue in TTC stained brain slices 
may account for the significant overestimation of infarct volume demonstrated by this 
method, since the process of delineation is extremely subjective. However, the same can be 
said when transcribing areas of ischaemic damage onto line diagrams from H & E stained 
sections. It can be difficult to determine the boundaries of ischaemic tissue damage when 
there is evidence of a substantial border zone, where both ischaemic and normal neurons 
are identified. Since transcribing areas of ischaemic damage onto line diagrams corrects for 
brain swelling and prevents overestimation of infarct volume, it was considered that this 
may explain the larger infarct volumes demonstrated with the TTC staining method. 
However, when the hemispheric areas of TTC stained brain slices were examined, there  
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Figure 2-6. Comparison of the TTC and H & E staining methods for determination of infarct 
volume following 4 hours permanent MCAO in the Sprague-Dawley rat.  Infarct volume as 
determined by TTC staining (n=6) is significantly greater than infarct volume calculated by 
examination of H & E stained brain sections (n=5) *p=0.0043.  
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was no significant difference between the ipsilateral and contralateral hemispheres, 
indicating that there was no evidence of cerebral oedema. This result was as expected since 
brain oedema is not usually evident until at least 4 hours post ischaemia in permanent 
rodent stroke models (Tyson et al, 1982). 
 
Therefore, the results of the stroke reproducibility study indicate that in order to determine 
infarct volume following permanent MCAO of 4 hours duration, H & E staining of brain 
tissue should be the preferred method. Despite TTC determination of infarct volume being 
comparable to that observed by the H & E staining method following 24 hours of MCAO, 
at earlier time points there is no clear delineation between ischaemic and unaffected brain 
tissue. 
 
 
2.2.3 MRI RARE T2 Weighted Imaging 
 
In chapters 3, 4 and 5, infarct volume was determined using MRI RARE T2 weighted 
imaging. T2 weighted imaging can be reliably used to identify ischaemic brain tissue 12 to 
24 hours following stroke but during the critical period of 6-12 hours, this method does not 
adequately assess the severity and extent of ischaemia (Baird & Warach, 1998). In acute 
stroke, the changes in blood flow and tissue swelling which occur are associated with very 
subtle signal changes in T2 images. Areas of injured tissue produce higher signal intensity 
than normal brain tissue allowing the infarct to be clearly distinguished. 
 
All MRI data were acquired using a Bruker Biospec 7T/30cm system with a gradient coil 
(internal diameter=121mm, 400mT/m) and a 72mm birdcage resonator. MRI RARE T2 
weighted imaging was used to calculate infarct volume at 24 hours following permanent 
MCAO or at 72 hours following transient MCAO. Rats were anaesthetised in an 
anaesthetic chamber, as described previously, and were then immediately transferred to the 
MRI scanner, secured within the cradle by tooth and ear bars, to restrict head movement, 
and a 4-channel phased array surface receiver coil was placed on the head. Body 
temperature was maintained within physiological range (37±0.5
o
C) during the MRI 
scanning procedure by a closed circuit thermal jacket. 
 
Once a pilot sequence had been obtained to ensure correct geometry, a RARE T2 weighted 
sequence was acquired (TE=72.7ms, TR=5086.1ms, matrix=256x256, 16 coronal slices; 
0.75mm thick) to allow calculation of final infarct volume. 
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Final infarct was defined as the hyperintense area on T2 weighted images. The hyperintense 
area was manually delineated on each of the 16 T2 slices spanning the territory of the 
middle cerebral artery using Image J software (Figure 2-7). The area of the contralateral 
and ipsilateral hemisphere on each slice was also measured. The volumes of the 
contralateral and ipsilateral hemispheres and infarct volume were calculated by multiplying 
the total area across the 16 slices by the slice thickness (0.75mm). Total infarct volume 
was corrected for oedema using published equations which take compression of the 
contralateral hemisphere into account (Gerriets et al, 2004), in addition to swelling of the 
ipsilateral hemisphere (Swanson et al, 1990). 
 
For the calculation of infarct volume corrected for swelling of the ipsilateral hemisphere 
the following equation was used: 
 
 Corrected lesion = volume of contralateral   -  ( volume of ipsilateral – lesion volume) 
        volume                      hemisphere                         hemisphere 
 
 
A correction factor which accounts for compression of the contralateral hemisphere is 
calculated by the following equation: 
 
Compression Factor=(ipsilateral volume + contralateral volume)/(2 x contralateral volume) 
 
To calculate infarct volume which is corrected for both ipsilateral swelling and 
contralateral compression, the following equation was used: 
 
Infarct volume = corrected lesion volume x compression factor 
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Figure 2-7. MRI RARE T2 images from a representative SHRSP rat acquired at 24h following permanent occlusion of the middle cerebral artery. Row A shows 
6 coronal slices spanning the territory of the MCA. Infarcted tissue is clearly visible as the hyperintense area within the ipsilateral hemisphere. Note also the extensive 
swelling of the ipsilateral hemisphere and compression of the contralateral hemisphere. Image J software was used to delineate the infarcted tissue, as shown in red in 
row B. Infarct volume was calculated by multiplying the summation of infarct area across 16 coronal slices and multiplying by slice thickness. Infarct volume was 
corrected for both ipsilateral swelling and contralateral compression using published equations (Swanson et al, 1990; Gerriets et al, 2004).
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2.3 Behavioural Assessment 
 
2.3.1 Modified Bederson Scale 
 
In chapter 5, neurological function following stroke was assessed using a modified 
Bederson Scale. The original 4 point scale was developed by Bederson et al. (1986b) 
(Table 2-3a) and was used to grade stroke severity in rats following occlusion of the 
middle cerebral artery. The original Bederson scale has been modified and expanded by 
various study groups (Suzuki et al, 2004; Braeuninger et al, 2010 and others). The 
modified scale used in chapter 5 to assess functional outcome was a 6 point scale, where 
animals were assigned a grade of 0 to 5 (Table 2-3b). Animals were assessed by gently 
holding the base of the tail to suspend the rat in the air and the normal response is to extend 
both forelimbs. However, rats with infarction will consistently flex the forelimb 
contralateral to the ischaemic hemisphere. Rats which displayed no observable deficit and 
extended both forelimbs were scored a grade 0 and rats which exhibited flexion of the 
contralateral forelimb but no other deficits were scored a grade 1. Rats were then 
suspended by the base of the tail and allowed to grip the bars of their cage while being 
gently pulled away from the cage to assess grip strength. If any weakness of the 
contralateral forelimb was observed by the loss of grip, then the rat was scored a grade of 
2. Rats were then allowed to move freely on the floor to assess circling behaviour. Rats 
that consistently circled to the paretic side, in addition to forelimb flexion and reduced grip 
strength, were assigned a grade of 3. In more severe cases, animals which exhibited no 
spontaneous movement were given a grade of 4 and rats which died prior to functional 
testing were assigned a grade of 5.  
 
2.3.2 Vibrissae-evoked Forelimb Placement 
 
In addition to the modified Bederson Scale, functional outcome was also assessed by the 
vibrissae-evoked forelimb placement test. This test assesses sensorimotor function and 
proprioceptive capacity and is sensitive to damage to the striatum and sensorimotor cortex 
in addition to the spinal cord and other sensorimotor structures (Schallert et al, 2000). It 
assesses placement of the forelimb in response to detection of a table top by the vibrissae. 
When the vibrissae of either side are brushed against a table top, the normal response is the 
placement of both forelimbs on to the table top. In functionally impaired animals, there is a 
reduced capacity to place the affected forelimb.  
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A 
 
 
 
B 
 
Neurological Assessment Scale Observed Functional Deficits 
Grade 0 No observable deficit 
Grade 1 Flexion of the contralateral forelimb 
Grade 2 As grade 1 and with reduced grip 
strength of the contralateral forelimb 
Grade 3 As grade 2 and with consistent circling 
Grade 4 No spontaneous activity 
Grade 5 Dead 
 
 
Table 2-3. Neurological tests developed to assess function in rats following middle cerebral 
artery occlusion. Table A illustrates the original grading system devised by Bederson and 
colleagues. Reproduced from Bederson et al, (1986b). Table B shows the modified and extended 
neurological grading scale used to assess functional outcome in chapter 5. 
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In chapter 5, the vibrissae-evoked forelimb test was performed as described by Schallert et 
al (2000). All rats were handled frequently in the week prior to performing this test to  
ensure that they would not be stressed during the procedure. The test involved holding the 
rat loosely in the palm of the hand so that all four limbs were hanging freely. The rat is 
then moved laterally towards the table top and the vibrissae ipsilateral to the damaged 
hemisphere are gently brushed against the table top, whilst the contralateral forelimb is 
restrained by the forefinger so that only placement of the ipsilateral forelimb is assessed. 
This is repeated to assess the placement of the contralateral forelimb by restraining the 
ipsilateral forelimb and brushing the ipsilateral vibrissae against the table top. A successful 
placement is given a score of one. This is repeated ten times on each side to obtain a score 
out of ten for the number of successful placements achieved by the ipsilateral and 
contralateral forelimbs. Animals with unilateral brain damage will display varying degrees 
of impaired contralateral limb placing ability while the unaffected ipsilateral forelimb will 
typically show no evidence of impairment. The severity of brain injury can then be graded 
by calculating the percentage of unsuccessful contralateral placements (number of 
incorrect placements x 10).  
This test was performed prior to surgery to ensure that there was no evidence of functional 
impairment or limb preference before experimental stroke was induced. There was no 
evidence of limb preference or functional impairment in any of the rats tested prior to 
stroke surgery. 
 
2.3.3 18 point Neurological Score 
 
In addition to the modified Bederson Scale and the vibrissae-evoked forelimb placement 
test, an 18 point composite neurological score (Garcia et al, 1995) was used to assess 
functional outcome in rats where transient ischaemia was induced (Chapter 5). This score 
comprises 6 neurological tests which assess spontaneous activity, symmetry in limb 
movement, forepaw outstretching, climbing ability, body proprioception and response to 
vibrissae touch, with each test scored with a maximum of 3 points. The maximum score 
which can be achieved is 18, which indicates that there is no neurological deficit and the 
lowest score which can be achieved is 3, for animals with the most severe impairment 
(Table 2-4). 
 
 
 
 84 
 
 
 
 
Test Neurological Score 
 
0 1 2 3 
 
Spontaneous activity (in 
cage for 5 min) 
No movement Barely moves Moves but does not 
approach at least three 
sides of cage 
Moves and approaches 
at least three sides of 
cage 
Symmetry of movements 
(four limbs) 
Contralateral side: no 
movement 
Contralateral side: 
slight movement 
Contralateral side: moves 
slowly 
Both sides: move 
symmetrically 
Symmetry of forelimbs 
(outstretching while held 
by tail) 
Contralateral side: no 
movement, no 
outreaching 
Contralateral side: 
slight movement to 
outreach 
Contralateral side: moves 
and outreaches less than 
right side 
Symmetrical outreach 
Climbing wall of wire cage ... Fails to climb Contralateral side is weak Normal climbing 
Reaction to touch on 
either side of trunk 
... No response on 
contralateral side 
Weak response on 
contralateral side 
Symmetrical response 
Response to vibrissae 
touch 
... No response on  
contralateral side 
Weak response on 
contralateral side 
Symmetrical response 
 
 
 
Table 2-4. The 18 point composite neurological score to test functional outcome in rats following middle cerebral artery occlusion. This neurological 
evaluation comprises 6 tests which are each given a score up to 3. The scores for each test are added to given an overall score of functional outcome, where the 
maximum score of 18 indicates no observable deficit and the minimum score of 3 indicates severe neurological impairment. Adapted from Garcia et al (1995). 
 
1. Spontaneous Activity 
The rat was observed for a period of 5 minutes in its home cage with the cage top removed. 
 
The spontaneous activity of the rat was assessed by its ability to approach all four
 
walls of 
the cage and was scored from 0 to 3. A score of 3 indicates that the rat moved around the 
cage, explored the environment and approached at least three walls of the cage. A score of 
2 was given if the rat moved around in the cage but didn‟t approach all four walls, although 
it eventually reached at least one upper rim of the cage. A score of 1 indicates that the rat 
barely moved in the cage and didn‟t rise up on its hindlimbs to approach any of the cage 
walls and a score of 0 was given if the rat did not move at all during the observation 
period. 
 2. Symmetry in the Movement of Four Limbs 
Symmetry in the movement of the four limbs was assessed by suspending the rat in the air 
by holding the base of the tail. Scores were assigned as follows: a score of 
 
3 was given if 
all four limbs extended symmetrically and scored 2 if the limbs on the contralateral side
 
extended less or more slowly than those on the unaffected side. A score of 1 was assigned 
if limbs
 
on the contralateral side showed minimal movement and 0, if the contralateral 
forelimb did not move at all.
 
 
3. Forepaw Outstretching 
The rat was held by the base of the tail so that it had to walk along the surface of the table 
using its forelimbs only. The hindlimbs were kept in the air and symmetry in the 
outreaching of both forelimbs was observed. Scores
 
indicate the following: 3, both 
forelimbs were outstretched,
 
and the rat walked symmetrically on forepaws; 2, the 
contralateral forepaw outstretched
 
less than the ipsilateral forepaw, and forepaw walking 
was impaired; 1, the contralateral
 
forelimb exhibited minimal movement; and 0, the 
contralateral forelimb did not move at all.
 
 
4. Climbing 
The rat was placed on wire grid and was then pulled off the wire by gripping the base of 
the tail and the
 
strength of attachment was noted. A score of 
 
3 was given if the rat climbed 
easily and gripped tightly to the wire. The rat scored 2 if the contralateral side was 
impaired while climbing or did not grip as hard as
 
the ipsilateral side and a score of 1 
indicates that the rat failed to climb or tended to circle
 
instead of climbing.
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5. Body Proprioception 
The rat was sharply prodded with a blunt wooden pencil on each side of the body, and
 
the 
reaction to the stimulus was observed. A score of 
 
3 indicates that the rat reacted by turning 
head and was equally startled by the
 
stimulus on both sides. A score of 2 was given if the 
rat reacted slowly to stimulus on
 
the contralateral side and a score of 1 if the rat did not 
respond to the stimulus at all
 
on the contralateral side.
 
 
6. Response to Vibrissae Touch 
A wooden pencil was brushed against the vibrissae on each side;
 
the stick was moved 
toward the whiskers from the rear of the animal
 
to avoid entering the visual fields. A score 
of 
 
3 was assigned if the rat reacted by turning head or was equally startled by the
 
stimulus 
on both sides. A score of 2 indicates that the rat reacted slowly to stimulus on
 
the 
contralateral side and a score of 1 was given if there was no response to the stimulus on the 
contralateral
 
side.
  
 
The scores from each test are added to give an overall neurological score, where the 
maximum score of 18 is achieved where there is no observable deficit and the minimum 
score of 3 indicates the most severely impaired animals. 
 
2.4 Blood Pressure Determination 
 
2.4.1 The Tail Cuff Method 
 
It is necessary to regularly monitor systolic blood pressure in both the SHRSP and the 
WKY to ensure that the stroke-prone strain is indeed hypertensive compared to the 
normotensive control strain. The American Heart Association recommends indirect 
measurement of blood pressure to detect substantial group differences in systolic blood 
pressure (Kurtz et al, 2005). The tail cuff method of systolic blood pressure (BP) 
measurement is a non-invasive technique which was developed by the West of Scotland‟s 
Department of Clinical Physics and Bioengineering, based at the Southern General 
Hospital in Glasgow (Evans et al, 1994). This technique involves the placement of a cuff 
around the proximal end of the rat‟s tail which is then inflated with air until the point at 
which the pressure in the cuff matches that of the tail artery, resulting in a transient 
occlusion of the vessel. This leads to an absence of a pulse which is detected by a signal 
transducer, which is also located on the tail of the rat, at a more distal position than the tail 
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cuff. The signal is relayed to a central monitoring system which is connected to a laptop 
(Dell, UK) which then displays the systolic blood pressure reading in mmHg and the cuff 
is then deflated. This technique is advantageous as it does not require catheterisation of an 
artery as required for direct methods of blood pressure measurement and has been 
validated against direct measures of blood pressure measurement (Feng et al, 2008). 
Furthermore, it allows BP measurements to be obtained in conscious animals without the 
influence of anaesthesia on BP, as is the case with invasive methods. However, there may 
be an element of stress associated with the mild restraint involved which will be reflected 
in the measurements obtained but this can be minimised by incorporating an extensive 
acclimatisation and training period into the regime. 
 
2.4.2 Tail Cuff Apparatus 
 
Prior to BP measurement, the animals must be pre-warmed to induce maximal 
vasodilatation of the tail artery. This is achieved by placing the animals in an insulated heat 
box (dimensions 37cm x 35cm x 40cm) (Figure 2-8). The upper surface of the box has a 
circular opening (diameter 7cm) to allow the box to be warmed to a temperature of 34
o
C 
using a hairdryer (Boots, UK) with temperature maintained by positioning an angle poise 
lamp over the opening of the box. A thermometer situated on the inner wall of the chamber 
is used to monitor the temperature within the box. The front panel of the heat box has a 
door to allow ease of removing animals from the chamber and an insulating tile can be 
removed from the door to observe the animals through a perspex screen. The screen also 
promotes heat loss if the temperature rises above 35
o
C. 
The tail cuff is constructed by cutting the medial portion of a 5ml syringe (Plastipak, UK) 
to a length of 2cm and a length of latex tubing (length 6cm, width 1.5cm) is inserted into 
the syringe. A 10 gauge catheter, cut to 4cm in length was inserted into the latex tubing 
and secured in place by tying 5-0 thread around the tubing. The opposite end of the latex 
tubing was turned over to the outer face of the syringe and was secured using a plastic o-
ring (1.7cm diameter) (Figure 2-9). The catheter was then connected to the central BP 
measurement system. The central monitoring system was also connected to a cylinder of 
medical air (BOC Gases, UK) via a hose, a laptop (Dell, UK) and a piezoceramic 
transducer (Figure 2-8). 
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Figure 2-8. The tail cuff apparatus. The top image shows the central blood pressure monitoring 
system which is connected to a laptop, where the systolic blood pressure measurements are 
displayed and recorded. A heat mat and a towel are used to keep the rat warm and lightly restrain 
movement. The bottom image shows the heat box, which is pre-warmed to 34
o
C. The rat is placed 
in the box for 10-15 minutes to induce maximal vasodilation of the tail artery prior to blood pressure 
measurement. 
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Figure 2-9. The tail cuff and transducer. The top image shows the tail cuff which is placed on the 
base of the tail and inflates and deflates in cycles. The bottom image shows the piezoceramic 
transducer which relays the blood pressure signal to the central blood pressure monitoring system.  
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2.4.3 Animal Training Procedure 
 
All rats were subjected to an intensive 5 day training period to acclimatise them to 
handling and the tail cuff apparatus. On day one of training rats were taken to the room 
where the tail cuff apparatus was set up in their home cage. The animals were then handled 
for a period of 20-30 minutes and were allowed to explore the table where the tail cuff 
apparatus was set up. They were also wrapped in a towel to accustom them to mild 
restraint. On day two, rats were subjected to the same handling procedure as the previous 
day, with the addition of being placed in the heat box for 10 minutes, which had not been 
pre- warmed. The training on day 3 was the same as day two, except that the heat box was 
pre-warmed to 34
o
C prior to the animals entering it. On day 4, the training procedure was 
as described for day 3 and then the tail cuff and transducer were positioned on the rats tail 
(Figure 2-10) whilst the rat was being mildly restrained within a towel. On the final day of 
training, the tail cuff apparatus was again positioned on the rat‟s tail following 10 minutes 
in the heat box and the cuff was inflated and deflated to allow the rat to acclimatise to the 
pressure of the tail cuff. At the end of each training day, rats were rewarded with a treat of 
10 pumpkin seeds each. 
 
2.4.4 Systolic BP Measurement Protocol 
 
The tail cuff method was used to measure systolic blood pressure in WKY and SHRSP 
rats, three times a week for at least 2-3 weeks prior to the induction of experimental stroke. 
All BP measurement was performed in the afternoon between the hours of 2-3pm. BP 
measurement was not performed on a Monday afternoon, as the rats tended to be more 
stressed on this day and I discovered that their cages were cleaned out every Monday and 
this was likely to be the cause of their increased stress levels. 
Rats were placed in the pre-warmed heat box with their cage-mates for 10-15 minutes and 
no longer than 20 minutes. Care was taken to regularly assess the temperature in the box 
by looking at the thermometer attached to the inner wall of the box. If the temperature was 
above 36
o
C, then the front panel of the box was removed to aid heat loss. The front panel 
of the heat box also allowed the animals to be observed. The rats were deemed to be warm 
enough when there was very little spontaneous movement and the ears looked very pink.  
At this stage the rat was removed from the box and swiftly wrapped in a towel with only 
the tail exposed. The rat was placed onto the heat mat to keep it warm and the tail cuff and 
the signal transducer were positioned on the tail (Figure 2-10). Once the rat was settled and 
was sitting on the heat mat, wrapped in the towel, with no need for restraint, then BP  
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Figure 2-10. The tail cuff method of non-invasive blood pressure measurement. The top 
image illustrates the positioning of the tail cuff and the signal transducer on the tail of the rat, where 
the cuff is positioned at the base and the transducer is placed distal to the cuff. The bottom image 
shows the computer screen as displayed when blood pressure measurements are being recorded. 
The strength of the signal is shown in the green box in the top right hand corner of the display and 
the measurements are recorded in the box on the bottom right corner.  
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measurements were taken. The laptop was used to inflate and deflate the cuff in cycles to 
obtain measurements of systolic blood pressure. This was repeated until 8-10 consistent 
measurements of systolic blood pressure were acquired and the mean and standard 
deviation were then calculated. Only the most consistent measurements were used to 
calculate the mean systolic blood pressure for each animal. Measurements which were 
acquired when an animal was visibly stressed were excluded. After the tail cuff procedure, 
the rats were returned to their home cage and were rewarded with pumpkin seeds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 3. 
Establishing strain-specific MRI perfusion and diffusion 
thresholds in SHRSP and WKY rats 
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3.1 Introduction 
 
MRI perfusion-diffusion mismatch is widely used to identify potentially salvageable 
penumbra in both clinical and pre-clinical research. Perfusion weighted imaging identifies 
tissue at risk of infarction, while diffusion weighted imaging identifies the core of 
ischaemic injury. The mismatch between the perfusion deficit on PWI and the region of 
abnormality on DWI provides an approximation of the ischaemic penumbra. Despite this 
technique being used for well over a decade, there is still no consensus on where to set 
perfusion and diffusion thresholds to accurately define the penumbra in both clinical and 
pre-clinical stroke research. This is particularly important where the presence of penumbra 
is used as a criterion for recruiting stroke patients into clinical trials. If the diffusion 
threshold is set too low then irreversibly injured tissue could be identified as being 
potentially salvageable and the penumbra will be overestimated. Conversely, if the 
diffusion threshold is set too high, then the ischaemic core will include a component of the 
penumbra, where tissue is hypoperfused but not yet experiencing bioenergetic failure. If 
the perfusion threshold is set too high, then the outer boundary of the penumbra will 
include benign oligaemic tissue which is not at risk of infarction, thereby overestimating 
the penumbra and if the threshold is set too low, then penumbra will be underestimated. 
This highlights the importance of defining perfusion and diffusion thresholds to accurately 
identify potentially salvageable tissue following stroke.  
 
To date, there are no consistent thresholds in use in clinical (Bandera et al, 2006) or pre-
clinical stroke research. In clinical research, thresholds of perfusion and diffusion 
abnormality have been calculated to identify the ischaemic penumbra and predict stroke 
outcome. In a retrospective study of 37 stroke patients, where DWI, PWI and MR 
angiography had been performed within 6 hours of stroke onset, an ADC threshold of 80% 
of contralateral hemispheric ADC was applied to identify the region of ischaemic injury 
(Thomalla et al, 2003).  This group also performed perfusion imaging using contrast agent 
bolus tracking, where a gadolinium based contrast agent was administered into the 
patient‟s circulation intravenously. A time-intensity curve was constructed from the 
changes in signal intensity as the contrast agent passed through the circulation. The 
perfusion deficit was defined using the time to peak (TTP) of the contrast agent with a TTP 
delay of greater than 4 seconds compared to the contralateral hemisphere used to define 
hypoperfused tissue. These results are in agreement with earlier studies which reported that 
a TTP delay of between 4 and 6 seconds was the best predictor of hypoperfused tissue 
which would progress to infarction without reperfusion (Neumann-Haefelin et al, 1999). 
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However, this TTP delay threshold was later challenged by Sobesky et al (2005), who 
compared the ability of perfusion MR to identify the penumbra with PET and reported that 
a TTP delay threshold of 4-6 seconds grossly overestimated the PET defined penumbra. 
The greatest challenge when establishing perfusion deficit thresholds is to define the 
penumbra with the exclusion of benign oligaemic tissue to prevent overestimation of 
potentially salvageable tissue. 
 
The perfusion deficit can also be defined by parameters other than TTP delay but there is 
no consensus on which perfusion parameter to use clinically to define the perfusion deficit. 
It has been reported that the volume of penumbra quantified by the mismatch technique 
can vary considerably depending on the perfusion parameter used to define hypoperfused 
tissue (Kane et al, 2007). In a study of 32 patients, these authors demonstrated that the 
proportion of those patients presenting with perfusion-diffusion mismatch varied from 9% 
to 72% using 10 different MRI methods to detect the perfusion deficit in each patient. The 
lack of a validated method to define the perfusion deficit will impact on patient 
management where the volume of potentially salvageable tissue is used to determine 
suitability for therapy.
  
Tmax is the measured TTP of the residual function and many groups 
use this parameter rather than TTP since it allows comparisons to be made across 
individual stroke patients. Shih and colleagues defined a Tmax delay threshold of between 6 
and 8 seconds as the most effective for the identification of tissue which would proceed to 
infarction without reperfusion by day 7 post stroke onset (Shih et al, 2003). However, 
Olivot et al (2009) defined the penumbra as hypoperfused tissue with a Tmax delay of 4-6 
seconds, in agreement with an earlier clinical study (Tawasaka et al, 2008). Therefore there 
still appears to be some uncertainty with regards to the perfusion thresholds used for the 
clinical identification of the ischaemic penumbra and regarding which parameter is the 
most appropriate measure of hypoperfused tissue. MRI based quantitative measures of 
perfusion are available, like arterial spin labelling, however, many clinical centres do not 
yet have the facilities available to use this technique. 
 
In rodent stroke models, some groups have defined MRI perfusion and diffusion thresholds 
to define penumbra. Mancuso and colleagues (1995) assessed the relationship between the 
ADC derived lesion and cerebral blood flow, as measured by autoradiography. This group 
defined the ADC lesion as a 15% reduction when compared to the mean ADC value in the 
contralateral hemisphere.  This threshold was selected by examining pre-ischaemic ADC 
maps and diffusion weighted images. Thirty minutes post-MCAO, the ADC-derived lesion 
correlated with a reduced CBF of ≤25ml/100g/min. In another group, where rats were 
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subjected to permanent MCAO, the ADC-derived lesion at 90 minutes correlated with 
CBF of 30-35ml/100g/min, demonstrating the temporal evolution of the ADC derived 
lesion to incorporate less severely hypoperfused tissue into the lesion as the ADC value of 
ischaemic tissue reduces further over time (Mancuso et al, 1995). 
  
One study group in particular have worked extensively to establish thresholds of tissue 
viability in rat models of middle cerebral artery occlusion. Early studies by this group 
identified an absolute ADC threshold value of 0.55 x 10
-3 
mm
2
/sec, when the ADC lesion 
at 2 hours post-MCAO most closely matched the TTC defined final infarct at 24 hours 
post-occlusion (Dardzinski et al, 1993). In later studies by this group (Shen et al, 2003; 
Meng et al, 2004) ADC and CBF thresholds were established by adjusting the respective 
thresholds until the ADC-derived and PWI-defined perfusion deficit at 3 hours post-
MCAO were closely matched to the final infarct, defined at 24 hours post-MCAO by TTC 
processing of the brain. The absolute ADC threshold defined by this group was 0.53 ± 0.03 
x 10
-3 
mm
2 
/sec, which equates to a 30 ± 2% reduction in ADC compared to the mean ADC 
value of the contralateral hemisphere. The abnormal perfusion threshold was defined as 
0.30 ± 0.09ml/g/min, which is a 57 ± 11% reduction in CBF, as compared with the mean 
contralateral hemisphere values. Therefore, pixels on ADC and CBF maps which fall 
below these thresholds defined the regions of ischaemic injury and hypoperfusion, 
respectively. These maps were then co-registered to define areas of perfusion-diffusion 
mismatch and therefore to identify the potentially salvageable penumbra. Later in the same 
year this group published another paper, using the same methods, to establish an absolute 
ADC threshold and a percent reduction ADC threshold relative to the mean ADC of the 
contralateral hemisphere (Kazemi et al, 2004). Optimum ADC thresholds were established 
as those which provided the best correlation between ADC- and TTC-derived lesion 
volume estimates. They defined the absolute ADC threshold value as 0.47 x 10
-3 
mm
2 
/sec 
and the percent ADC reduction threshold at 33%, which is in agreement with their 
previous reports. 
 
Li et al (2000) used a different approach to define ADC thresholds for the prediction of 
final infarct volume following permanent MCAO in the rat. They defined an ADC 
threshold specific to each time point post-MCAO. The threshold derived ADC lesions 
were correlated with the final infarct volume which was derived by TTC staining 24 hours 
post MCA occlusion. By 210 minutes following onset of ischaemia, the ADC lesion had 
fully evolved and at later time points the thresholds were unchanged. The authors state that 
defining a range of thresholds at various time points will allow prediction of the final 
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infarct volume as little as 25 minutes post-ischaemia and enables early prediction of stroke 
outcome. At early time points, the ADC derived lesion will include both injured tissue and 
penumbra. As the ADC values further decrease, the penumbra will become incorporated 
into the final infarct.  
 
Other methods used to define perfusion and diffusion thresholds in rat models of focal 
cerebral ischaemia include using the empirical rule of mean ± 2SD from baseline ADC and 
CBF values of the ipsilateral hemisphere (Foley et al, 2010). In addition, ADC lesion area 
has been defined as the area in which ADC values decreased below a threshold value of 2 
standard deviations from mean contralateral ADC values (Hoehn-Berlage et al, 1995). 
Hoehn-Berlage and colleagues reported that when reductions in ADC were matched to the 
corresponding areas of ATP depletion determined by bioluminescence imaging, the area of 
energetic failure corresponded to a 23% reduction in ADC. Both Hoehn-Berlage et al 
(1995) and Kohno et al (1995) reported a 70% reduction in CBF was associated with ATP 
depletion and progression to infarction. Foley et al (2010) also defined the perfusion deficit 
using a CBF threshold of 70% reduction from baseline ipsilateral CBF using voxel 
analysis. 
 
To date, perfusion and diffusion thresholds have only been established in normotensive rat 
strains. Differences in lesion evolution between strains following experimental stroke may 
mean that thresholds defined in one rat strain may not be applicable to other rat strains, 
particularly those with genetic stroke risk factors, like the spontaneously hypertensive 
stroke-prone rat (SHRSP). Bardutzky et al (2005) demonstrated differences in the 
evolution of the ADC-derived lesion in Sprague-Dawley and Wistar Kyoto rats (WKY), 
the normotensive control strain from which SHR and SHRSP were derived. Following 
permanent MCAO induced by intraluminal filament, the ADC-derived lesion rapidly 
evolves over the first 3 hours and has fully evolved by the 3 hour time point in Sprague-
Dawley rats. However, at 3 hours post-MCAO in Wistar Kyoto rats, the ADC lesion is still 
evolving. It may therefore be inappropriate to use the same ADC and CBF thresholds for 
both strains if the ADC lesion is continuing to evolve beyond the 3 hour time point in 
Wistar Kyoto rats. Therefore it is of utmost importance that thresholds of perfusion and 
diffusion abnormality are established for each strain used in experimental stroke, 
particularly since the evolution of the ischaemic lesion can vary between strains. 
Furthermore, each laboratory should aim to establish their own in-house thresholds for 
each strain of rat and each model used to induce focal cerebral ischaemia. This will serve 
to reduce the influence of additional variables, such as strain and stroke model differences, 
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and surgical technique, on the results obtained by using thresholds defined by other study 
groups.  Inter-strain thresholds would allow accurate identification of the penumbra and 
prediction of final infarct regardless of the rat strain used. Furthermore, when assessing the 
efficacy of potential stroke therapies, one must be confident that the thresholds of 
abnormality are accurate to allow cross strain tissue salvage to be evaluated. This is 
becoming increasingly important since in order to demonstrate therapeutic efficacy, 
potential treatments should be assessed using a range of experimental stroke models with 
and without stroke co-morbidities before being translated to clinical trial. Unfortunately 
this has not been commonplace and may have contributed to the poor outcomes of 
neuroprotective drugs in clinical trials (O‟Collins et al, 2006; Crossley et al, 2008; Howells 
et al, 2010). 
 
Study Aims 
The aims of this study were to define strain-specific MRI perfusion and diffusion 
thresholds in the SHRSP and WKY rat. These thresholds would then be applied to 
quantitative perfusion and diffusion data acquired in the acute phase following 
experimental stroke to allow the temporal evolution of ischaemic injury and perfusion 
deficit to be assessed and compared between the strains. 
 
3.2 Methods 
 
3.2.1 Animal Preparation and Surgical Procedures 
 
SHRSP and WKY rats aged 8-10 weeks of age, were obtained from inbred colonies within 
the Institute of Cardiovascular and Medical Sciences within the University of Glasgow. 
From 11 weeks of age until surgery, systolic blood pressure was measured and recorded 3 
times weekly as previously described (Chapter 2.4.4). The mean systolic blood pressure for 
each rat was calculated and the data were compiled to compare the mean systolic blood 
pressure of each strain. 
 
From this group of animals, age-matched (16-20 weeks) male WKY (n=13) and SHRSP 
(n=16) weighing 250-350g, were anaesthetised, intubated and artificially ventilated 
(Chapter 2.1.1). The ventral surface of the right and left hindlimbs, the chest and the neck 
were shaved using an electric shaver. All rats were then given an intraperitoneal injection 
of 0.4ml of atropine sulphate (600µg/ml, Martindale Pharmaceuticals, UK) which is an 
anti-muscarinic drug used to prevent bronchial secretions building up in the airways for the 
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duration of the experiment. The right femoral artery was cannulated to allow continuous 
monitoring of heart rate and MABP (Biopac) with regular blood sampling every hour to 
ensure blood pH, PaCO2 and PaO2 (Bayer, Rapidlab 248) were maintained within the 
physiological range. Body temperature was assessed by a rectal thermocouple and 
maintained at 37±0.5ºC.           
 
Permanent focal cerebral ischaemia was then induced as previously described (Chapter 
2.1.2), where a silicon tipped filament was advanced along the internal carotid artery to 
block the origin of the middle cerebral artery. The filament was secured in place by 
electrocoagulation of the incision site located within the external carotid artery stump, 
using diathermy forceps. The neck was stitched using a 4-0 silk suture. Electrode gel 
(Sigma) was applied onto the shaved area of the left hindlimb and the right and left sides of 
the chest to allow placement of ECG leads. The rat was then disconnected from the 
ventilator and was immediately transferred to the MRI cradle where the intubation tube 
was reconnected to a ventilator to maintain anaesthesia. 
 
3.2.2 MRI Scanning Protocol 
 
 The rat was secured within the cradle by tooth and ear bars, to restrict head movement, 
and was then transferred to the MRI scanner where a 4-channel phased array surface 
receiver coil was placed on the head. Body temperature was maintained during the MRI 
scanning procedure by a closed circuit thermal jacket and was monitored by a rectal 
thermocouple. 
 
Once a pilot sequence had been obtained to ensure correct geometry, a 4-shot spin-echo 
echo planar imaging (EPI) DWI scan (TE=22.5ms, TR=4000.3ms, matrix=96x96, 
FOV=25x25mm, 3 directions=x, y, z, B-values=0 and 1000s/mm
2
, 8 coronal slices; 1.5mm 
thick) was performed at 30 minutes post-MCAO to allow generation of quantitative ADC 
maps for assessment of ischaemically injured tissue. DWI scans were then repeated on the 
hour from 1 to 4 hours post-MCAO. 
 
Non-invasive quantitative cerebral blood flow (CBF) measurements were carried out on 6 
coronal slices within the MCA territory (slices 2-7 of the DWI scan) using a form of 
continuous arterial spin labelling (cASL) based on a train of adiabatic inversion pulses 
(Moffatt et al, 2005).
 
The sequence employs a spin-echo EPI imaging module (TE=20ms, 
TR=7000ms, matrix=96x96, FOV=25x25mm, slice thickness 1.5mm, 16 averages, 4 shots) 
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preceded by 50 hyperbolic secant inversion pulses in a 3 second train. Inversion pulse 
frequency offset and gradient strength were set to provide 10mm wide label/control bands 
centred at ±30mm from the centre of the imaging slice. For quantification of CBF maps, T1 
maps were also acquired, using an EPI inversion recovery sequence (TE=20ms, 
TR=10000ms, matrix=96x96, FOV=25x25mm, slice thickness 1.5mm, 16 averages, 4 
shots, using 16 inversion times from 200ms to 7700ms). CBF maps and T1 maps were 
acquired every hour for 4 hours post-MCAO. 
DWI scans across 8 coronal slices were acquired within 2 minutes. The ASL scans for each 
coronal slice took 7 minutes to acquire. Therefore, within each hour, ASL scans could only 
be acquired to match slices 2-7 of the DWI scan. 
 
3.2.3 Animal Recovery 
 
At the end of the 4 hour data acquisition session, the rat was removed from the MRI 
scanner within the cradle. When the rectal thermocouple, the thermal jacket, ECG leads 
and the ear bars were removed, the rat was disconnected from the ventilator and 
immediately transferred back into the operating theatre where it was reconnected to the 
ventilator to maintain anaesthesia. The dose of isoflurane was reduced to 1% to aid the 
speed of recovery when anaesthesia was withdrawn. The suture of the right hindlimb was 
cut and the tissue was pulled back to reveal the femoral artery. The ligatures were cut and 
the cannula was removed. The vessel was sealed by electrocoagulation using diathermy 
probes. The hindlimb wound was then re-sutured. At this point, the isoflurane and nitrous 
oxide were turned off and the rat was allowed to breathe 100% oxygen for a period of 15-
20 minutes to aid recovery from anaesthesia. When the rat had been breathing against the 
ventilator for around 5 minutes, the intubation tube was disconnected from the ventilator. 
If the rat continued to breathe unassisted for another 5 minutes then the intubation tube was 
carefully removed. However, if the animal‟s breathing was inconsistent, then the intubation 
tube was reconnected to the ventilator until it could breathe unaided. Once the rat was 
recovering from the effects of anaesthesia and was attempting to move, it was transferred 
to a recovery cage. The cage was lined with absorbent pads instead of sawdust, which may 
irritate the wounds of the rat. Bedding and a cardboard tube were also placed in the cage to 
enrich the rat‟s environment with free access to water and soft diet. The soft diet consisted 
of rat chow pellets with had been softened with warm water and mixed with egg custard 
and rice baby food (Heinz). All animals were individually housed following surgery and 
their general condition was assessed at least 4 times throughout the working day and was 
recorded. 
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At 24 hours following surgery, animals were re-anaesthetised and transferred to the MRI 
scanner where anaesthesia was maintained via a face mask (2% isoflurane in 70/30 N20/02 
mixture) and a RARE T2 weighted sequence was acquired to allow calculation of final 
infarct volume (Chapter 2.2.3). Animals were then sacrificed by perfusion-fixation 
(Chapter 2.1.3). 
 
3.2.4 MRI Data Analysis 
 
Quantitative ADC maps, in units of square millimetres per second, were generated in 
Paravision 5 software and subsequently processed using Image J software to produce an 
ADC map for each of the 8 coronal slices. Quantitative CBF maps (ml/100g/min) for each 
of 6 coronal slices were generated at each time point using the following equation 
(Williams et al, 1992): 
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where  is the inversion pulse efficiency (0.8),  is the blood tissue partition function 
(assumed to be 0.9).  S
control
 and S
label
   are the signal intensity from the control and labelled 
images, acquired with inversion pulses applied above the head and in the neck, 
respectively.  
 
The labelled ASL image was subtracted from the control image and the resulting image 
was then divided by the control image to produce a relative CBF map. The relative CBF 
map was then divided by the T1 map of the same coronal slice to produce a quantitative 
CBF map in units of millilitres per 100g of tissue per min (ml/100g/min).  
 
Final infarct at 24 hours post-stroke was defined and calculated as previously described 
(Chapter 2.2.3).The hyperintense area was manually delineated on the T2   slices which 
anatomically corresponded to the 6 ADC (slices 2-7) and CBF slice maps and multiplied 
by the slice thickness. The final infarct volume was then corrected for brain swelling and 
compression of the contralateral hemisphere. Final infarct was also expressed as a 
percentage of the ipsilateral hemisphere (%HLV) to correct for any differences in brain 
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volume between the strains (Gerriets et al 2004). The following equation was used to 
define the %HLV and correct for oedema (Gerriets et al, 2004): 
 
 
 
 
The absolute ADC threshold for each rat was determined by applying a range of increasing 
threshold values to the quantitative ADC maps acquired at 4 hours post-MCAO to generate 
ADC-derived lesion volume across the 6 coronal slices. This was achieved by manually 
delineating the ipsilateral and contralateral hemispheres on each coronal slice and using the 
histogram function within Image J to count the number of pixels within a given range for 
both hemispheres on each slice (0-2 x 10
-3
 mm
2
/sec for ADC).  These data were exported 
to Excel where the ADC threshold was adjusted to count the number of pixels below each 
threshold. The total number of pixels across the 6 slices was converted to an area by 
multiplying the number of pixels by the area of a pixel (0.0678mm
2
) and lesion volume 
was calculated by multiplying the total area by slice thickness (1.5mm). The threshold 
value which generated a lesion volume which was equal to the oedema-corrected T2 
derived final infarct volume across the same anatomically matched coronal slices was 
identified as the specific ADC threshold for each rat. The same technique was used to 
define the absolute CBF threshold for each rat, where Image J was used to count the 
number of pixels within the range of -100-400ml/100g/min. Negative perfusion values 
were generated in some pixels with low or zero flow as a consequence of subtracting the 
magnitude images (S
control
, S
Label
), where the signal difference was comparable to image 
noise (Karlsen et al, 1999).  These negative ASL-derived CBF values were assumed to 
represent zero flow.   
In Excel, the CBF threshold was adjusted until the volume of the threshold defined 
perfusion deficit on the 4 hour quantitative CBF maps across 6 coronal slices, matched the 
volume of the corrected final infarct (Figure 3-1). The 4 hour post-MCAO time point was 
used to match the ADC and CBF lesion volumes with the 24 hour final infarct volume as 
previous studies have shown that the DWI defined ischaemic core has 
 
 
contralateral        ipsilateral           lesion 
    hemisphere        hemisphere        volume 
 
contralateral hemisphere 
x 100 
%HLV = - + 
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Figure 3-1. ADC and CBF thresholds adjusted to match the volume of ischaemic injury and 
perfusion deficit with the T2 defined final infarct at 24 hours post-MCAO. The data presented 
are from a representative WKY rat and show the ADC and CBF thresholds applied to quantitative 
ADC and CBF maps of a coronal slice acquired at 4 hours post-MCAO. The ADC threshold defines 
ischaemic injury (shown in white) and the CBF threshold defines the perfusion deficit (shown in 
red). The T2 defined infarct is delineated in red outline. 
 
 
fully evolved by 3 hours post-MCAO and correlates well with final infarct at 24 hours 
post-MCAO (Reith et al, 1995; Li et al, 2000). Therefore, in the present study, we assumed 
that by 4 hours post-MCAO there is no further lesion expansion. The individual ADC and 
CBF thresholds for each rat were compiled to generate mean thresholds for WKY and 
SHRSP. The mean ADC and CBF thresholds for each strain were then applied 
retrospectively to the quantitative ADC and CBF maps acquired at each time point to 
calculate ADC-derived lesion and PWI perfusion deficit volumes at each time point over 
the first 4 hours following stroke.  
 
Quantitative ADC and CBF values of the contralateral hemisphere were also determined in 
each rat from 1-4 hours post-MCAO using Image J. Using quantitative ADC and CBF 
maps at each time point, the ADC and CBF values of each pixel across the contralateral 
hemisphere of the 6 coronal slices were summed and divided by the total number of pixels. 
This generated a mean ADC or CBF value for the contralateral hemisphere for each rat 
from 1-4 hours post-MCAO. Pixels located in the ventricles of the contralateral 
hemisphere were excluded from the calculation to prevent their influence on mean ADC 
and CBF values, since the slow flow of CSF throughout the ventricular system results in 
high ADC and low CBF values which are not representative of the parenchyma. The ADC 
and CBF thresholds for each rat were then expressed as the percentage reduction from 
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contralateral ADC and CBF respectively, at 4 hours post-MCAO. The relative ADC and 
CBF thresholds for each rat were then compiled to generate mean relative ADC and CBF 
thresholds for each strain. 
 
In addition, total brain volume was determined in each rat from 1-4 hours post-MCAO 
using Image J software. The area of the ipsilateral and contralateral hemisphere on each of 
the 6 coronal slices was manually delineated to determine the volume of the ipsilateral and 
contralateral hemispheres. These volumes were added together to calculate total brain 
volume across the 6 slices. 
 
3.2.5 Statistical Analysis 
 
All statistical analyses were undertaken using GraphPad Prism software and all data are 
presented as mean ± SD. An unpaired t-test was used to assess potential strain differences 
in mean systolic blood pressure, final infarct volume, % HLV and threshold values. The 
temporal evolution of ischaemic injury, perfusion deficit, physiological parameters, 
hemispheric volume and contralateral CBF for each strain were assessed by Repeated 
Measures ANOVA, with Bonferroni‟s multiple comparisons post-test. Temporal 
comparisons between strains were assessed by 2-way ANOVA with Bonferroni‟s post-test. 
Level of statistical significance was set at p<0.05. All analyses were undertaken blind to rat 
strain. Each rat was given a numbered code which was only broken on the completion of 
all data analysis. 
 
 
3.3 Results 
 
 
3.3.1 Mortality and Excluded Animals 
 
 
Two out of twelve WKY rats and five out of fifteen SHRSP rats died overnight before final 
infarct could be determined by T2 weighted imaging at 24 hours post-MCAO. Examination 
of the brains of the rats which died revealed large infarcts with extensive brain swelling. 
Another SHRSP rat was sacrificed during the acute phase following stroke when DWI 
revealed that the animal had suffered a spontaneous stroke prior to middle cerebral artery 
occlusion. A WKY rat was also excluded as DWI showed a small subcortical lesion, 
indicating incomplete occlusion of the middle cerebral artery. This animal was then 
euthanased. Therefore, the ADC and CBF thresholds were generated from the animals 
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which successfully recovered until 24 hours post-MCAO and demonstrated complete 
occlusion of the middle cerebral artery, where both cortical and subcortical injury was 
evident (WKY: n=10, SHRSP: n=10). However, the calculated thresholds were applied 
retrospectively to all rats to determine the acute evolution of ischaemic injury and 
perfusion deficit (WKY: n=12, SHRSP: n=15). 
 
3.3.2 Systolic BP and Physiological Parameters 
 
 
All SHRSP rats were severely hypertensive compared to the normotensive control strain 
WKY in the weeks prior to the induction of experimental stroke. Mean systolic blood 
pressure was significantly higher in SHRSP (183±12mmHg, n=15) than WKY 
(133±9mmHg, n=12, P<0.0001) (Figure 3-2). All of the WKY rats used in the present 
study were normotensive and mean systolic pressure recorded for each rat ranged from 
117mmHg to 147mmHg. All of the SHRSP rats in the present study demonstrated severe 
hypertension, with mean systolic blood pressure ranging from 165mmHg to 202mmHg. 
 
Throughout the duration of surgical procedures and the 4 hour MRI scanning period, all 
physiological parameters were maintained within physiological range in both WKY and 
SHRSP (P>0.05, Table 3-1). All parameters were comparable between the strains during 
the entire experimental procedure (P>0.05), with the exception of mean arterial blood 
pressure and arterial PO2, which were significantly higher in the hypertensive strain at all 
time points (P<0.05). It is unknown why arterial PO2 was higher in SHRSP as the same 
anaesthetic regime and ventilation parameters were used for all rats in the study and were 
adjusted as necessary. In WKY rats, MABP ranged from 85±5mmHg to 93±7mmHg and 
in SHRSP rats MABP ranged from 105±10mmHg to 109±10mmHg, illustrating that 
arterial blood pressure was kept within a narrow range throughout the experimental 
procedure.  
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Figure 3-2. Mean systolic blood pressure of WKY and SHRSP rats. Mean systolic blood 
pressure was measured in WKY (n=12) and SHRSP (n=15) rats using the non-invasive tail cuff 
method. Mean systolic blood pressure was measured at least 3 times weekly prior to experimental 
stroke. The data presented show the mean systolic blood pressure of each rat as measured over 
the 3 weeks prior to stroke surgery. *p<0.0001, unpaired t test. 
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Physiological 
Parameter                  
Baseline 1 hour 4 hours 
WKY    
Body Temp 
(oC)  
36.9±0.4 37.0±0.5 37.0±0.3 
MABP 
(mmHg) 
85±5 92±7 89±7 
Heart Rate 
(bpm) 
342±23 351±25 358±19 
Blood pH 7.42±0.04 7.35±0.04 7.37±0.03 
PaO2  (mmHg) 119±18 119±23 124±19 
PaCO2  
(mmHg) 
39±6 44±5 41±6 
SHRSP    
Body Temp 
(oC) 
36.8±0.4 37.1±0.3 37.0±0.4 
MABP 
(mmHg) 
109±10 106±9 107±10 
Heart Rate 
(bpm) 
348±28 358±33 359±20 
Blood pH 7.43±0.06 7.40±0.04 7.41±0.03 
PaO2  (mmHg) 147±27 158±31 148±24 
PaCO2  
(mmHg) 
39±4 41±7 38±3 
 
 
 
Table 3-1. Physiological parameters of anaesthetised WKY (n=12) and SHRSP (n=15) measured 
prior to permanent middle cerebral artery occlusion (baseline) and 1 and 4 hours following surgery. 
 
 
 
 
 108 
3.3.3 Brain and Final Infarct Volume 
 
 
Brain volume, across the 6 coronal slices, was smaller in SHRSP compared to WKY but 
the difference in brain volume between strains was not statistically significant at any time 
point from 30 minutes to 4 hours post-MCAO (P>0.05). There was also no evidence of 
brain swelling in the acute phase in either strain, as brain volume did not change 
significantly over the 4 hour time course. In WKY, brain volume was stable from 30 
minutes (1115±55mm
3
) to 4 hours post-MCAO (1115±54mm
3
, P=0.56). Similarly in 
SHRSP, brain volume was also unchanged from 30 minutes (1063±30mm
3
) to 4 hours 
post-MCAO (1060±33mm
3
, P=0.17). The volume of the ipsilateral hemisphere was 
unchanged from 30 minutes to 4 hours post-MCAO in both WKY and SHRSP (P>0.05). In 
WKY, the volume of the ipsilateral hemisphere was relatively stable from 30 minutes 
(560±28mm
3
) to 4 hours post-MCAO (564±29mm
3
, P>0.05). Similarly, in SHRSP, the 
volume of the ipsilateral hemisphere was maintained from 30 minutes (543±16mm
3
) to 4 
hours post-MCAO (547±15mm
3
, P>0.05). 
 
SHRSP demonstrated a significantly larger infarct volume at 24 hours post-MCAO than 
WKY (387±55mm
3 
vs 303±59mm
3
, P=0.004, infarct volume of SHRSP and WKY, 
respectively, Figure 3-3A). Expressed as a percentage of the ipsilateral hemisphere, in 
SHRSP, 72±9% of the ipsilateral hemisphere was infarcted, compared to 53±10% in WKY 
rats (P=0.0002, Figure 3-3B). Difference in infarct volume between strains was 
particularly evident in the more caudal brain slices, where the infarct area was substantially 
larger in SHRSP compared to WKY (Figure 3-4). In SHRSP, the infarct extended further 
in the rostral and caudal planes than demonstrated in WKY. Substantial swelling of the 
ipsilateral hemisphere was evident in both strains by 24 hours post-MCAO in addition to 
compression of the contralateral hemisphere. Ipsilateral swelling and contralateral 
compression were observed to a greater degree in the hypertensive strain (Figure 3-4). 
 
3.3.4 Strain Specific Perfusion and Diffusion Thresholds 
 
The mean ADC value of the whole contralateral hemisphere across the 6 coronal slices was 
not significantly different between the strains and did not change significantly over the 4 
hour time course. In WKY, mean contralateral ADC was 0.76±0.02 x 10
-3
 mm
2
/sec at 1 
hour post-MCAO and was not significantly different at 4 hours (0.77±0.01 x 10
-3
 mm
2
/sec, 
P>0.05). Similarly, in SHRSP, mean contralateral ADC was maintained at 0.76±0.01 x 10
-3
 
mm
2
/sec from 1-4 hours post-MCAO.  
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Figure 3-3. Final infarct in SHRSP and WKY rats at 24h following permanent occlusion of the middle cerebral artery. Final infarct was expressed as a volume 
(A) and as a percentage of the ipsilateral hemisphere (B). Both methods were corrected for swelling of the ipsilateral hemisphere and compression of the contralateral 
hemisphere. Horizontal line denotes the mean. *P<0.01, unpaired t tests. WKY; n=10, SHRSP; n=10.  
 
 
A B 
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Figure 3-4. The spatial distribution of infarct area at 24h post-stroke in SHRSP and WKY rats following permanent MCAO. Representative MRI T2-weighted 
images are shown for each strain to illustrate the spatial distribution of the infarct at 24h post-MCAO. The 8 coronal slices shown are representative of the rostro-
caudal extent of the territory supplied by the MCA which was examined using T2-weighted imaging. The infarct area was determined by manually delineating the 
hyperintense area on each of 16 coronal T2 slices. Infarct volume was determined across the T2 slices which anatomically matched the 6 coronal slices used to 
calculate the ADC-derived lesion and the CBF-defined perfusion deficit. Eight of the sixteen slices are shown, with and without the infarct outlined in red.  
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The absolute ADC threshold for WKY, determined from final infarct volume, was 
0.61±0.03 x 10
-3
 mm
2
/sec, representing a 21±4% reduction from mean contralateral ADC 
at 4 hours post-MCAO.  The calculated ADC threshold for the hypertensive strain was 
0.59±0.03 x 10
-3
 mm
2
/sec, which represents a 23±4% reduction from the mean 
contralateral ADC value. Both the absolute and the % reduction ADC thresholds were 
comparable between the strains (P>0.05, Figure 3-5A).  
 
Mean contralateral CBF was not significantly different between WKY and SHRSP and did 
not change significantly over the 4 hour time course in either strain. In WKY, mean 
contralateral CBF remained relatively stable from 135±23ml/100g/min at 1 hour post-
MCAO to 124±21ml/100g/min at 4 hours (P=0.1). In SHRSP, mean contralateral CBF was 
unchanged from 1-4 hours post-MCAO (113±22ml/100g/min and 116±13ml/100g/min at 1 
hour and 4 hours post-MCAO, respectively, P=0.6).  
The mean CBF threshold determined from final infarct volume in WKY rats was 23±8 
ml/100g/min, which was an 81±7% reduction in flow from the 4 hour contralateral CBF 
value. The calculated CBF threshold for SHRSP was 36±13 ml/100g/min, representing a 
70±9% reduction from 4 hour contralateral CBF. Both the absolute and % reduction CBF 
thresholds were significantly higher for SHRSP than WKY (P<0.05, Figure 3-5B).                       
 
3.3.5 Acute Evolution of Ischaemic Injury 
 
The mean absolute ADC thresholds were applied to the 30 minutes-4 hour ADC maps to 
assess the acute evolution of ischaemic injury in WKY and SHRSP. The thresholded ADC 
maps at 4 hours post-MCAO matched well spatially with the 24 hours T2 infarct in both 
strains. The area of ischaemic injury identified by application of the strain specific ADC 
threshold was comparable to the hypointense areas on ADC maps across the 6 coronal 
brain slices being examined. Similarly, the threshold defined areas of injured tissue 
matched well with the hyperintense infarct area on T2 slices (Figure 3-6).  
 
At all time points following MCAO, ADC-derived lesion volume was significantly larger 
in SHRSP than WKY and this was evident from as early as 30 minutes post-MCAO 
(WKY; 203±70mm
3
, SHRSP; 336±63mm
3
, P<0.001). The ADC-derived lesion volume 
increased significantly over the 4 hour time course in both strains (P<0.001, Figure 3-7).  
In SHRSP, ADC-derived ischaemic injury increased from 336±63mm
3 
at 30 minutes, to 
410±56mm
3 
at 4 hours post-MCAO. In WKY, the ADC-derived lesion evolved from 
203±70mm
3 
at 30 minutes following stroke, to 311±57mm
3 
at 3 hours, at which point the 
lesion volume reaches a plateau. This suggests that using this model of stroke, the  
 112 
 
 
 
 
 
  
 
Figure 3-5. Strain-specific MRI diffusion (A) and perfusion thresholds (B) calculated in WKY and SHRSP rats following permanent MCAO. Thresholds were 
calculated by adjusting the diffusion and perfusion thresholds on quantitative ADC and CBF maps until the volume of the ADC-derived lesion and the perfusion deficit 
at 4h post-MCAO matched the volume of the T2 defined final infarct at 24h. *p<0.05, unpaired t test.
A B 
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Figure 3-6.  Ischaemic injured tissue at 4 hours post-MCAO as determined by strain-specific diffusion thresholds. ADC thresholds were adjusted until the 
ADC-derived lesion matched the volume of the corrected final infarct, defined by manually delineating the hyperintense areas on T2 weighted images at 24h post-
MCAO (shown in red). The data shown are from a representative SHRSP and WKY rat.  
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Figure 3-7. The acute evolution of ischaemic injury in SHRSP (n=15) and WKY (n=12) 
following permanent MCAO. Strain-specific ADC thresholds were applied to quantitative ADC 
maps acquired from 30min to 4h post-MCAO to determine the temporal evolution of ischaemic 
injury. *p<0.01, 2-way ANOVA with Bonferroni’s post-test. 
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Figure 3-8. ADC-derived ischaemic injury in SHRSP and WKY rats at 30 minutes following permanent MCAO. Strain-specific ADC thresholds were applied to 
quantitative ADC maps acquired at 30 minutes post-MCAO to assess the spatial distribution of ischaemic injury between strains. The area of ischaemic injury is 
depicted by white shading on 6 coronal brain slices within the territory of the middle cerebral artery. The data presented are from a representative SHRSP and WKY 
rat. 
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Figure 3-9. ADC profiles of the ipsilateral hemisphere in SHRSP and WKY rats from 1-4h post-MCAO. The graphs show the mean number of pixels with a 
particular ADC value from 0-1.6 x 10
-3
 mm
2
/sec. The calculated ADC threshold for each strain is shown by the dotted line, where the SHRSP ADC threshold is shown 
in red (0.59 x 10
-3
 mm
2
/sec) and the WKY ADC threshold is shown by the blue dotted line (0.61 x 10
-3
 mm
2
/sec). The data presented show the mean data for each 
strain.
1h post-MCAO 2h post-MCAO 
3h post-MCAO 4h post-MCAO 
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evolution of ischaemic injury is complete by 3 hours following MCAO in the WKY.  The 
observed greater area of ischaemic injury in SHRSP is particularly evident in the most 
caudal coronal brain slices, especially in slices 2 and 3 (Figure 3-8).  
 
These results are also illustrated by the pixel analysis of ADC maps of the entire ipsilateral 
hemisphere of WKY and SHRSP, where the hypertensive strain had a greater proportion of 
pixels with low ADC values. In both strains, the number of pixels which fall below the 
strain-specific ADC threshold increases over time as the ischaemic core expands. The 
ipsilateral ADC profile of WKY has a biphasic shape which allows clear distinction 
between injured and normal tissue. However, this biphasic profile is only evident in the 
SHRSP at 1 h post-MCAO and at later time points the biphasic shape is lost as most of the 
hemisphere becomes incorporated into the core of ischaemic injury (Figure 3-9). These 
ADC profiles demonstrate that ischaemic injury is greater in SHRSP compared to WKY, 
irrespective of the application of a ADC threshold to quantify the ADC-derived lesion 
volume.  
 
3.3.6 Acute Evolution of Perfusion Deficit 
 
 
The mean absolute CBF thresholds were applied to the quantitative CBF maps acquired 
from 1-4 hours post-MCAO to determine the acute evolution of the perfusion deficit for 
each strain. There was also good spatial matching between the thresholded 4 hour CBF 
maps and the 24 hour T2 final infarct, where the threshold defined hypoperfused area on 6 
coronal slices matched well with the hyperintense area on corresponding T2 slices (Figure 
3-10).  
 
At all time points following stroke, the perfusion deficit was significantly greater in 
SHRSP than WKY (P<0.001, Figure 3-11). At 1 hour following stroke, a perfusion deficit 
of 368±45mm
3 
was observed in SHRSP, compared to 273±69mm
3 
in WKY rats (Figure 3-
12). The greater perfusion deficit observed in the SHRSP was particularly evident on the 
caudal slices 2 and 3, where the hypoperfused area was substantially larger (Figure 3-12).  
 
A significant increase in the volume of perfusion deficit over the 4 hour time course was 
observed in both strains. In WKY, the perfusion deficit increased from 273±69mm
3 
at 1 
hour post-MCAO to 318±65mm
3 
by 4 hours (P<0.001; Figure 3-11). In SHRSP, the 
volume of perfusion deficit increased from 368±45mm
3 
at 1 hour to 411±48mm
3 
at 4 hours 
post-stroke (P<0.001). There was no significant difference in the growth of the perfusion
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Figure 3-10. Quantitative CBF maps displaying hypoperfused tissue at 4 hours post-MCAO. CBF thresholds were adjusted until the volume of CBF defined 
perfusion deficit matched the volume of the oedema-corrected final infarct, defined by manually delineating the hyperintense areas on T2 weighted images at 24 hours 
post-MCAO (shown in red). The data shown are from a representative SHRSP and WKY rat. 
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Figure 3-11. Temporal evolution of the perfusion deficit following permanent MCAO in 
SHRSP (n=15) and WKY (n=12) rats. Strain-specific perfusion thresholds were applied to 
quantitative CBF maps to compare the volume of hypoperfused tissue between strains and to 
assess the acute evolution of the perfusion deficit from 1-4h post-MCAO. *p<0.01, 2-way ANOVA 
with Bonferroni’s post-test. 
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Figure 3-12. The perfusion deficit observed in SHRSP and WKY rats at 1h following permanent MCAO. Strain-specific CBF thresholds were applied to 
quantitative CBF maps acquired at 1h post-MCAO to assess the spatial distribution of hypoperfused tissue between strains. The perfusion deficit is depicted by red 
shading on 6 coronal brain slices within the territory of the middle cerebral artery. The data shown are from a representative SHRSP and WKY rat.
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Figure 3-13. Cerebral blood flow profiles of the ipsilateral (A) and contralateral hemisphere (B) in SHRSP and WKY rats from 1-4h post-MCAO. 
The figures show the CBF values of each pixel in the ipsilateral and contralateral hemispheres at 1 and 4h post-MCAO. The strain specific CBF thresholds are 
indicated by the dotted vertical lines. The mean SHRSP threshold (36ml/100g/min) is shown by the red dotted line and the WKY threshold (23ml/100g/min) is shown by 
the blue dotted line.
1h post-MCAO 4h post-MCAO 
1h post-MCAO 
A 
B 
deficit between strains over the first 4 hours post-stroke. In SHRSP, the perfusion deficit 
increased by 43±27mm
3
 compared to an increase of 48±20mm
3
 in WKY (P=0.65). 
 
 These results are also illustrated by the CBF pixel profiles of the ipsilateral hemisphere of 
WKY and SHRSP, where the hypertensive strain had a greater proportion of pixels with 
low CBF values. In both strains, the number of pixels which fall below the strain-specific 
CBF threshold increases over time, as hypoperfused tissue becomes incorporated into the 
perfusion deficit (Figure 3-13A). The CBF profiles also demonstrate that a greater number 
of pixels have a low CBF value compared to WKY, irrespective of the application of a 
ADC threshold to quantify the ADC-derived lesion volume. The CBF profiles of the 
contralateral hemisphere show that the vast majority of pixels have a CBF value above the 
strain specific CBF thresholds (Figure 3-13B). In addition, the contralateral CBF profiles 
are similar between the strains and do not change over time. 
 
3.4 Discussion 
 
This is the first study to define strain-specific thresholds of diffusion and perfusion 
abnormality in a clinically relevant rodent stroke model with recognised risk factors. In-
house ADC and CBF thresholds of abnormality were established for the SHRSP and WKY 
strain based on final infarct volume at 24 hours post-stroke, defined by T2-weighted 
imaging. The mean calculated thresholds were retrospectively applied to MRI diffusion 
and perfusion data to compare the acute evolution of ADC-derived ischaemic injury and 
CBF defined perfusion deficit in the SHRSP and the normotensive control strain, WKY.  
 
The calculated ADC thresholds were comparable between the strains, with thresholds 
associated with a 23% and 21% reduction in ADC for SHRSP and WKY respectively. 
These thresholds are similar to those reported previously in Wistar rats by examining 
metabolic failure following MCAO (Hoehn-Berlage et al, 1995; Olah et al, 2001) where an 
ADC threshold of 77% of control corresponds with the breakdown of energy metabolism. 
However, the ADC thresholds calculated in the present study, differ from those determined 
in Sprague-Dawley rats where a 30% reduction in ADC was reported to predict final 
infarct volume (Shen et al, 2003; Foley et al, 2010). Similarly, an ADC threshold of 30% 
reduction was reported in male Sprague-Dawley rats within our laboratory, using the same 
methodology as described in the present study (TA Baskerville, unpublished observations). 
Furthermore, using a method similar to the one employed in the present study, Shen and 
colleagues matched the 3 hour lesion volumes with the TTC (2,3,5-triphenyltetrazolium 
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chloride) defined final infarct at 24 hours post-MCAO in Sprague-Dawley rats and found 
that a 30% reduction in ADC matched final infarct. Similarly, a 30% reduction in ADC 
was determined using the empirical rule (by calculating the mean ± 2SD of the mean ADC 
prior to stroke) in Sprague-Dawley rats (Foley et al, 2010). These studies suggest that the 
threshold for ischaemic injury may be different between rat strains since ADC thresholds 
calculated by various study groups using different methods in Sprague-Dawley rats are 
consistently less severe than those determined in Wistar Kyoto rats.  
 
The perfusion threshold calculated for Wistar Kyoto rats in the present study 
(23ml/100g/min) is lower than the perfusion threshold calculated previously in Sprague-
Dawley rats (30ml/100g/min, Shen et al, 2003). In addition, the present study shows that 
the mean CBF threshold was significantly different between SHRSP (70% reduction from 
contalateral CBF) and WKY rats (81% reduction from contralateral CBF). This suggests 
that SHRSP may have a greater sensitivity to ischaemia than the normotensive control 
strain. It has been previously reported that in vitro, cortical neurons from SHRSP are more 
vulnerable in hypoxic conditions than those of WKY, with a significantly greater rate of 
cell death following 36 hours of hypoxia (Tagami et al, 1998).  The strain-specific CBF 
thresholds calculated in the present study from the T2-defined final infarct at 24 hours 
differ from those previously determined in Wistar rats (Hoehn-Berlage et al, 1995) where a 
40% reduction in ipsilateral CBF was associated with tissue acidosis. Our CBF thresholds 
also differ from those determined previously in Sprague-Dawley rats (Shen et al, 2003) 
where a threshold of 57% reduction in CBF was defined. Furthermore, data from our 
laboratory show that a 63% reduction in CBF predicts final infarct at 24 hours post-MCAO 
in male Sprague-Dawley rats (TA Baskerville, unpublished observations). 
 
One factor which may influence the calculation of CBF thresholds in the present study is 
the temporal evolution of the perfusion deficit. The CBF threshold was defined by 
matching the volume of perfusion deficit to the final infarct but the data show that the 
perfusion deficit increased from 1-4 hours post-MCAO. It was assumed that the volume of 
perfusion deficit would be relatively stable over the 4 hour time course in agreement with 
previous studies where a similar method was used to define perfusion thresholds (Shen et 
al, 2003; Meng et al, 2004). In the present study it was assumed that there would be no 
further recruitment of hypoperfused tissue into the perfusion deficit but this may not be the 
case and the perfusion deficit could expand beyond the 4 hour time point. Further 
expansion of the perfusion deficit would render the calculated CBF thresholds invalid as in 
this study the CBF threshold was adjusted until the volume of hypoperfused tissue at 4 
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hours post-MCAO matched the volume of the final infarct at 24 hours, with the assumption 
that there is no further expansion of the perfusion deficit at later time points. However, 
withdrawal of anaesthesia at 4 hours post-MCAO would result in an increase in mean 
arterial blood pressure in both strains which may support CBF in the ipsilateral hemisphere 
and prevent further increase in the size of the perfusion deficit. 
 
Many factors can influence the calculation of viability thresholds, including methods used 
(autoradiography, MRI sequences), rat strain, stroke model and surgical technique. The 
technique used by Shen et al (2003), where ADC and CBF thresholds were established 
after 3 hours of permanent MCAO where the volume of ADC abnormality and perfusion 
deficit matched the volume of the TTC-defined final infarct at 24 hours, has recently been 
criticised. Foley et al (2010) argue that this technique may create bias in their results as it 
assumes that the ADC derived lesion has fully evolved to encompass the entire perfusion 
deficit by 3 hours post-MCAO but later time points were not examined to confirm that 
there was no further growth beyond this time point. This criticism can also be directed at 
the present study, although thresholds were matched at the 4 hours time point instead of the 
3 hour time point used by Shen et al (2003). It would have been desirable to acquire MRI 
data for up to 6 hours to assess the evolution of perfusion deficit and ischaemic injury but 
this would have caused additional problems. Firstly, keeping animals under anaesthetic for 
that length of time is likely to increase the mortality rate and would have reduced the 
likelihood of successful recovery to 24 hours post-MCAO. Mortality rate in SHRSP was 
high when anaesthetic was maintained for 4 hours of MRI scanning, with one in every 
three rats failing to survive, resulting in unacceptable levels of morbidity and mortality. 
Secondly, after 4 hours of permanent MCAO, any further increases in the volume of 
perfusion deficit and ischaemic injury is likely to result from vasogenic oedema, as the 
integrity of the blood-brain barrier becomes compromised, resulting in a shift of water 
from the vasculature to the brain (Ayata et al, 2002). Previous work from our study group 
where the MRI scanning procedure was extended to 6 hours post-MCAO in non-recovery 
experiments demonstrated that ADC lesion volume is maximal in WKY and SHRSP by 4 
hours (McCabe et al, 2009). 
 
The present study demonstrates that final infarct, determined at 24 hours by T2-weighted 
imaging, is significantly larger in SHRSP than WKY. This is in agreement with previous 
studies which have reported an increased sensitivity to experimental stroke in SHRSP 
(Coyle & Jokelainen, 1983; Jeffs et al, 1997; Carswell et al, 1999; Marks et al, 2001; 
McGill et al, 2005; McCabe et al, 2009). The present study has also shown that despite 
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comparable ADC thresholds, ADC-derived ischaemic injury was greater in SHRSP than 
WKY over the initial 4 hour time course. This confirms earlier reports from our laboratory, 
where the ADC lesion was significantly greater in SHRSP compared to WKY from 1-6 
hours post-MCAO (McCabe et al, 2009). McCabe et al (2009) reported that within the first 
hour following permanent MCAO, the volume of ADC derived ischaemic injury in SHRSP 
(275±75mm
3
) was significantly larger than in WKY (171±30mm
3
, P<0.05) and increased 
significantly over time in both strains (P<0.05).  
 
The extent of ischaemic injury demonstrated in SHRSP in the present study cannot solely 
be attributed to the development of severe hypertension in this strain, since an increased 
sensitivity to experimental stroke is observed in young SHRSP before the onset of 
hypertension (Coyle & Jokelainen, 1983). These authors demonstrated that SHRSP aged 
35-40 days displayed a large cortical lesion following permanent MCAO induced by the 
method of Tamura et al (1981). In age-matched WKY rats, the lesion was significantly 
smaller. Other genetic factors which may contribute to increased ischaemic injury in 
SHRSP include increased levels of oxidative stress, where it has been reported that 
superoxide dismutase activity is reduced in SHRSP compared to WKY, resulting in 
increased levels of superoxide anions (Kishi et al, 2004). More recently it has been 
demonstrated that levels of 20-hydroxyeicosatetraenoic acid (20-HETE) are twice as high 
in the cerebrovasculature of SHRSP compared to WKY.  20-HETE is a potent 
vasoconstrictor which contributes to increased stroke sensitivity in SHRSP by mediating 
endothelial dysfunction and increasing oxidative stress by stimulating superoxide 
production (Cheng et al, 2008). Inhibition of 20-HETE has been shown to significantly 
reduce infarct volume in SHRSP (Dunn et al, 2008).  
 
A heightened inflammatory response may also have contributed to the increased infarct 
volume observed in the present study. Previously, Marks and colleagues reported that the 
activation of microglia following permanent focal cerebral ischaemia, was significantly 
higher in SHRSP compared to WKY rats. In the region of the ischaemic core, 183 
activated microglia were identified per mm
2
, compared to 156/mm
2 
in WKY rats (Marks et 
al, 2001). Activated microglia can release neurotoxins including oxygen radicals, nitric 
oxide and glutamate, which can lead to lipid peroxidation, oedema and necrosis. 
 
In addition, dysfunction of the BBB may also have contributed to the larger infarcts 
observed in SHRSP. It has been demonstrated that there is an alteration in the polarity of 
endothelial cells of the BBB prior to stroke onset and this may predispose the SHRSP to 
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stroke-induced breakdown of the BBB (Lippoldt et al, 2000). This may also contribute to 
the increased brain swelling observed in the hypertensive strain in the present study, where 
swelling of the ipsilateral hemisphere and compression of the contralateral hemisphere 
were more apparent in SHRSP than WKY.  
 
The results also show that the CBF-defined perfusion deficit was significantly larger in 
SHRSP compared to WKY from 1-4 hours following stroke. The larger perfusion deficit 
exhibited by the hypertensive strain may be attributable to the higher CBF threshold in 
SHRSP, where a greater volume of tissue will fall below the perfusion threshold, compared 
to WKY rats. A CBF threshold of 50ml/100g/min has been reported previously in the SHR 
rat strain, when ischaemia persists for at least 3 hours (Jacewicz et al, 1992). This study 
highlights that rat strains may have different viability thresholds, particularly those strains 
which have underlying stroke risk factors, like the SHR and SHRSP. In addition, impaired 
blood flow through collateral vessels which connect the three major cerebral arteries in 
each hemisphere is likely to contribute to the increased perfusion deficit in SHRSP. 
Although the number of collateral vessels is the same between the strains, it has been 
reported that the internal diameter of anastomoses is reduced in SHRSP, therefore reducing 
vasodilator capacity following MCAO and contributing to the larger infarct size observed 
in the hypertensive strain (Coyle & Heistad, 1987).  
 
Furthermore, the results demonstrate that the perfusion deficit significantly increases from 
1-4 hours following stroke in both the WKY and SHRSP strains. This has been previously 
reported in a previous study from our laboratory, where the perfusion deficit in SHRSP 
significantly increased from 1-6 hours post-MCAO (McCabe et al, 2009). This study, 
which used published ADC and CBF thresholds, examined the area of perfusion deficit on 
a single coronal slice within the territory of the MCA and showed that in SHRSP, the 
perfusion deficit increased from 44±9mm
2
 at 1 hour to 49±7mm
2
 at 6 hours post-MCAO 
(P=0.01). However, in WKY, the area of perfusion deficit on the same coronal slice was 
unchanged from 1-6 hours post-MCAO. This finding differs from those reported in the 
present study where both the SHRSP and WKY strains display a significant increase in 
perfusion deficit in the acute phase following permanent MCAO. However, McCabe et al 
(2009) only examined CBF on a single coronal slice within the MCA territory and 
therefore would not have detected any increases in perfusion deficit which may have been 
evident on brain slices located further rostrally and caudally. The increase in perfusion 
deficit which was observed in both strains in the present study was unlikely to result from 
global changes in CBF as a result of prolonged anaesthesia as the data shows that 
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contralateral CBF did not change significantly over the 4 hour time course in either WKY 
or SHRSP. The temporal increase in perfusion deficit suggests that there is a gradual 
failure of collateral blood supply over time in SHRSP and WKY rats. This may occur as a 
result of disruption of the blood-barrier barrier, where water will be drawn from the 
collateral vessels, thereby reducing blood flow to hypoperfused tissue on the boundary of 
the perfusion deficit. As blood flow to this region of tissue declines, it will become more 
severely hypoperfused and will fall below the CBF threshold and consequently become 
incorporated into the perfusion deficit.  
 
It is particularly interesting that this apparent failure of collateral flow occurs in both 
SHRSP and WKY. It is unsurprising that the perfusion deficit increases over time in the 
hypertensive strain as it is well established that the SHRSP exhibits an impaired collateral 
flow and increased dysfunction of the blood-brain barrier, as previously discussed. Both of 
these factors would therefore contribute to expansion of the perfusion deficit over time. It 
has been reported that the severity of blood-brain barrier disruption and brain oedema 
correspond with the duration and severity of ischaemia (Todd et al, 1986). This may 
explain why there appears to be evidence of collateral failure in WKY, as despite being 
normotensive, the WKY strain exhibits larger infarcts following permanent MCAO than 
other normotensive strains like the Sprague-Dawley rat. Data from our laboratory show 
that Sprague-Dawley rats, subjected to the same experimental procedure as described in 
this chapter, demonstrate a final infarct volume of 208±48mm
3
, which is significantly 
lower than that observed in WKY rats in the present study (303±59mm
3
, P=0.001). In 
Sprague-Dawley rats the CBF defined perfusion deficit was relatively stable from 1-4 
hours post-MCAO (TA Baskerville, unpublished observations). This suggests that there 
may be structural or physiological differences between normotensive rat strains which 
could contribute to the observed differences in the severity of ischaemia between WKY 
and Sprague-Dawley rats. To date, the potential differences in the structural and 
physiological characteristics of collateral blood vessels in WKY and Sprague-Dawley rats 
has yet to be examined. The failure of collateral blood supply in WKY suggested by the 
data in the present study, conflicts with previous reports where collateral vessels in WKY 
rats vasodilate to restore flow to levels comparable with the contralateral hemisphere one 
month after permanent MCAO (Coyle & Heistad, 1987). However, these authors used a 
different model of MCAO, where the artery was occluded distally by drilling through the 
skull to expose the middle cerebral artery, which was then tied using a nylon ligature 
(Coyle, 1982). This model induces the formation of a small cortical lesion and reduced 
brain swelling as a result of craniectomy and therefore the demands on the collateral 
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vessels is markedly reduced and collateral blood supply is sufficient to maintain blood 
supply and prevent infarction. 
 
Summary 
In summary, the present study has defined strain-specific MRI perfusion and diffusion 
thresholds in SHRSP and WKY rats following permanent MCAO. These thresholds were 
retrospectively applied to acute MRI data to assess and compare the temporal evolution of 
ischaemic injury and perfusion deficit in both strains. SHRSP rats demonstrated a 
significantly larger infarct at 24 hours post-MCAO, confirming previous reports of 
increased sensitivity to experimental stroke in the hypertensive strain. Despite comparable 
ADC thresholds, the absolute CBF threshold in SHRSP was significantly higher, indicating 
a greater sensitivity to ischaemia compared to WKY. The volume of ADC-derived 
ischaemic injury and perfusion deficit was significantly greater in SHRSP from 1-4 hours 
post-MCAO and increased significantly over time in both strains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 4. 
A comparison of penumbra calculation methods to identify 
potentially salvageable tissue in SHRSP and WKY rats 
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4.1 Introduction 
 
Positron emission tomography (PET) remains the “gold-standard” imaging modality for 
penumbra detection, identifying penumbral tissue on the basis of specific metabolic 
parameters (Sobesky et al, 2005) but the radiation exposure, complex logistics and costs of 
PET limit its wider use. Perfusion-diffusion mismatch is widely used to identify the 
penumbra, both in clinical and basic stroke research (Heiss, 2010). In acute stroke, MR 
diffusion weighted imaging (DWI) can identify tissue in which diffusion is restricted as a 
result of cytotoxic oedema, leading to a reduction in the apparent diffusion coefficient 
(ADC) value of the tissue. This evidence of brain injury is used within perfusion-diffusion 
mismatch methodology to represent the irreversibly damaged ischaemic core. Perfusion 
weighted imaging (PWI) delineates the perfusion deficit, identifying hypoperfused tissue 
destined to proceed to infarction and the mismatch between the PWI defined perfusion 
deficit and DWI defined ischaemic core is used to provide an approximation of the 
ischaemic penumbra: potentially salvageable tissue with a finite lifespan which will 
proceed to infarction over time.  
 
At present, there is no consensus on which MRI measure of cerebral blood flow to use 
clinically or what threshold to apply to determine the perfusion deficit. It has been reported 
that the volume of penumbra quantified by the mismatch technique can vary considerably 
depending on the perfusion parameter used to define hypoperfused tissue (Kane et al, 
2007). In a study of 32 patients, these authors demonstrated that the proportion of those 
patients presenting with perfusion-diffusion mismatch varied from 9% to 72% using 10 
different MRI methods to detect the perfusion deficit in each patient. This will impact on 
patient management where the volume of potentially salvageable tissue is used to 
determine suitability for therapy.
  
This report highlights the need for agreement in the 
method used to identify potentially salvageable tissue in stroke patients in clinical research.  
 
In pre-clinical research there is a notable absence of literature examining the PWI/DWI 
mismatch methodology and studies investigating the use of PWI and DWI data to define 
penumbra are urgently required. In addition, there is a lack of pre-clinical data examining 
the effect of potential neuroprotective strategies on the evolution of the mismatch defined 
penumbra. In this respect, the perfusion-diffusion mismatch model has been relatively 
underused and may yet prove to be a useful tool in the development of stroke therapies in 
experimental animal models.  
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In experimental stroke models using MRI, mismatch volume is commonly calculated by 
subtracting the ADC lesion volume from the volume of perfusion deficit without any 
anatomical co-registration (Meng et al, 2004; Bråtane et al, 2009; Henninger et al, 2009). 
This method provides no information on the location or spatial distribution of the 
penumbra and therefore may be of limited use when examining the temporal evolution of 
potentially salvageable tissue following experimental stroke. 
 
Furthermore, there are limited data examining the lifespan of the penumbra in animal 
models with genetic stroke risk factors. Legos and colleagues reported that SHR rats 
demonstrated no evidence of perfusion-diffusion mismatch as early as 1 hour following 
MCAO. At the same time point, Sprague-Dawley rats exhibited a substantial volume of 
mismatch tissue (Legos et al, 2008). Similarly, Letourneur and colleagues found that 
perfusion-diffusion mismatch volume was significantly reduced in SHRs compared to 
WKY rats from as early as 30 minutes following permanent focal cerebral ischaemia. An 
alternative model of induced renovascular hypertension in normotensive rats, using a 
kidney clip procedure was also studied. This group of rats also exhibited a significantly 
reduced mismatch volume compared to normotensive WKY rats (Letourneur et al, 2011). 
 
 At present, only one study group has compared the acute evolution of the ischaemic 
penumbra in SHRSP and WKY strains but assessment of mismatch was limited to the 
examination of one coronal slice from within the territory of the middle cerebral artery 
(McCabe et al, 2009). Multi-slice determination of mismatch volume has not yet been 
assessed in WKY and SHRSP. However, previous reports suggest that the extent and 
lifespan of the ischaemic penumbra may be reduced in SHRSP compared to the 
normotensive control, WKY. 
 
Study Aims 
The aims of the study were firstly, to assess and compare three different methods of 
calculating penumbra volume to evaluate the strengths and limitations of each method. The 
second aim was to compare the extent and lifespan of the ischaemic penumbra following 
permanent MCAO in SHRSP and WKY rats.  
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4.2 Methods 
 
4.2.1 Data Analysis 
 
Determination of Penumbra Volume 
The MRI data generated from the study in Chapter 3 were used to assess penumbra in 
SHRSP (n=15) and WKY (n=12) rats following permanent MCAO. Strain-specific 
perfusion and diffusion thresholds were applied to quantitative ADC and CBF maps 
acquired over the first 4 hours post-MCAO. This allowed determination of the volume of 
ADC-derived ischaemic injury and the volume of CBF-defined perfusion deficit over 6 
coronal brain slices for both strains at each time point, as previously described in Chapter 
3. Penumbra volume was assessed in 3 ways: 
 
1. By volumetric perfusion-diffusion mismatch, where the volume of ADC-derived 
ischaemic injury was subtracted from the volume of the perfusion deficit at each 
time point from 1-4 hours post-MCAO. 
 
2.  Spatial assessment of the perfusion-diffusion mismatch was carried out on each of 
the 6 coronal slices. Using Image J and Matlab® software, the strain specific 
perfusion and diffusion thresholds were applied to the quantitative CBF map and 
ADC map, respectively, for each coronal slice. The ADC-derived area of ischaemic 
injury was overlaid onto the thresholded CBF map and the remaining perfusion 
deficit was manually delineated and measured as mismatch tissue. The ventricles 
were excluded when delineating the mismatch area. The mismatch areas on each 
slice were combined and multiplied by slice thickness (1.5mm) to generate 
mismatch volume. This was repeated for each time point post-MCAO. 
 
3. Penumbra volume was determined by measuring the growth of the volume of 
ADC-derived ischaemic injury over time. This was achieved by subtracting the 
ADC-derived lesion volume at each time point, from 30 minutes to 4 hours post-
MCAO, from the final infarct at 24 hours, defined by T2 weighted imaging. ADC 
lesion growth was therefore only assessed in rats which survived to 24 hours post-
MCAO (WKY: n=10, SHRSP: n=10).  
 
All MRI data analyses were undertaken blind to rat strain. The data from each animal 
were identified by a numbered code, which gave no indication as to strain identity. The 
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code was broken on the completion of all data analysis to allow assessment of potential 
strain differences. 
 
Pixel-by-Pixel Analysis 
Pixel-by-pixel analysis was undertaken to evaluate the ADC and CBF values of each pixel 
of the ipsilateral and contralateral hemispheres across 6 coronal slices using Matlab® 
software (Mathworks Inc). Quantitative ADC and CBF maps were prepared for pixel-by-
pixel analysis using ImageJ software. ROIs of each hemisphere were generated and used to 
split the ADC and CBF maps for each coronal slice into ipsilateral and contralateral 
hemispheres. The ADC and CBF maps for each of the 6 coronal slices were put together in 
a stack for each hemisphere at each time point from 1-4 hours post-MCAO. The ADC and 
CBF hemispheric stacks for each rat were uploaded into Matlab® and the strain specific 
ADC and CBF thresholds were inserted into the following command: 
 
ThresholdMRI(„ADC_ipsi.tif‟,„CBF_ipsi.tif‟,„ADC_contra.tif‟,„CBF_contra.tif‟,ADC 
threshold,CBF threshold) 
 
Matlab® software defined four tissue compartments: (1) a „normal‟ compartment, where 
pixels had a ADC and CBF value above threshold; (2) a „core‟ compartment, where pixels 
had a ADC and CBF value which were below the thresholds; (3) a „mismatch‟ 
compartment, where ADC was above the diffusion threshold but CBF was below the 
perfusion threshold; and (4) a „negative-mismatch‟ compartment, where ADC was below 
the threshold and CBF was above the threshold.  
The number of pixels in each compartment in each hemisphere across 6 slices at each time 
point was calculated by Matlab®. This allowed the total area of each compartment to be 
determined by multiplying the total number of pixels by the area of a pixel (0.0678m
2
). 
The volume of each compartment was then calculated by multiplying the total pixel area 
by slice thickness (1.5mm). 
 
The mean CBF of the negative mismatch tissue compartment was also assessed at each 
time point for both SHRSP and WKY. For each rat, the area of negative mismatch on each 
slice was selected as a region of interest (ROI). The ROI was then restored onto the 
quantitative CBF map of the appropriate slice at the same time point using ImageJ and the 
CBF value of each pixel in the ROI was determined. This was performed for each of the 6 
coronal slices and mean CBF was calculated by summing the CBF value for each pixel and 
dividing by the total number of pixels.  
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4.2.2 Statistical Analysis 
 
All statistical analyses were undertaken using GraphPad Prism software and all data are 
presented as mean ± SD. The temporal evolution of mismatch volume and ADC-derived 
lesion growth for each strain were assessed by Repeated Measures ANOVA, with 
Bonferroni‟s multiple comparisons post-test. Temporal comparisons in mismatch volume 
and ADC-derived lesion expansion between strains were assessed by 2-way ANOVA with 
Bonferroni‟s post-test. A comparison of penumbra volume by the 3 different calculation 
methods for each strain was also assessed by 2-way ANOVA with Bonferroni‟s post-test. 
Level of statistical significance was set at p<0.05. 
 
4.3 Results 
 
In order to examine the differences between the three different methods of penumbra 
calculation, it is important to identify the effect of time on the two components which are 
used to determine penumbra volume; the ADC-derived lesion volume and the perfusion 
deficit. As previously described in Chapter 3, there is a significant increase in the volume 
of ADC-derived ischaemic injury and the volume of the perfusion deficit over the first 4 
hours post-MCAO in SHRSP and WKY. 
 
4.3.1 Volumetric Perfusion-Diffusion Mismatch 
 
Determination of perfusion-diffusion mismatch volume by the simple subtraction method 
revealed a limited volume of penumbra in both SHRSP and WKY, even at the earliest time 
point examined. At 1 hour post-MCAO, mismatch volume was comparable between the 
strains (22±59mm
3
 and 31±50mm
3
 in WKY and SHRSP respectively, P>0.05, Figure 4-
1A). The volume of perfusion-diffusion mismatch did not change significantly over time in 
WKY. This is likely to be attributable to the temporal increase in perfusion deficit 
observed in both strains, as the ADC-derived lesion and the perfusion deficit both expand 
over time (see Discussion section for greater detail). In WKY, mismatch volume decreased 
from 22±59mm
3
 at 1 hour to 7±34mm
3
 at 4 hours post-MCAO (P=0.24). However, in 
SHRSP, mismatch volume decreased significantly from 31±50mm
3
 at 1 hour to 1±33mm
3
 
at 4 hours post-MCAO (P=0.01). There was no significant difference in mismatch volume 
between the strains at any time point (P=0.63). The data were highly variable in both 
strains, as illustrated by the high standard deviations observed in both WKY and SHRSP at 
all time points post-MCAO (Figure 4-1). 
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Figure 4-1. Perfusion-diffusion mismatch volume in SHRSP and WKY rats following 
permanent MCAO.  Mismatch volume was calculated by a simple subtraction method, where the 
volume of ADC-derived ischaemic injury was subtracted from the volume of perfusion deficit. There 
was no significant difference in mismatch volume between the strains (2-way ANOVA, P=0.63). 
Data are displayed as mean±SD, WKY; n=12, SHRSP; n=15.  
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4.3.2 Spatial Assessment of Mismatch Volume 
 
Pixel-by-pixel analysis of quantitative ADC and CBF maps revealed that the core tissue 
compartment was significantly larger in SHRSP compared to WKY at all time points post-
MCAO (Figures 4-2A, 4-3 & 4-4). At 1 hour post-MCAO, core tissue in SHRSP was 
284±48mm
3
 compared to 193±49mm
3
 in WKY (P<0.001, Figure 4-2A). The ischaemic 
core expanded significantly from 1-4 hours post-MCAO in both strains. In WKY, core 
tissue increased from 193±49mm
3
 at 1 hour to 263±41mm
3
 at 4 hours post-MCAO 
(P<0.001, Figure 4-2A). Similarly, in SHRSP, the ischaemic core increased from 
284±48mm
3
 at 1 hour to 354±46mm
3
 at 4 hours post-MCAO (P<0.001, Figure 4-2A). The 
differing profiles of the ipsilateral and contralateral hemispheres are illustrated in Figures 
4-4 & 4-5. In the ipsilateral hemisphere, the majority of pixels are located in the „core‟ 
quadrant in both WKY and SHRSP. However, as expected in the contralateral hemisphere, 
the vast majority of pixels are located within the „normal‟ quadrant.  
 
Spatial assessment of perfusion-diffusion mismatch produced larger volumes of penumbral 
tissue in both WKY and SHRSP. At 1 hour post-MCAO, mismatch volume was larger in 
WKY compared to SHRSP but this was not statistically significant (43±43mm
3
 and 
36±15mm
3
 in WKY and SHRSP respectively, P>0.05). The volume of perfusion-diffusion 
mismatch decreased over time in both WKY and SHRSP. In WKY, mismatch volume 
decreased from 43±43mm
3
 at 1 hour to its lowest value of 27±24mm
3
 at 3 hours post-
MCAO (P=0.15) and mismatch volume at 4 hours was 29±18mm
3
. In SHRSP, mismatch 
volume significantly decreased from 36±15mm
3
 at 1 hour to 23±19mm
3
 at 4 hours post-
MCAO (P<0.05). However, there was no significant difference in mismatch volume 
between the strains at any time point post-MCAO (P=0.9, Figure 4-2B).The spatial 
distribution of mismatch tissue was similar in WKY and SHRSP. In both strains, mismatch 
tissue was mainly located in the cortex. Perfusion-diffusion mismatch was particularly 
evident on the rostral and caudal slices, where a larger mismatch area was exhibited on 
caudal slices 2 and 3 in both WKY and SHRSP. There was also evidence of mismatch on 
the most rostral slice (slice 7) in both strains. However, there was little evidence of 
mismatch tissue on coronal slices 4, 5 and 6 and this was particularly evident in SHRSP 
(Figure 4-3). In both strains, there was evidence of a limited volume of existing perfusion-
diffusion mismatch at 4 hours post-MCAO.  
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Figure 4-2. Pixel-by-pixel analysis of ADC and CBF values following permanent MCAO in SHRSP & WKY rats. Pixel-by-pixel analysis defined the ischaemic 
core, where pixels fall below the strain specific ADC and CBF thresholds (A). Mismatch was defined where pixels had an ADC value above threshold but CBF fell 
below the strain-specific CBF threshold (B). Data are presented as mean±SD, WKY; n=12, SHRSP; n=15. *p<0.0001, 2-way ANOVA with Bonferroni’s Multiple 
comparisons post-test. 
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Figure 4-3. Pixel-by-pixel analysis of ADC and CBF values in WKY and SHRSP following permanent MCAO. The data shown are from a representative SHRSP 
and WKY rat. Pixel-by-pixel analysis identified four tissue compartments: normal tissue, where ADC and CBF values are above threshold; core tissue (blue shading), 
where ADC and CBF are below threshold; perfusion-diffusion mismatch (yellow shading), where ADC is normal and CBF is below threshold and negative mismatch 
(orange shading), where CBF is normal and ADC is below threshold. Note the larger ventricles in WKY compared to SHRSP.  
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Figure 4-4. Pixel-by-pixel analysis of ADC and CBF values in the ipsilateral hemisphere at 1 hour following permanent MCAO. The data shown are from a 
representative WKY (A) and SHRSP (B). The mean ADC and CBF thresholds for each strain are shown by the dotted lines. Pixels are assigned to one of four 
quadrants depending on their ADC and CBF value: normal, core, mismatch or negative mismatch. 
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Figure 4-5. Pixel-by-pixel analysis of ADC and CBF values in the contralateral hemisphere at 1 hour following permanent MCAO. The data shown are from a 
representative WKY (A) and SHRSP (B). The mean ADC and CBF thresholds for each strain are shown by the dotted lines. Pixels are assigned to one of four 
quadrants depending on their ADC and CBF value: normal, core, mismatch or negative mismatch. 
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4.3.3 Negative Mismatch 
 
Pixel-by-pixel analysis also revealed evidence of negative mismatch tissue, where the 
ADC-derived lesion expands outside the boundary of the perfusion deficit, in both WKY 
and SHRSP (Figures 4-3 & 4-4). Negative mismatch tissue was identified in both strains at 
all time points following MCAO. Greater negative mismatch volumes were recorded in 
WKY but differences between the strains were not statistically significant. At 1 hour post-
MCAO, negative mismatch volume was 55±17mm
3
 in WKY compared to 41±19mm
3
 in 
SHRSP (P>0.05, Figure 4-6). The volume of negative mismatch tissue was persistent and 
did not change significantly over the 4 hour time course in either strain (P>0.05, Figure 4-
6). In WKY, negative mismatch volume was maintained from 55±17mm
3
 at 1 hour to 
53±20mm
3
 at 4 hours post-MCAO (P>0.05). In SHRSP, mismatch volume persisted from 
41±19mm
3
 at 1 hour to 42±11mm
3
 at 4 hours post-MCAO (P>0.05, Figure 4-6). Negative 
mismatch tissue was identified on all 6 coronal slices and was found sub-cortically at the 
boundary of the ischaemic core in both strains (Figure 4-3). 
 
Analysis of CBF values revealed negative mismatch tissue was significantly hypoperfused 
compared to contralateral CBF in both strains but blood flow was significantly higher than 
the strain specific CBF thresholds (Figure 4-7). In WKY at 1 hour post-MCAO, CBF in 
negative mismatch tissue was 49±4 ml/100g/min compared to 135±23 ml/100g/min in the 
contralateral hemisphere (P<0.001), and significantly higher than the strain-specific CBF 
threshold (23±8 ml/100g/min, P<0.001, Figure 4-7A). Similarly, in SHRSP at the same 
time point, negative mismatch tissue was 71±9 ml/100g/min compared to a contralateral 
CBF of 113±22 ml/100g/min (P<0.001), and significantly higher than the SHRSP 
perfusion threshold (36±13 ml/100g/min, P<0.001, Figure 4-7B). 
 
4.3.4 Penumbra determined from ADC-derived lesion expansion 
 
The volume of the ADC-derived lesion increased over time in both strains as the penumbra 
became incorporated into the ischaemic core, until it matched the final (oedema-corrected) 
infarct volume. ADC lesion enlargement can therefore be used to indirectly measure the 
penumbra. Expansion of the ADC-derived lesion decreased with time and by 3 hours post-
stroke, the lesion matched the final (oedema-corrected) infarct volume in both strains. In 
SHRSP, penumbra volume, derived from ADC lesion volume versus final infarct volume, 
was 43±45mm
3
 at 30 minutes and decreased in size to 0±44mm
3
 at 3 hours post-MCAO 
(P<0.001). In WKY, penumbra volume was 106±73mm
3
 at 30 minutes, declining 
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Figure 4-6. The temporal evolution of negative mismatch tissue in SHRSP and WKY rats 
following permanent MCAO. Negative mismatch represents tissue where CBF is above threshold 
and ADC is below threshold and identifies expansion of the ADC-derived lesion beyond the 
boundaries of the perfusion deficit. There was no significant difference in negative mismatch 
volume between the strains (2-way ANOVA, p>0.05). Data are displayed as mean±SD, WKY;  
n=12, SHRSP; n=15.
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Figure 4-7. Perfusion in the region of negative mismatch compared to the contralateral hemisphere in WKY and SHRSP. The dotted line demarcates the mean 
CBF threshold for each strain. Negative mismatch CBF vs contralateral CBF *p<0.001, 2-way ANOVA with Bonferroni’s post-test. Negative mismatch vs strain-specific 
CBF threshold +p<0.001, 1-sample t test. Data are presented as mean±SD, WKY; n=12, SHRSP; n=15). 
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significantly over time to 0±41mm
3
 at 3 hours post-MCAO (P<0.001). Penumbra volume 
was significantly higher in WKY compared to SHRSP at 30 minutes post-MCAO 
(43±45mm
3
 vs 106±73mm
3
, for SHRSP and WKY respectively, P<0.05, Figure 4-8) but 
was not significantly different between the strains at later time points. There was no 
significant difference in penumbra volume between the strains calculated using ADC 
expansion from 1-4 hours post-MCAO (P>0.05, Figure 4-9). 
 
The ADC-derived lesion evolves in an annular pattern, whereby the lesion expands 
relatively uniformly at its boundary and expansion of the ADC lesion is evident across all 
6 coronal slices in both WKY and SHRSP. (Figure 4-10).  The ADC-derived lesion and 
perfusion deficit expand in a similar anatomical direction in both strains from 1-4 hours 
post-MCAO (Figure 4-10). 
 
4.3.5 Comparing penumbra calculation methods 
 
Volumetric analysis generated lower volumes of mismatch tissue compared to spatial 
assessment in both strains from 1-4 hours post-MCAO (Figure 4-11). However, this 
difference did not reach the level of statistical significance at any time point. In WKY, 
mismatch volume defined by spatial assessment was 2 fold larger than mismatch volume 
determined by the volumetric method at 1 hour post-MCAO (43±43mm
3 
vs 22±59mm
3
, for 
spatial and volumetric assessment respectively, P>0.05, Figure 4-11A). However, in 
SHRSP at the same time point, mismatch volume identified by spatial assessment was 
comparable to the mismatch volume defined by volumetric assessment (36±15mm
3 
vs 
31±50mm
3
, for spatial and volumetric assessment respectively, P>0.05, Figure 4-11B). In 
addition, the volumetric data were more variable than the data analysed using the spatial 
method in both WKY and SHRSP. In WKY, the coefficient of variation for the volumetric 
method was 268% compared to 100% for the spatial assessment method at 1 hour post-
MCAO. Similarly, in SHRSP at the same time point, the coefficient of variation was larger 
for the volumetric mismatch method compared to the spatial assessment method (161% vs 
42% for volumetric and spatial assessment, respectively).
 
 
There was no significant difference in penumbra volume calculated by volumetric or 
spatial perfusion-diffusion mismatch or ADC expansion from 1-4 hours post-MCAO in 
both strains (P>0.05, Figure 4-11). However, at 1 hour post-MCAO, penumbra volume as 
measured by ADC growth was higher than mismatch volume in both SHRSP and WKY. In 
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Figure 4-8. Growth of ischaemic injury from 30 minutes to 24 hours post-MCAO in SHRSP 
and WKY rats. Line denotes the mean. *p<0.05, Student’s unpaired t test. WKY; n=10, SHRSP; 
n=10. 
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Figure 4-9. Growth of the ADC-derived lesion from 30 minutes to 4 hours post-MCAO. The 
ADC lesion at each time point was subtracted from final (oedema corrected) infarct volume to 
calculate the volume of penumbra in WKY (n=10) and SHRSP (n=10) following permanent MCAO. 
Data are presented as mean±SD. *p<0.05, 2-way ANOVA with Bonferroni’s post-test.  
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Figure 4-10. Comparison of potentially salvageable penumbra at 1 hour post-MCAO as 
determined by perfusion-diffusion mismatch (using pixel-by-pixel method) and ADC lesion 
expansion in a representative SHRSP and WKY rat. Pixel-by-pixel analysis assigns pixels to a 
tissue compartment according to the ADC and CBF value of each pixel. Penumbra volume was 
also defined by growth of the ADC-derived lesion, where penumbra at 1 hour post-MCAO can be 
defined by subtracting the ADC lesion at 1h from the ADC lesion at 4 hours post-MCAO, which 
matches the final infarct at 24 hours. The spatial distribution of the areas of perfusion deficit growth 
from 1-4 hours post-MCAO are also shown. 
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Figure 4-11. Comparison of the 3 methods used to define penumbra in SHRSP and WKY rats following permanent MCAO. Penumbra volume was determined; 
1. by volumetric perfusion-diffusion mismatch, where the volume of ADC-derived ischaemic injury is subtracted from the volume of perfusion deficit (blue, WKY: n=12, 
SHRSP: n=15). 2. spatially, where mismatch area is manually delineated on each of 6 coronal slices to determine total mismatch volume (red, WKY: n=12, SHRSP: 
n=15). 3. by growth of the ADC-derived lesion, where the ADC lesion at each time point from 30 minutes to 4 hours post-MCAO was subtracted from the final, oedema-
corrected infarct volume at 24h (green, WKY: n=10, SHRSP: n=10). 
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WKY, ADC expansion defined penumbra was 65±41mm
3
 compared to 43±43mm
3
 and  
22±59mm
3
 as determined by spatial and volumetric mismatch, respectively, although this 
was not statistically significant (P>0.05, Figure 4-11A). Similarly, in SHRSP at 1 hour 
post-MCAO, ADC expansion-defined penumbra was 41±45mm
3
 compared to 36±15mm
3
 
and 31±50mm
3
 as determined by spatial and volumetric mismatch, respectively (P>0.05, 
Figure 4-11B). At later time points, as penumbra volume, defined by ADC lesion growth, 
declines, penumbra defined by spatial assessment of mismatch volume persists until 4 
hours.  
 
The ADC-derived lesion evolves in an annular pattern, whereby the lesion expands 
relatively uniformly at its boundary (Figure 4-10). The anatomical location of the 
penumbra defined by this method therefore differs from that identified by perfusion-
diffusion mismatch, where the penumbra is found almost exclusively within the cortex 
(Figure 4-10). 
 
4.4 Discussion 
 
Clinical research has recognised the need for a consensus in the method used to identify 
potentially salvageable tissue in stroke patients, as well as the need for universally 
accepted thresholds of tissue abnormality (Bandera et al, 2006). The perfusion-diffusion 
mismatch method of penumbra determination has yet to be validated in clinical and pre-
clinical stroke research.  This study is the first to compare different methods to define the 
ischaemic penumbra in a clinically relevant rodent stroke model with recognised risk 
factors. Strain-specific diffusion and perfusion thresholds were retrospectively applied to 
MRI data to define the ADC lesion and perfusion deficit used to calculate mismatch 
volume (volumetrically or spatially) during the acute phase of stroke in the SHRSP and its 
normotensive control strain, WKY. In addition to perfusion-diffusion mismatch, the 
ischaemic penumbra was determined indirectly by assessing expansion of the ADC-
derived lesion over time. 
 
Previous studies have reported a reduced volume of penumbral tissue in rat models with 
stroke risk factors. Following permanent MCAO induced by intraluminal filament, 
perfusion-diffusion mismatch was assessed over time in spontaneously hypertensive (SHR) 
and renovascular hypertensive WKY (RH-WKY) and normotensive WKY rats. Mismatch 
volume was comparable in both hypertensive groups at 30 minutes post-MCAO 
(66±25mm
3
 and 55±17mm
3
 in SHR and RH-WKY respectively), however, at the same 
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time point, normotensive WKY rats exhibited a significantly larger volume of mismatch 
tissue (117±14mm
3
, P<0.01) (Letourneur et al, 2011). The mismatch volumes reported by 
this study group are comparable to the volume of penumbra reported in the present study at 
30 minutes post-MCAO using the ADC lesion expansion method, where penumbra was 
significantly larger in normotensive WKY compared to the hypertensive SHRSP strain 
(106±73mm
3
 and 43±45mm
3
 in WKY and SHRSP respectively). However, Letourneur and 
colleagues reported that mismatch defined penumbra volume was significantly larger in 
normotensive WKY compared to SHR and RH-WKY at all time points, from 30 minutes 
to 4 hours post-MCAO. This differs from the findings of the present study where, 
penumbra volume was only significantly higher in WKY compared to SHRSP at 30 
minutes post-MCAO and at all later time points there was no significant difference 
between the strains, irrespective of the penumbra calculation method used. This suggests 
that there may only be an increased potential for tissue salvage in the WKY within the first 
hour following stroke, compared to SHRSP, where penumbra salvage may be limited at all 
acute time points following permanent MCAO.  
 
Furthermore, Legos and colleagues found no evidence of perfusion-diffusion mismatch in 
SHR rats from 1-3 hours following permanent MCAO and the DWI lesion at 1 hour 
matched the final infarct at 24 hours (Legos et al, 2008). The authors demonstrated a 
significant mismatch volume in normotensive Sprague-Dawley rats up to 2.5 hours post-
MCAO. However, the SHR and Sprague-Dawley groups cannot be directly compared 
since SHRs underwent distal MCAO by electrocoagulation while Sprague-Dawley rats 
underwent proximal MCAO by intraluminal filament. Nevertheless, these studies suggest 
that hypertensive rat strains may have a limited potential for tissue salvage following 
permanent MCAO.   
 
Previously, only one study has compared penumbra in SHRSP and WKY rat strains. 
McCabe and colleagues reported that perfusion-diffusion mismatch was significantly 
reduced in SHRSP compared to WKY at 1 hour following permanent MCAO (McCabe et 
al, 2009). However, mismatch was only assessed on a single coronal slice within the 
territory of the MCA and this limitation was recognised by the authors. Mismatch area in 
SHRSP was 3±6mm
2
 compared to 10±4mm
2
 in WKY (P<0.05). This differs from the 
present study, where there was no significant difference in mismatch volume, defined 
spatially and volumetrically, at 1 hour post-MCAO. The advantage of the present study is 
that the volume of mismatch (rather than area) was assessed across 6 slices covering the 
 151 
MCA territory and therefore a more accurate assessment of differences in mismatch tissue 
was determined.   
 
Mismatch volume has previously been determined in rodent stroke models by volumetric 
analysis (Meng et al, 2004; Bråtane et al, 2009; Henninger et al, 2009) and by spatial co-
registration of MRI perfusion and diffusion images (Letourneur et al, 2011). In the current 
study, spatial assessment of penumbra gave rise to a small but measurable mismatch 
volume in SHRSP and WKY and although the SHRSP strain demonstrated a significantly 
larger perfusion deficit and ADC-derived lesion, mismatch volume was not significantly 
different between strains from 1-4 hours post-MCAO. However, volumetric analysis 
revealed a smaller mismatch volume in both strains. It has been reported previously in 
clinical research, that simple arithmetic subtraction of the DWI lesion from the PWI 
defined perfusion deficit underestimates penumbral mismatch by 40% compared to 
mismatch calculated by co-registering DWI and PWI (Ma et al, 2009). In addition, these 
authors reported that underestimation of mismatch by the simple volumetric method is 
exacerbated over time, as the ischaemic core expands to encompass the penumbra. 
 
In the present study, pixel-by-pixel analysis revealed the presence of negative mismatch 
tissue, where the ADC-derived ischaemic lesion expands beyond the boundary of the 
perfusion deficit. The phenomenon of negative mismatch has been identified previously in 
rodent stroke models
 
(Foley et al, 2010; Letourneur et al, 2011). Foley and colleagues 
defined tissue with a low ADC value and CBF above threshold, as a compartment of high-
flow infarction. The term high-flow infarction may be misleading as tissue in this 
compartment may be hypoperfused relative to control CBF but is above the perfusion 
threshold (as shown in Figure 4-8). In addition, the tissue cannot be classed as infarct since 
it is being examined in the first 4 hours following stroke. There is both clinical and 
preclinical evidence that the ADC lesion has the capacity to return to normal ADC values 
following reperfusion within the first few hours following stroke (Minematsu et al, 1992; 
Hasegawa et al, 1994; Kidwell et al, 2000). Nevertheless, Foley and colleagues 
consistently identified tissue which was below their calculated ADC threshold and above 
their CBF threshold in the acute time period post-MCAO in Sprague-Dawley rats.  
Similarly, Letourneur and colleagues detected a tissue compartment which they defined as 
inverse perfusion-diffusion mismatch, where ADC is reduced but perfusion is normal. 
However, this study group only detected inverse mismatch tissue in hypertensive SHRs 
and RH-WKYs and did not identify inverse mismatch tissue in the normotensive control 
strain, WKY (Letourneur et al, 2011). This differs from the results of the present study, 
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where negative mismatch was identified in SHRSP and in WKY. However, these authors 
demonstrated evidence of inverse mismatch tissue located subcortically, in a similar 
anatomical location as reported in the present study. 
 
Despite reports of negative mismatch tissue in the preclinical literature, the physiological 
basis of this tissue compartment has yet to be discussed. Negative mismatch tissue may 
potentially occur as a consequence of peri-infarct spreading depolarisations from the 
ischaemic core, which may increase cellular injury independently of cerebral blood flow, 
therefore extending the outer boundary of injured tissue beyond the perfusion deficit. High 
levels of potassium ions and glutamate in the ischaemic core can actively propagate tissue 
depolarisation, ionic imbalances and glutamate release into adjacent tissue and it has been 
reported that in rats, peri-infarct depolarisations can originate in the striatum (Hartings et 
al, 2003). This may explain the location of negative mismatch tissue observed in this study 
and by others (Foley et al, 2010; Letourneur et al, 2011). Increased levels of potassium 
ions and glutamate can induce vasodilatation, where glutamate acts via several calcium 
dependent mechanisms (Drake & Iadecola, 2007). This may increase blood flow in 
hypoperfused tissues at the boundary of the ischaemic core and contribute to the 
phenomenon of negative mismatch.  Flow independent infarct growth has been reported 
both in human stroke patients (Heiss et al, 2001) and more recently, in rodent stroke 
models, where at 12 hours post MCAO, 9% of brain tissue was necrotic but did not 
demonstrate any flow restrictions (Woitzik et al, 2009). In addition, the extracellular 
concentration of excitatory amino acids and free radicals produced by severely 
hypoperfused tissue within the ischaemic core may be increased by cytotoxic oedema, 
enhancing the spread of detrimental effects to neighbouring tissue, and contributing to 
expansion of the core (Loubinoux et al, 1997).  This illustrates how the influence of toxic 
mediators is not restricted to their site of origin and can influence tissue which does not fall 
below the critical blood flow threshold. 
 
It has been previously suggested that the phenomenon of negative mismatch arises from 
intersubject variations associated with the use of fixed perfusion and diffusion thresholds 
(Shen et al, 2003). However, the present study demonstrated that although the negative 
mismatch tissue compartment is hypoperfused relative to the contralateral hemisphere, 
blood flow is significantly higher than the CBF threshold calculated for each strain. This 
eliminates the possibility that negative mismatch tissue arises solely as a result of 
inaccuracy in determining perfusion thresholds and suggests that it is a true phenomenon 
which can be detected in acute stroke.  
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In the present study, negative mismatch tissue is consistently identified in the sub cortex, 
particularly in the region of the caudate putamen and the globus pallidus. This finding is in 
agreement with previous reports, where negative mismatch tissue was found in a similar 
anatomical location (Foley et al, 2010; Letourneur et al, 2011). In the present study, 
negative mismatch tissue was consistently identified across all 6 coronal slices. However, 
Letourneur and colleagues only detected inverse perfusion-diffusion mismatch on coronal 
slices located within the core of the MCA territory, equivalent to slices 4, 5 and 6 as 
defined in the present study. 
The volume of negative mismatch tissue was comparable between the strains and did not 
change over time. This finding is in agreement with Foley et al (2010) who recently 
reported the persistence of negative mismatch tissue over the first 4 hours following 
permanent MCAO.   
 
Although the volumetric analysis method can be used to provide a quick and simple 
measure of penumbra, the inclusion of negative mismatch tissue by this method limits its 
use, as penumbra volume may be underestimated. Conversely, the volumetric mismatch 
method may overestimate penumbra as the ventricles are included as a component of the 
perfusion deficit. Study groups who have used this method have failed to report whether 
they excluded the ventricles (Meng et al, 2004; Bråtane et al, 2009; Henninger et al, 2009). 
This may have a major influence on strain comparisons of penumbra volume. This is 
particularly evident when comparing WKY and SHRSP, since the ventricles are 
substantially larger in WKY, as observed in the present study. However, this did not 
appear to influence strain comparisons in this study as mismatch volume was not 
significantly different in SHRSP and WKY. However, it is still an important point to 
consider, as failure to exclude the ventricles could potentially contribute to false positive 
results when comparing perfusion-diffusion mismatch in SHRSP and WKY rat strains.  
 
 In addition, the volumetric method provides no information regarding the anatomical 
location of penumbra or its extent throughout the territory of the middle cerebral artery. 
Furthermore, there is greater variability in the data analysed using the volumetric method 
compared to spatial assessment of mismatch. This may arise due to intersubject variation in 
the volume of negative mismatch tissue which is included when using the volumetric 
mismatch method. The concept of negative mismatch does not apply with the spatial 
mismatch method since only regions of perfusion deficit which show no ADC abnormality 
are included in the calculation of penumbra. Using this method, the volume and anatomical 
location of the penumbra can be determined throughout the MCA territory and temporal 
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changes in the evolution of ischaemic injury and the region of hypoperfused tissue can be 
investigated, making it a much more informative method than simple arithmetic 
subtraction of the two volumes.  
 
Despite its widespread use as a research tool, the mismatch model has been criticised for 
the inclusion of benign oligaemic tissue within the perfusion deficit and for the assumption 
that the diffusion lesion represents irreversibly damaged infarct core, when it has been 
demonstrated that the DWI lesion can be completely or partially reversed if reperfused 
within 3 hours of stroke (Minematsu et al, 1992; Hasegawa et al, 1994; Kidwell et al, 
2000), although more recent data suggest that only a small component of the DWI lesion is 
reversible.  Chemmanam and colleagues reported that only 6 out of 93 stroke patients 
demonstrated minor regions of DWI lesion reversal when acute DWI data was compared to 
subacute DWI or T2 weighted images acquired at 90 days following stroke onset 
(Chemmanam et al, 2010). Criticisms of the PWI/DWI mismatch model led to the 
construction of a revised technique where thresholds are used to distinguish between the 
perfusion deficit and benign oligaemic tissue and also recognises that a component of the 
DWI lesion may be salvaged and therefore comprises a component of the penumbra 
(Kidwell et al, 2003). 
 
In clinical research, DWI lesions provide an approximation of ischaemic injury, whereas 
more often in experimental stroke research, the ADC-derived lesion is favoured. 
Calculating growth of the DWI or ADC lesion over time is an alternative indirect method 
of determining potentially salvageable tissue and this technique has been used in clinical 
research to examine infarct growth and define penumbra in patients where perfusion 
imaging was unavailable (Dani et al, 2010). Karonen et al, (2000) reported a significant 
correlation between DWI lesion growth and the zone of hypoperfused tissue at the 
boundary of the iachaemic core, which correlated significantly with infarct growth over the 
following week in 16 stroke patients. Furthermore, these authors reported that infarct 
growth correlated significantly with clinical outcome.  Conversely Butcher et al (2005) 
failed to identify a significant correlation between mismatch volume and infarct growth. 
The correlation between DWI lesion growth and mismatch volume may be dependent on 
the perfusion parameter, as these conflicting studies used different parameters to define the 
hypoperfused region. Karonen et al, assessed tissue hypoperfusion using SPECT, while 
Butcher and colleagues used contrast agent bolus tracking to acquire MRI perfusion 
weighted images.  
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The DWI lesion growth method provides a retrospective analysis of penumbral volume as 
the DWI lesion must proceed to infarction to allow salvageable tissue at a particular time 
point post-stroke to be calculated. Therefore, although a useful research tool, this method is 
unsuitable for identifying patients suitable for acute stroke therapy. In addition, Dani et al 
(2010) recognised that this method could potentially overestimate penumbra due to acute 
tissue swelling. However, in the present study, during the acute phase (within the first 4 
hours) there was no evidence of brain swelling, which could influence the calculation of 
lesion growth, as discussed in the previous chapter. 
 
Penumbra as assessed by ADC lesion growth provides no information regarding temporal 
alterations in the volume of perfusion deficit and therefore limits the use of this method. 
Serial imaging in our study revealed an increase in the volume of perfusion deficit over the 
first 4 hours post-MCAO in both SHRSP and WKY, as described in detail in the previous 
chapter. Temporal increases in perfusion deficit of a similar magnitude to the growth in 
ADC lesion will result in a persistence of penumbra volume over time as demonstrated by 
spatial mismatch analysis, with some existing penumbra being recruited into ischaemic 
core, as new tissue is incorporated into penumbra. Differences in the anatomical location 
of the penumbra as defined by the spatial mismatch method and ADC lesion expansion can 
be explained by the increase in perfusion deficit over time. Growth of the ADC-derived 
lesion volume at each time point does not take into account the evolving perfusion deficit 
since it is derived from diffusion data at a later time point or the final infarct volume at 24 
hours. In contrast, spatial assessment of mismatch volume uses the perfusion deficit at that 
each time point and therefore provides a snapshot of hypoperfused tissue capable of 
responding to reperfusion or neuroprotective intervention.  
 
Summary 
The results from this study demonstrate that the hypertensive SHRSP strain may have a 
reduced potential for penumbra salvage compared to the normotensive control, WKY. 
However, this is only evident within the first hour following stroke onset. At later time 
points, from 1-4 hours post-MCAO, neither strain exhibits a significant penumbra volume 
and there is no significant difference in penumbra volume between the strains, irrespective 
of the method used to calculate penumbra.  The results of this study have also 
demonstrated that volumetric assessment of mismatch determines a lower volume of 
mismatch tissue, compared to the spatial assessment method, where a measurable volume 
of penumbra is detected in both strains. ADC lesion expansion was also examined but this 
method does not utilise perfusion data and can only be used retrospectively. The method 
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used to detect penumbra is crucial in pre-clinical MRI research, particularly if assessing 
potential therapeutic strategies to salvage penumbra, and clinically, where penumbral 
volume is used as a criterion for identifying those patients who are most likely to benefit 
from thrombolytic therapy or for recruitment of patients into clinical trials. On the basis of 
the results of the present study, the spatial assessment method is the most informative 
method of penumbra determination, as it utilises both perfusion and diffusion data and 
allows spatial evaluation of mismatch. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 5. 
The effect of NADPH oxidase inhibition with apocynin on 
stroke outcome following permanent and transient ischaemia 
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5.1 Introduction 
 
Oxidative stress pathways are a major mediator of irreversible cellular injury following 
ischaemic stroke. Ischaemia induces the generation of free radical species which 
overwhelm the endogenous scavenging capacity of cellular antioxidant defences. Free 
radical species contribute to cellular injury by mediating enzyme inactivation, protein 
denaturation, lipid peroxidation and damage to DNA and cytoskeletal components (Brouns 
& De Deyn, 2009). In addition to the reactive oxygen species, superoxide (O2
-
), hydroxyl 
(OH
-
) and the non radical, hydrogen peroxide (H2O2), a number of reactive nitrogen 
species are generated following cerebral ischaemia. These include nitric oxide (NO), which 
has a protective role by mediating vasodilatation to increase cerebral blood flow. However, 
increased levels of superoxide under ischaemic conditions reduce the bioavailabity of nitric 
oxide and therefore limit its vasoprotective action. Superoxide and endothelium derived 
nitric oxide react to form peroxynitrite (OONO
-
), which is a highly reactive nitrogen 
species which also contributes to cellular injury. 
 
Under normal physiological conditions, superoxide is constitutively produced and can act 
as a cell signalling molecule to influence the tone and proliferation of vascular smooth 
muscle cells (Miller et al, 2006). However, superoxide has poor membrane permeability 
due to its negative charge and it has a very short half life which may limit its direct impact 
on vascular function under normal conditions (Miller et al, 2006). Nevertheless, superoxide 
can promote vasodilatation of cerebral microvessels although under ischaemic conditions, 
it generally promotes vasoconstriction by inactivating endothelial nitric oxide synthase 
(Paravacini et al, 2004). 
 
Until recently, it was widely accepted that under ischaemic conditions, mitochondria were 
the major source of reactive oxygen species, such as superoxide. However, recent evidence 
suggests that NADPH oxidase is the principal source of superoxide anions during 
ischaemia (Brennan et al, 2009). NADPH oxidases are a family of enzyme complexes with 
the sole function of generating reactive oxygen species. Each isoform of NADPH oxidase 
is distinguished by the membrane spanning catalytic subunit that it utilises to transfer 
electrons from NADPH to molecular oxygen to generate superoxide (Selemidis et al,  
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Figure 5-1. The cellular distribution of NADPH oxidase isoforms in the vascular wall. Nox1, 
Nox2, Nox4 and Nox5 are expressed in endothelial cells (EC). Adventitial fibroblasts express Nox2 
and Nox4 and vascular smooth muscle cells (VMSCs) express Nox1 and Nox4. Reproduced from 
Selemidis et al (2008). 
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2008). Four isoforms of NADPH oxidase are expressed in the vascular wall (Figure 5-1). 
Nox1 is expressed in endothelial and vascular smooth muscle cells; Nox2 is expressed in 
endothelial cells and adventitial fibroblasts; Nox4 is expressed in vascular smooth muscle 
cells, adventitial fibroblasts and endothelial cells and Nox5 is expressed in endothelial cells 
only (Selemidis et al, 2008). In addition, the Nox2 isoform is also expressed in neutrophils, 
macrophages, T cells and platelets. However, the specific role of reactive oxygen species 
derived from each isoform in stroke is unclear (Miller et al, 2006). Localisation studies 
have demonstrated that Nox2 and Nox4 are highly localised in the hippocampus and 
cerebral cortex of mouse brain, with Nox2 upregulation following stroke reported to 
contribute to oxidative stress-induced neuronal cell death (Serrano et al, 2003; Vallet et al, 
2005). 
 
The role of NADPH oxidase in the generation of reactive oxygen species during ischaemia 
has made it an important target for neuroprotection and there is great interest in developing 
therapeutic strategies that target NADPH oxidase-derived reactive oxygen species in the 
treatment of vascular disease. Apocynin (4‟-hydroxy-3‟-methooxyacetophenone) is a 
methoxy-substituted catechol which was originally isolated from the roots of Canadian 
hemp in the late 1800s. It is capable of crossing the blood brain barrier (BBB) and has low 
toxicity (Tang et al, 2008). It inhibits NADPH oxidase activity by blocking the association 
of cytosolic components (i.e. the migration of the cytosolic p47phox subunit) with the 
membrane bound catalytic core (Stolk et al, 1994). However, the mechanism of action of 
apocynin is not well understood and it is not yet clear whether it inhibits NADPH oxidase 
directly or by blocking the activity of an upstream element which leads to assembly of the 
enzyme (Selemidis et al, 2008). Furthermore, there is evidence to suggest that apocynin is 
a pro-drug and requires activation by cellular myeloperoxidase activity to form 
metabolically active diapocynin, before it can inhibit NADPH oxidase subunit assembly 
(Simons et al, 1990; Stolk et al, 1994).  
 
Inhibition of NADPH oxidase by apocynin has been shown to have neuroprotective effects 
in rodent stroke models. However, to date, all the published studies evaluating the efficacy 
of apocynin have used transient ischaemia models and there are no reports of the efficacy 
of apocynin treatment following permanent cerebral ischaemia. Wang and colleagues 
demonstrated the protective effect of apocynin in a global ischaemia-reperfusion model, 
where apocynin protected against oxidative stress in the hippocampus of the gerbil (Wang 
et al, 2006). In a mouse transient focal cerebral ischaemia model, pre-treatment with 
apocynin reduced brain superoxide levels at 24 hours post-ischaemia (Jackman et al, 
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2009).  Significant improvements in stroke outcome have been reported following 
apocynin treatment in mouse ischaemia-reperfusion models, where infarct volume has 
been reduced by up to 50% of control groups at 24 hours post-MCAO (Tang et al, 2008; 
Chen et al, 2009). Similar results have been observed in rat ischaemia-reperfusion models. 
Tang and colleagues observed a significant reduction in infarct volume at 24 hours post-
MCAO following apocynin administration 1 hour hour after stroke onset in Sprague-
Dawley rats. NADPH oxidase activity and superoxide levels were also significantly 
reduced (Tang et al, 2007). More recently, Genovese and colleagues reported that 
intraperitoneal administration of 5mg/kg apocynin 5 minutes prior to reperfusion 
significantly improved behavioural outcome and reduced both cortical and striatal damage 
compared to vehicle-treated rats (Genovese et al, 2011).  
 
Despite these encouraging reports, there is a lack of pre-clinical studies examining the 
potential neuroprotective effects on animals with stroke risk factors. To date, only one 
group has evaluated apocynin in an animal model with a known stroke risk factor, in this 
case, age. It was reported that apocynin treatment exhibited a neuroprotective effect in 
young rats, however, when administered to aged rats, apocynin exacerbated ischaemic 
injury and increased mortality rate (Kelly et al, 2009). Furthermore, NADPH oxidase 
inhibition with apocynin has yet to be evaluated in rodent stroke models with genetic 
stroke risk factors, such as hypertension. It is essential that all potential neuroprotective 
therapies are assessed in animal models with stroke co-morbidities before being considered 
for clinical trial, to improve the likelihood of a favourable outcome in human stroke 
patients. The Stroke Therapy Academic Industry Roundtable (STAIR) recommended the 
use of preclinical models with stroke co-morbidities following the repeated failures of 
stroke therapies in clinical trials. The predominant use of homogenous animal models with 
optimised physiological variables is believed to be a factor in the failure of translation from 
bench to bedside (Saver et al, 2009).  
 
Oxidative stress in the vasculature has been associated with genetic and experimental 
hypertension. In SHR rats it has been reported that expression of NADPH oxidase subunits 
is increased, as well as increased activity of the enzyme in the vasculature (Zalba et al, 
2000). This leads to increased production of superoxide anions which can reduce the 
bioavailability of nitric oxide by promoting the formation of peroxynitrite (Figure 5-2) 
resulting in dysfunction of the endothelium and impaired vasodilatation (Alexander et al, 
2000). It has also been demonstrated that NO bioavailability is reduced in aged WKY and 
SHRSP compared to young rats. An increase in superoxide production in aged WKY and  
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Figure 5-2. The role of oxidative stress in vascular dysfunction. Hypertension induces 
increased expression and activity of NADPH oxidase leading to enhanced production of superoxide 
anions (O2
-
) (shown in green) and subsequently, nitric oxide (NO) bioavailabilty is reduced with 
increased formation of peroxynitrite (OONO
-
). Increased levels of oxidative stress in hypertension 
contribute to vascular dysfunction by inhibiting endothelium-mediated vasodilatation and increasing 
vascular tone, which exacerbates hypertension. Modified from Didion et al (2008). 
 
eNOS 
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SHRSP may contribute to the reduced NO bioavailability by scavenging (Hamilton et al, 
2001). In addition, SHRSPs demonstrate increased levels of 20-HETE, which is a potent 
vasoconstrictor which further promotes the generation of superoxide (Cheng et al, 2008;  
Dunn et al, 2008). Increased levels of superoxide in SHRSP also arise as a result of 
reduced activity of SOD (Kishi et al, 2004). Furthermore, the activity of endothelial nitric 
oxide synthase (eNOS) is impaired in SHRSP compared to WKY rats (Yoshitomi et al, 
2011). All of these factors contribute to the increased levels of oxidative stress 
demonstrated by SHRSP and therefore this strain may be particularly amenable to 
neuroprotection by inhibition of NADPH oxidase with apocynin.  
 
Study Aims 
 
The aims of this study were: 
 
(1) to assess the effects of apocynin treatment on stroke outcome following permanent 
MCAO 
(2) to assess the effects of apocynin treatment on stroke outcome in a model of 
transient focal ischaemia 
(3) to evaluate the influence of apocynin treatment on the acute evolution of penumbral 
tissue in a rat model displaying known stroke risk factors (SHRSP) using the MRI 
perfusion-diffusion mismatch model 
 
5.2 Methods 
 
5.2.1 Power Calculations 
 
The sample size in each treatment group was determined prior to the commencement of 
each study using a priori power analysis calculator (http://www.stat.ubc.ca/~rollin/st/ssize). 
Based on the reductions in infarct volume with apocynin treatment reported previously 
(Tang et al, 2007; Genovese et al, 2011), to detect a 35% reduction in infarct volume with 
a common standard deviation (σ) of 20, would require a sample size of 6 rats in each 
group, where the type I error rate (α) is 0.05 and the power is 0.80. 
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5.2.2 Apocynin Dosage 
 
Low (5mg/kg) and high dose (30mg/kg) apocynin treatment was evaluated in this study. 
These doses were selected due to the disparity in apocynin dosage reported in previous rat 
studies, where some study groups administered apocynin intraperitoneally at a dose of 
50mg/kg (Tang et al, 2007), while other investigators demonstrated neuroprotective 
efficacy using smaller doses of apocynin, up to 5mg/kg (Kelly et al, 2009; Genovese et al, 
2011).  
 
Apocynin was dissolved in 0.1% dimethylsulphoxide (DMSO). The vehicle used was 0.1% 
DMSO. The rats in all studies discussed in this chapter received 5 mg/kg apocynin, 
30mg/kg apocynin or 1.5ml of 0.1% DMSO (vehicle). In the permanent MCAO study 
(Study 1) rats received treatment by intraperitoneal injection. In the transient MCAO 
studies (Studies 2 and 3) treatment was administered intravenously. 
 
5.2.3 Randomisation and Blinding 
 
Allocation of rats to treatment group was randomised using a random number generator 
(http://www.randomization.com). Each rat was given a number and the generator randomly 
allocated a treatment of vehicle, low dose or high dose apocynin to each number. A copy 
of this treatment schedule was kept by 3 colleagues within the department. On the day of 
each experiment, the rat was weighed and the volume of 5mg/kg and 30mg/kg to be 
administered was calculated and written on the back of an experimental procedures card 
along with 1.5ml of vehicle. Prior to drug administration, one of the three colleagues with 
the treatment schedule would prepare the appropriate drug treatment by drawing up the 
appropriate volume of drug into a 2ml syringe following consultation of the experimental 
procedures card. Sticky tape was then wrapped around the syringe to conceal the volume 
of drug. The unused eppendorfs and the flask containing the vehicle were then returned to 
the freezer and the fridge respectively. These procedures ensured total blinding of the 
treatment administered to each animal. At the end of the experiments, when all behavioural 
assessments had been performed and all data analysis pertaining to stroke outcome had 
been analysed, the treatment administered to each animal was revealed. This prevented any 
bias when analysing the stroke outcome data.  
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5.2.4 Permanent Focal Ischaemia (Study 1) 
 
Male WKY rats (n=24) aged 12-16 weeks and weighing 270-330g were used in this study. 
Rats were randomly allocated to one of the three treatment groups as described previously: 
1.5ml vehicle (0.1% DMSO) (n=8), 5mg/kg apocynin (n=8), 30mg/kg apocynin (n=8). On 
the day prior to surgery, vibrissae evoked forelimb placement was assessed as described in 
Chapter 2 to ensure that rats showed no limb preference or neurological impairment.  
On the day of surgery, rats were initially anaesthetised in an anaesthetic chamber where 
5% isoflurane was administered in a 30%/70% mixture of oxygen and nitrous oxide, 
respectively. Once deeply anaesthetised, rats were immediately transferred to a face mask 
where surgical anaesthesia was maintained with 2-2.5% isoflurane delivered in a 30%/70% 
mixture of oxygen and nitrous oxide. The face mask was secured by to the cork surgical 
board using sticky tape. Body temperature was measured by a rectal thermocouple and 
maintained at 37±0.5ºC using an angle poise lamp. The neck of the rat was shaved using an 
electric shaver and permanent focal ischaemia was induced as previously described 
(Chapter 2.1.2), where a silicon tipped filament (diameter 0.31-0.35mm, length 5-6mm, 
Doccol) was introduced into the external carotid artery and advanced along the internal 
carotid artery to block the origin of the middle cerebral artery. The filament was secured in 
place by electrocoagulation of the incision site located within the external carotid artery 
stump, using diathermy forceps. The neck was stitched using 4-0 silk suture. Drug 
treatment was then administered at 5 minutes post-MCAO by intraperitoneal injection.  
The rat was then allowed to recover from anaesthesia by delivery of 100% oxygen through 
the facemask. When the rat started to move, it was transferred to a recovery cage lined with 
soft absorbent pads and bedding, with a cardboard tube for environmental enrichment. The 
cage was kept in a small quiet room, where temperature was maintained between 22-24
o
C. 
Rats were given a soft diet of baby food mixed with rat chow pellets, with water and solid 
chow pellets freely available. The general condition of the rat was assessed at least 3 times 
on the day of surgery and was recorded.  
At 24 hours post-MCAO, functional outcome was assessed using the vibrissae-evoked 
forelimb placement test and the modified Bederson Score, as described in detail in Chapter 
2. Following behavioural assessment, the rat was anaesthetised in an anaesthetic chamber 
(5% isoflurane in 70/30 N20/02 mixture) and transferred to the MRI scanner where 
anaesthesia was maintained via a face mask (2% isoflurane in 70/30 N20/02 mixture) and a 
RARE T2 weighted sequence was acquired to allow calculation of final infarct volume 
(Chapter 2.2.3). The rat was then sacrificed by perfusion-fixation (Chapter 2.1.3).  
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5.2.5 Transient Focal Ischaemia (Study 2) 
 
 Male Sprague-Dawley rats (n=24) weighing 300-350g were randomly allocated to one of 
the three treatment groups: 1.5ml vehicle (0.1% DMSO) (n=9), 5mg/kg apocynin (n=8), 
30mg/kg apocynin (n=7). On the day prior to surgery, vibrissae evoked forelimb placement 
was assessed as described in Chapter 2 to ensure that rats showed no limb preference or 
neurological impairment.  
On the day of surgery, rats were anaesthetised, intubated and artificially ventilated 
(Chapter 2.1.1). Rats were then given an intraperitoneal injection of 0.4ml of atropine 
sulphate (600mcg/ml) to limit bronchial secretions The ventral surface of the right 
hindlimb and the neck were shaved using an electric shaver. The right femoral artery was 
cannulated to allow continuous monitoring of heart rate and MABP (Biopac) with blood 
sampling performed 30 minutes prior to MCAO and 30 minutes post-MCAO to ensure 
blood pH, PaCO2 and PaO2 (Bayer, Rapidlab 248) were maintained within the 
physiological range. The right femoral vein was cannulated to allow intravenous 
administration of drug treatment. It was decided that intravenous administration was 
preferable to intraperitoneal administration to reduce potential variability in the dose of 
drug delivered and to speed up the drug reaching a therapeutic concentration  in the brain. 
Body temperature was measured by a rectal thermocouple and maintained at 37±0.5ºC by 
an angle poise lamp.  
Transient focal ischaemia was induced as previously described in detail (Chapter 2.1.2). In 
brief, a silicon tipped filament was introduced into the common carotid artery and 
advanced along the internal carotid artery to occlude the proximal origin of the middle 
cerebral artery. Drug treatment was administered at 5 minutes following the induction of 
ischaemia by gradually infusing the drug intravenously over a period of 3 minutes. At 1 
hour post-MCAO, the intraluminal filament was removed by slowly retracting it using 
curved edge forceps and the incision point was electrocoagulated using diathermy forceps. 
The neck was flushed with sterile saline to clean the surgical area and was then stitched, as 
previously described (Chapter 2.1.2).   
At this point, the dose of isoflurane was reduced to 1% to aid the speed of recovery from 
anaesthesia at the end of surgery. The ligatures around the right femoral artery were cut 
and the cannula was removed. The vessel was sealed by electrocoagulation using 
diathermy probes. The same procedure was performed to remove the venous cannula. Care 
was taken when electrocoagulating the artery and vein to preserve flow within the vessel. 
This was achieved by only electrocoagulating the incision point. Restoration of flow within 
the femoral vessels will aid the recovery and minimise post-operative pain. The hindlimb 
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incision site was then sutured and the rat was allowed to breathe 100% oxygen for a period 
of 15-20 minutes to aid recovery from anaesthesia before removal of the intubation tube, as 
described previously (Chapter 3.1.3). 
The rat was then placed in a recovery cage with soft bedding and soft diet. General 
condition was assessed at least 4 times daily and was recorded. Behavioural testing was 
performed at 24, 48 and 72 hours post-MCAO. The 18-point neurological score assessment 
was followed by vibrissae-evoked forelimb placement and the modified Bederson score. 
Animals were also weighed following behavioural assessment as an additional indicator of 
general condition. At 72 hours post-MCAO, rats were euthanased in an anaesthetic gas 
chamber and the brain was processed for TTC staining as previously described in detail 
(Chapter 2.2.2). The TTC defined infarct volume was corrected for swelling of the 
ipsilateral hemisphere using the following equation (Swanson et al, 1990): 
 
Corrected lesion = volume of contralateral   -  ( volume of ipsilateral – lesion volume) 
        volume                      hemisphere                         hemisphere 
 
 
5.2.6 Effect of Apocynin on the Acute Evolution of Ischaemic Injury in the SHRSP 
(Study 3) 
 
In the third study examining the potential neuroprotective effects of apocynin, 12 SHRSP 
rats aged 16-20 weeks, weighing 250-300g, were used. Mean systolic blood pressure was 
determined in the weeks prior to surgery using tail cuff plethysmography (Chapter 2.4.4). 
Rats were randomly allocated to the vehicle group (n=6) or the 5mg/kg apocynin group 
(n=6). Treatment was administered at 5 minutes post-MCAO, which was 55 minutes prior 
to reperfusion. Only one dose of apocynin treatment was evaluated due to time constraints 
and the lower dose was selected on the basis of the results from the previous ischaemia-
reperfusion study.  
 
Rats were initially anaesthetised in an anaesthetic gas chamber, intubated and artificially 
ventilated as previously described (Chapter 2.1.1) and then given an intraperitoneal 
injection of 0.4ml of atropine sulphate (600mcg/ml) to limit bronchial secretions. The right 
femoral artery and vein were cannulated to allow for continuous monitoring of 
physiological parameters and drug administration, respectively. Arterial blood sampling 
every hour ensured blood pH, PaCO2 and PaO2 (Bayer, Rapidlab 248) were maintained 
within the physiological range. Transient focal ischaemia was induced (Chapter 2.1.2) 
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using a silicon tipped filament (diameter 0.31-0.35mm, length 5-6mm, Doccol) which was 
glued to a 30cm length of 2-0 thread at its distal portion. The ligatures around the common, 
internal and external carotid arteries were tied securely to hold the filament in place and to 
prevent blood loss. The neck was sutured and the length of 2-0 thread was allowed to hang 
freely outside the wound. At 5 minutes post-MCAO, drug treatment was administered 
intravenously over a 3 minute period.  
ECG leads were positioned on the ventral surface of the chest and the left hindlimb and the 
rat was then immediately transferred to the MRI scanner (Bruker, 7T Pharmascan). The rat 
was secured in the cradle by tooth and ears bars and a 4-channel phased array rat head 
surface receiver coil was placed on the head. Body temperature was maintained during the 
MRI scanning procedure by a heat pad placed over the body and was monitored by a rectal 
thermocouple. 
 
Once a pilot sequence had been obtained to ensure correct geometry, a 4-shot spin echo 
planar imaging (EPI) DWI scan (TE=22.5ms, TR=4000.3ms, matrix=96x96, 
FOV=25x25mm, 3 directions=x, y, z, B-values=0 and 1000s/mm
2
, 8 coronal slices; 1.5mm 
thick) was immediately performed and was repeated at 30 minutes post-MCAO to allow 
quantitative ADC map production and assessment of ischaemic injured tissue. This was 
followed by a time of flight (TOF) angiography scan to ensure that the middle cerebral 
artery had been completely occluded. A DWI scan was acquired just prior to reperfusion, 
at 1 hour post-MCAO. The filament was then retracted while the rat was in the MRI 
scanner. This was achieved by pulling the length of 2-0 thread 1.5cm distally, to retract the 
filament from the origin of the middle cerebral artery to permit reperfusion of the MCA 
territory. A TOF angiography scan was then performed to confirm that the left middle 
cerebral artery had reperfused. This was followed by a DWI scan and further DWI scans 
acquired every 30 minutes following reperfusion until 3 hours post-MCAO.  
 
Perfusion weighted images were acquired using a form of continuous arterial spin labelling 
(cASL) based on a train of adiabatic inversion pulses (Moffatt et al, 2005).
 
The sequence 
employs a spin-echo EPI imaging module (TE=20ms, TR=7000ms, matrix=96x96, 
FOV=25x25mm, slice thickness 1.5mm, 16 averages, 4 shots) preceded by 50 hyperbolic 
secant inversion pulses in a 3 second train. Inversion pulse frequency offset and gradient 
strength were set to provide 10mm wide label/control bands centred at ±30mm from the 
centre of the imaging slice. PWI were acquired for slices 3-6 of the DWI scan, (as time did 
not permit data acquisition across all 8 slices) and were acquired every hour for 3 hours 
post-MCAO. For quantification of CBF maps, T1 maps were also acquired at each hour 
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post-MCAO, using an EPI inversion recovery sequence (TE=20ms, TR=10000ms, 
matrix=96x96, FOV=25x25mm, slice thickness 1.5mm, 16 averages, 4 shots, using 16 
inversion times).  
 
At 3 hours post-MCAO, the rat was removed from the MRI scanner and transferred back to 
the operating theatre where surgical anaesthesia was maintained. The sutures in the neck 
were cut and the ligatures around the internal carotid artery and the upper common carotid 
artery were loosened to allow the filament to be removed. The incision site was then 
electrocoagulated and the remaining ties were removed. The neck wound was then re-
sutured and the femoral arterial and venous cannulae were removed and the rat was 
allowed to recover from surgery as previously described (Chapter 5.1.4.). Behavioural 
testing was performed at 24, 48 and 72 hours post-MCAO. T2 weighted images were 
acquired at 24 hours and at 72 hours post-MCAO, animals were then euthanased and the 
brain was processed for TTC staining (Chapter 5.1.4). However, in this study, the rat 
brains did not fit into the rat brain matrix due to extensive brain swelling. Therefore, 
following removal from the skull, brains were rinsed in heparinised saline and put into the 
freezer at -46
o
C for 15 minutes. The brains were then cut freehand using a razor blade into 
coronal sections, approximately 2mm thick and TTC staining was then performed.   
 
5.2.7 Data analysis 
 
In all studies, infarct volume was corrected for brain oedema as previously described 
(Chapter 2.2.3). In the permanent MCAO study, final infarct volume was assessed at 24 
hours post-MCAO by manual delineation of hyperintense areas on T2 slices, as previously 
described in detail (Chapter 2.2.3). In the transient MCAO studies, infarct volume at 72 
hours post-MCAO was determined by manual delineation of infarcted tissue on TTC 
stained brain slices using Image J software (Chapter 2.2.2).  
The acute serial MRI study data were processed to generate quantitative ADC maps and 
CBF maps (Chapter 3.1.4). The calculated SHRSP ADC threshold of 0.59 x 10
-3
mm
2
/sec 
(determined in Chapter 3) was applied to the quantitative ADC maps acquired at each time 
point to assess the acute evolution of ischaemic injury over the first 3 hours post-MCAO. 
Similarly, the in-house strain specific CBF threshold of 36ml/100g/min was applied to 
quantitative CBF maps acquired during ischaemia to determine the volume of perfusion 
deficit. Perfusion-diffusion mismatch was then measured across coronal slices 3-6 by 
overlaying the area of ADC derived ischaemic injury at 1 hour post-MCAO onto the 
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corresponding thresholded CBF map. The remaining perfusion deficit was measured on 
each slice to calculate mismatch volume, with the exclusion of the ventricles. 
 
5.2.8 Statistical Analysis 
 
In the permanent MCAO study, infarct volume at 24 hours post-MCAO was compared 
across treatment groups using one-way ANOVA with Bonferroni‟s post-test. In the 
transient ischaemia study in Sprague-Dawley rats, infarct volume at 72 hours post-MCAO 
was also compared across the 3 treatment groups using one-way ANOVA with 
Bonferroni‟s post-test. Temporal changes in physiological parameters within treatment 
groups were assessed by a paired t test. Differences in physiological parameters between 
treatment groups over time were evaluated using a 2-way ANOVA with Bonferroni‟s post-
test.  
In the MRI transient ischaemia study, systolic BP, infarct volume and mismatch volume 
were compared between groups using an unpaired test. Temporal changes in physiological 
parameters within treatment groups were assessed by Repeated Measures ANOVA.  
Physiological parameters were compared between treatment groups over time using a 2-
way ANOVA with Bonferroni‟s post-test. The temporal evolution of ischaemic injury 
between groups was assessed by 2-way ANOVA with Bonferroni‟s post-test. Temporal 
changes in ischaemic injury within each treatment group were evaluated using a Repeated 
Measures ANOVA.  
All data are expressed as mean±SD with the exception of the behavioural data. All 
behavioural data were expressed as median and interquartile range (IQ) and treatment 
groups were compared using a non-parametric Mann-Whitney test or Kruskal-Wallis test 
with Dunn‟s post-test. Temporal changes in behavioural outcome within each group were 
assessed by Repeated Measures ANOVA. 
 
5.3 Results 
 
5.3.1 Study 1: Apocynin Treatment in a Model of Permanent MCAO 
 
5.3.1.1 Excluded Animals 
 
Rats were excluded from data analysis if they died before 24 hours post-MCAO or if the 
filament did not advance fully along the internal carotid artery. Two rats from the vehicle 
treated group were excluded from data analysis. One rat died overnight before 24 hours 
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post-MCAO and it was suspected that the other rat had an incomplete occlusion of the 
MCAO. During stroke surgery, there was some difficulty in advancing the filament along 
the internal carotid artery and as such the filament did not advance the required 22mm. 
Consequently, the data from this rat was not included in the subsequent data analysis. On 
T2 weighted imaging at 24 hours post-MCAO this animal showed evidence of a very small 
stroke. Consequently, the data from this rat was not included in the subsequent data 
analysis. 
 
5.3.1.2 Final infarct Volume 
 
MRI T2 defined infarct volume at 24 hours post-MCAO was not significantly different 
between treatment groups.  Infarct volume in the vehicle treated group was 301±46mm
3
 
compared to 289±117mm
3
 and 240±106mm
3
 for the 5mg/kg and 30mg/kg apocynin 
treated groups, respectively (P=0.47, Figure 5-3A). The data were more variable in the 
apocynin treated groups compared to the vehicle treated group, as illustrated by the high 
standard deviations in the apocynin treated groups. In the apocynin treated groups, there 
was one rat in each group which exhibited a very small infarct. In the 5mg/kg apocynin 
group, one rat had an infarct measuring 71mm
3 
and in the 30mg/kg apocynin treated group, 
one rat demonstrated a very small infarct of 25mm
3
 (Figure 5-3A). It is not known if this 
was a treatment effect or if the rats had an incomplete occlusion of the MCA.  
 
Infarct was also expressed as percentage of the ipsilateral hemisphere. There was no 
significant difference between the treatment groups (43±6% vs 41±17% and 35±16% for 
vehicle, 5mg/kg apocynin and 30mg/kg apocynin treated groups, respectively, P=0.54).  
Figure 5-4 illustrates the spatial distribution of infarcted tissue in a representative rat from 
each treatment group. In all groups, hyperintense infarct tissue is evident across all 16 T2 
slices and is located in the cerebral cortex and sub-cortex. The anatomical extent of the 
infarct is comparable between the treatment groups. 
 
5.3.1.3 Bederson Score 
 
Functional outcome at 24 hours post-MCAO, as assessed by the modified Bederson scale, 
was not significantly different between treatment groups (P=0.83, Figure 5-5A). The 
median score for the vehicle and 5mg/kg apocynin treated groups was 2 (IQ 2, 3) and the 
median score for the 30mg/kg apocynin group was 3 (IQ 2, 3). The rat in the vehicle group 
which died before 24 hours post-MCAO, was included in the Bederson scale analysis.  
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Figure 5-3. Final infarct in vehicle and apocynin treated WKY rats at 24h following permanent MCAO with drug treatment administered at 5 min post-MCAO. 
Infarct volume defined by T2 weighted imaging (A) was not significantly different between vehicle treated (n=6) and 5mg/kg (n=8) or 30mg/kg apocynin treated rats 
(n=8) (One-way ANOVA, P=0.47). Infarct expressed as a percentage of the ipsilateral hemisphere was also not significantly different between treatment groups (One-
way ANOVA, P=0.54). The horizontal line denotes the mean. 
 
A B 
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Figure 5-4. The spatial distribution of infarcted tissue in vehicle and apocynin treated rats following permanent MCAO. MRI T2 weighted images (16 coronal 
slices) were acquired at 24h post-MCAO and the hyperintense area was manually delineated on each slice to determine infarct volume. Eight of the sixteen T2 
weighted images from the median rat from each treatment group are shown with the hyperintense areas delineated (vehicle-green, 5mg/kg apocynin-blue, 30mg/kg 
apocynin-red).  
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Figure 5-5. Functional outcome scores of WKY rats at 24h post-MCAO following vehicle or apocynin treatment. Functional outcome was assessed by a 
modified Bederson Score (A): 0=no observable deficit, 1=forelimb flexion, 2=reduced grip strength, 3=circling, 4=no spontaneous activity, 5=dead. Vibrissae-evoked 
forelimb placement was also used to assess outcome, where the number of successful placements of the contralateral forelimb were scored out of 10 attempts (B). 
The horizontal line denotes the median score. No statistically significant differences were found between groups for both functional tests, P=0.8 (Kruskal-Wallis test). 
B A 
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5.3.1.4 Vibrissae-evoked Forelimb Placement 
 
Prior to stroke surgery, all rats scored 10 successful placements of the contralateral 
forelimb out of 10 attempts. Evaluation of functional outcome using the vibrissae-evoked 
forelimb placement test, revealed that there was no significant difference between the 
vehicle and apocynin treated groups at 24 hours post-MCAO. (P=0.78, Figure 5-5B). Most 
rats in all three treatment groups performed poorly and were unable to correctly place the 
contralateral forelimb in 10 attempts (Figure 5-5B). The median score for all treatment 
groups was 0, although 3 rats in the low dose apocynin group and one rat in the high dose 
apocynin group scored at least 4 correct placements out of 10 attempts.  
 
5.3.2 Study 2: Apocynin Treatment in a Model of Transient MCAO 
 
5.3.2.1 Mortality 
 
The mortality rate observed in this study following transient ischaemia, was higher than 
that observed in the previous study following permanent MCAO. Three rats died in the 
vehicle treated group (3/9, 33% mortality), two rats died following low dose apocynin 
treatment (2/8, 25% mortality) and one rat died in the high dose apocynin group (1/7, 14% 
mortality). These 6 rats died between 24 and 48 hours post-MCAO and were excluded 
from data analysis. All infarct data and behavioural data are from the animals which 
survived to 72 hours post-MCAO, with the exception of the Bederson scale, where the rats 
which died are also included. 
 
5.3.2.2 Physiological Parameters 
 
During anaesthesia, all physiological parameters were maintained within physiological 
range across the three treatment groups, with the exception of arterial PO2. Arterial PO2 in 
all three treatment groups was significantly higher than the physiological range of 80-
100mmHg (P<0.05, one sample t-test). This is likely to be attributed to the anaesthetic gas 
mixture, where 30% oxygen is used rather than the 21% oxygen found in air. Within each 
treatment group, each physiological variable was maintained from 30 minutes before 
stroke onset to 30 minutes post-ischaemia (P>0.05, paired t test). There were no significant 
differences in any of the physiological variables between treatment groups before or after 
the onset of ischaemia (P>0.05, One-way ANOVA, Table 5-1). No change in mean arterial 
blood pressure was observed following intravenous administration of vehicle or apocynin. 
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 30 min pre-MCAO 30 min post-MCAO 
Vehicle treated group   
      Body Temperature (oC) 37.2±0.3 37.3±0.2 
                    MABP (mmHg)  101±5 105±7 
                Heart Rate (bpm) 371±30 365±24 
                             Blood pH 7.42±0.03 7.40±0.03 
          Arterial PO2 (mmHg) 161±44 168±49 
       Arterial PCO2 (mmHg) 35±3 37±4 
5mg/kg apocynin 
treated group 
  
      Body Temperature (oC) 37.0±0.3 36.9±0.3 
                    MABP (mmHg)  101±7 108±6 
                Heart Rate (bpm) 361±19 368±27 
                             Blood pH 7.40±0.06 7.37±0.04 
          Arterial PO2 (mmHg) 163±25 171±29 
       Arterial PCO2 (mmHg) 37±4 36±4 
30mg/kg apocynin 
treated group 
  
      Body Temperature (oC) 37.1±0.4 37.2±0.3 
                    MABP (mmHg)  102±6 106±7 
                Heart Rate (bpm) 372±19 368±22 
                             Blood pH 7.38±0.04 7.40±0.02 
          Arterial PO2 (mmHg) 176±32 165±37 
       Arterial PCO2 (mmHg) 36±6 37±3 
 
 
Table 5-1. Physiological parameters in vehicle and apocynin-treated Sprague-Dawley rats 
before and after the induction of ischaemia by occlusion of the middle cerebral artery. Data 
presented as mean±SD, n=6 per group. MABP-mean arterial blood pressure, bpm-beats per 
minute.
 177 
5.3.2.3 Final Infarct Volume 
 
TTC defined final infarct volume at 72 hours post-MCAO was significantly lower in low 
and high dose apocynin treated rats compared to the vehicle treated group. In vehicle 
treated rats, infarct volume was 112±25mm
3
, compared to 40±35mm
3
 and 46±31mm
3
 in 
5mg/kg and 30mg/kg apocynin treated rats, respectively (P<0.01, Figure 5-6). This 
represents a reduction in infarct volume of approximately 60% in the apocynin treated 
groups. There were 2 apocynin treated rats which did not show a reduction in infarct 
volume compared to the vehicle treated group. One rat which received 5mg/kg apocynin 
had an infarct volume of 108mm
3 
and one rat which received 30mg/kg apocynin had an 
infarct volume of 102mm
3 
at 72 hours post-MCAO (Figure 5-6).  The infarcts exhibited by 
these rats were comparable to the infarcts observed in the vehicle treated group.  
In the vehicle treated group, infarcted tissue was observed in the cerebral cortex and the 
sub-cortex. The infarct area extended across the territory of the middle cerebral artery. 
However, in the apocynin treated groups, infarcted tissue was mainly identified sub-
cortically and did not extend as far in the rostral caudal plane as observed in the vehicle 
treated group (Figure 5-7). 
 
5.3.2.4 Bederson Score 
 
The Bederson scores of the animals which survived to 72 hours post-MCAO are shown in 
Figure 5-8A. There was no significant difference between treatment groups at any time 
point post-MCAO (P>0.05, Kruskal-Wallis test). The low dose apocynin treated group 
demonstrated less neurological impairment than the high dose apocynin and vehicle treated 
groups at all time points but did not reach the level of statistical significance (vehicle: 2 
(IQ 2, 3), 5mg/kg: 0 (IQ 0, 3), 30mg/kg: 2 (IQ 0, 3) at 24 hours post-MCAO, P>0.05).  
Furthermore, there was no significant change in score from 24 to 72 hours post-MCAO in 
any of the treatment groups (P>0.05, Repeated Measures ANOVA).  
The scores of the animals which died between 24 and 48 hours post-MCAO are shown in 
Figure 5-8B. The vehicle treated rats which died were more severely neurologically 
impaired than the apocynin treated rats which died.  
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Figure 5-7. TTC defined infarct volume at 72h post-MCAO in vehicle and apocynin treated 
Sprague-Dawley rats. Drug treatment was administered intravenously 5 min post-MCAO. The 
intraluminal filament was removed after 1h of ischaemia to allow reperfusion until 72h post-MCAO. 
Line denotes the mean. *p<0.01, One-way ANOVA with Bonferroni’s Multiple Comparisons test. 
 
 
 
 
 
 
* * 
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Figure 5-7. Spatial distribution of the TTC defined infarct at 72h post-MCAO in vehicle and apocynin treated Sprague-Dawley rats. Infarcted tissue appears 
white and unaffected tissue stains deep red with TTC.  
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5.3.2.5 Vibrissae-evoked Forelimb Placement 
 
Prior to surgery, all rats scored the maximum of 10 successful placements of the 
contralateral forelimb out of 10 attempts. There was no evidence of neurological 
impairment or limb preference in any of the rats used in this study.  
At all time points post-MCAO, rats which received low dose apocynin treatment 
performed better than rats in the vehicle and high dose apocynin groups. However, the 
observed improvement in forelimb placement was not statistically significant at any time 
point (P>0.05, Kruskal-Wallis test, Figure 5-9). The improvement in function was 
particularly evident at 24 hours post-MCAO (vehicle: 3 (IQ 0, 9), 5mg/kg: 8 (IQ 2, 10), 
30mg/kg: 5 (IQ 1, 9), P>0.05).  
In the vehicle treated group, the contralateral forelimb placement score was maintained at 3 
successful placements at 24 and 48 hours post-MCAO. This improved to 4 successful 
placements out of 10 attempts by 72 hours. However, in the apocynin treated groups, the 
number of successful placements decreased over time. In the low dose apocynin group, the 
number of successful placements decreased from 8 at 24 hours to 6 at 72 hours post-
MCAO. Similarly, in the high dose apocynin group, the number of successful placements 
reduced from 5 at 24 hours to 3 at 72 hours post-MCAO. The temporal changes in the 
number of successful contralateral placements were not significant in any of the treatment 
groups (P>0.05, Repeated Measures ANOVA). 
 
5.3.2.6 18-point Neurological Score 
 
There was no statistically significant improvement in neurological score between treatment 
groups. However in the low dose apocynin treated animals there was a trend towards an 
improvement in neurological function at all time points post MCAO (P>0.05, Kruskal-
Wallis test, Figure 5-10A). At 24 hours post-MCAO, the median score in the 5mg/kg 
apocynin group was 14 (IQ 11, 17), compared to 12 (IQ 10, 14) in the 30mg/kg apocynin 
group and 10 in the vehicle treated group (IQ 9, 14), P>0.05).  
It was also observed that the general condition of rats in the low dose apocynin group was 
improved compared to rats in the other treatment groups. Rats in the 5mg/kg apocynin 
group demonstrated more frequent grooming behaviour, were generally more alert and 
exhibited normal feeding behaviours compared to rats in the vehicle and high dose 
apocynin groups. 
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Figure 5-8. Evaluation of neurological function using a modified Bederson Scale following transient ischaemia in vehicle and apocynin treated Sprague-
Dawley rats. Rats were tested at 24, 48 and 72h post-MCAO. The median scores and the interquartile range are shown for the animals which survived to 72h post-
MCAO (A) (P>0.05, Kruskal-Wallis test). The 24 hour scores of the rats which died between 24 and 48h post-MCAO are also shown (B).  
 
 
B A 
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Figure 5-9. Assessment of neurological function following transient ischaemia in Sprague-
Dawley rats using the vibrissae-evoked forelimb placement test. Testing was performed at 24, 
48 and 72h post-MCAO in rats treated with vehicle, low dose or high dose apocynin treatment 
following ischaemia. Data presented as median and interquartile range, n=6 per group. P>0.05, 
Kruskal-Wallis test.  
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Figure 5-10. Assessment of functional outcome following apocynin treatment using an 18 point composite neurological scoring system. Rats were tested at 
24, 48 and 72h post-MCAO (A). A maximum score of 18 is achieved when there is no observable deficit. A score of 3 indicates severe neurological impairment. Data 
presented as median and interquartile range, n=6 per group. P>0.05, Kruskal-Wallis test. A statistically significant inverse correlation was found between final infarct 
volume at 72h post-MCAO and neurological score at 72h for all rats (B). Spearman’s non-parametric correlation, r=-0.51, P<0.05. 
 
A B 
r = -0.51 
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Neurological score at 72 hours post-MCAO correlated significantly with final infarct 
volume at the same time point (P<0.05, Figure 5-10B). Using the non-parametric 
Spearman‟s correlation, an r value of -0.51 demonstrates that there is an inverse 
relationship between infarct volume and neurological score, where as infarct volume 
decreases, neurological score increases. This shows that neurological function is improved 
in rats with smaller infarct volumes, compared to rats with larger infarcts, which are more 
severely functionally impaired. 
 
5.3.3 Study 3: MRI Assessment of the Acute Evolution of Ischaemic Injury in an 
Ischaemia-Reperfusion model in SHRSP rats 
 
5.3.3.1 Systolic Blood Pressure 
 
Tail cuff pleythsmography performed in the weeks prior to surgery revealed that there was 
no significant difference in the mean systolic pressures of the rats in each treatment group. 
Prior to stroke surgery, mean systolic blood pressure was not significantly different 
between groups of rats subsequently randomised to vehicle and apocynin (5mg/kg) 
treatment (181±25mmHg and 189±17mmHg for vehicle and apocynin treated rats, 
respectively, P=0.52, Figure 5-11). 
 
5.3.3.2 Mortality 
 
The mortality rate in this study was higher than that observed in the transient ischaemia 
study using Sprague-Dawley rats. Of the 12 SHRSP rats used in this study, 8 rats died 
before the 72 hours end point, representing a 67% mortality rate. In both the vehicle and 
apocynin treated group 4/6 rats died before 72 hours post-MCAO. 5 rats died before 24 
hours post-MCAO and 2 rats died between 24 and 48 hours. One vehicle treated rat was 
euthanased at 48 hours post-MCAO due to poor condition and lack of spontaneous 
movement. Only 2 rats in each treatment group survived until 72 hours post-MCAO. It was 
therefore decided that the study would not continue further on ethical grounds. However, 
the acute MRI data acquired up to 3 hours post-MCAO are presented for all rats in the 
vehicle treated (n=6) and low dose apocynin treated groups (n=6). 
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Figure 5-11. Mean Systolic Blood Pressure in SHRSP rats. Tail cuff plethysmography was 
performed in the weeks prior to stroke surgery. Mean systolic blood pressure was determined in 
each rat which was then randomly allocated to the vehicle or low dose apocynin treatment group. 
Horizontal line denotes the mean. P>0.05, unpaired t test. 
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5.3.3.3 Physiological Parameters 
 
With the exception of arterial PO2, as previously discussed, all physiological parameters 
were maintained within physiological range in both treatment groups at all time points 
post-MCAO. Arterial PO2 in all three treatment groups was significantly higher than the 
physiological range of 80-100mmHg (P<0.05, one sample t-test). Within each treatment 
group, each physiological variable was maintained from 30 minutes before stroke onset 
(baseline) to 3 hours post-MCAO (P>0.05, Repeated Measures ANOVA). There were no 
significant differences in any of the physiological variables between treatment groups 
before or after the onset of ischaemia (P>0.05, Two-way ANOVA, Table 5-2).  
 
5.3.3.4 Assessment of Reperfusion 
 
Immediately following the retraction of the intraluminal filament, MR angiography was 
acquired and examined in order to confirm successful reperfusion of the left middle 
cerebral artery. With the exception of one rat in the low dose apocynin treatment group, all 
rats demonstrated successful reperfusion. In the rat which did not reperfuse at 1 hour post-
MCAO, the filament was retracted further following examination of the angiographs at 1 
hour 10 minutes post-MCAO. Another angiography scan was then acquired and examined 
to confirm that the left middle cerebral artery had successfully reperfused. Figure 5-12 
illustrates reperfusion of the left middle cerebral artery. 
 
5.3.3.5 Acute Evolution of Ischaemic Injury 
 
DWI was carried out in order to determine if apocynin treatment influences the acute 
evolution of ischaemic injury following MCAO.  There was no significant difference in the 
volume of ADC defined ischaemic injury at any time point during ischaemia and following 
reperfusion in the vehicle treated and low dose apocynin groups (P>0.05, 2-way ANOVA, 
Figure 5-13). During the period of ischaemia, the volume of ischaemic injury peaked at 
357±63mm
3 
and 344±92mm
3 
in the vehicle treated and apocynin treated groups, 
respectively (P>0.05). At 1 hour post-MCAO, following retraction of the filament, the 
volume of ADC derived ischaemic injury sharply declined to less than a third of the 
volume observed in both groups during ischaemia. Within 30 minutes of reperfusion, the 
volume of ischaemic injury decreased to 101±73mm
3 
and 99±82mm
3 
in the vehicle treated 
and apocynin groups, respectively (P>0.05). By 2 hours post-MCAO, the volume of 
ischaemic injury began to increase in both groups and by 3 hours post-MCAO, it had  
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 Baseline 1h 2h 3h 
Vehicle      
 Body Temp (
o
C) 37.2±0.4 36.8±0.5 36.8±0.3 36.9±0.3 
   MABP (mmHg) 111±11 111±5 113±10 115±6 
            HR (bpm) 369±10 378±23 361±10 357±17 
            Blood pH 7.42±0.05 7.41±0.03 7.37±0.02 7.39±0.04 
     PaO2 (mmHg) 131±14 140±21 142±23 136±18 
  PaCO2 (mmHg) 36±2 39±5 40±4 43±5 
     
5mg/kg 
apocynin 
    
 Body Temp (
o
C) 37.1±0.2 36.7±0.3 37.1±0.3 36.9±0.3 
   MABP (mmHg) 109±12 112±10 110±8 110±9 
            HR (bpm) 358±17 355±14 355±17 361±9 
            Blood pH 7.44±0.03 7.38±0.03 7.38±0.03 7.41±0.03 
     PaO2 (mmHg) 136±13 152±14 147±18 141±25 
  PaCO2 (mmHg) 37±1 38±3 41±2 39±3 
 
Table 5-2. Physiological parameters assessed before the induction of ischaemia and at 1, 2 
and 3h post-MCAO in SHRSP rats. Data presented as mean±SD. MABP-mean arterial blood 
pressure, HR-heart rate, PaO2-arterial PO2, PaCO2-arterial PCO2. 
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Figure 5-12. Reperfusion of the middle cerebral artery following 1h of ischaemia. MR angiography was performed immediately following withdrawal of the 
intraluminal filament at 1h post-MCAO. Restoration of flow in the left middle cerebral artery is highlighted by the arrows. Data is from a representative vehicle treated 
rat.  
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increased to 149±126mm
3 
and 154±121mm
3 
in the vehicle and  apocynin treated groups, 
respectively (P>0.05). 
 
The spatial extent of injured tissue was comparable between the treatment groups during 
ischaemia and following reperfusion. During the 1 hour period of ischaemia, injured tissue 
was observed across 8 coronal slices within the MCA territory (Figures 5-14A & B). The 
extent of injury increased between 20 minutes and 1 hour post-MCAO in both groups and 
this was particularly evident on the coronal slices at the rostral and caudal extremities. 
Following reperfusion, ischaemic injury decreased but gradually began to rise by 2 hours 
post-MCAO. Growth of the ADC derived lesion was particularly evident on coronal slices 
3, 4 and 5, which are located within the core of the ischaemic MCA territory.  
 
5.3.3.6 Final Infarct Volume 
 
Statistical analysis of the infarct data was not undertaken because only 2 rats in each 
treatment group survived to the 72 hour end point. In the vehicle treated group, mean 
infarct volume was 309mm
3
, compared to 200mm
3
 in the apocynin treated animals. 
However, the difference in the treatment group means was mainly due to one of the 
apocynin treated rats which demonstrated a small infarct of 131mm
3
 at 72 hours post-
MCAO. In addition, TTC staining was performed on the brains of 2 rats which died 
overnight before 24 hours post-MCAO. Both rats were apocynin treated and displayed 
large infarcts of 352 and 360mm
3
. However, the precise time of death was unknown in 
these rats and the infarct data were excluded from the analysis of final infarct volume at 72 
hours.  
Furthermore, infarct volume at 24 and 72 hours was compared to the volume of ADC 
derived ischaemic injury at 1 hour post-MCAO, just prior to reperfusion (Figure 5-15). In 
the vehicle treated group, one rat demonstrated an infarct volume of 340mm
3
 at 72 hours, 
which exceeded the volume of ischaemic injury observed during ischaemia (271mm
3
). 
However, the other vehicle treated rat displayed an infarct at 72 hours which was smaller 
than the volume of ischaemic injury observed following 1 hour of ischaemia (infarct: 
278mm
3
 vs ADC lesion: 331mm
3
, Figure 5-15A). This was also observed in both apocynin 
treated rats, where the ADC derived lesion during the 1 hour period if ischaemia was larger 
than the infarct at 72 hours post-MCAO. In one rat, the volume of ischaemic injury 
291mm
3
 during ischaemia and infarct volume at 72 hours was 268mm
3
. The other rat 
demonstrated an ADC derived lesion volume of 178mm
3
 and infarct volume at 72 hours 
was 131mm
3
 (Figure 5-15B).  
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Figure 5-13. The acute evolution of ischaemic injury following reperfusion in vehicle and 
apocynin treated SHRSP rats.  Drug treatment was administered at 5min post-MCAO, which was 
55min prior to reperfusion. The strain specific ADC threshold of 0.59 x 10
-3
mm
2
/sec was applied to 
quantitative ADC maps to assess ischaemic injury during ischaemia and following reperfusion at 
60min post-MCAO. Dotted line denotes reperfusion by retraction of the intraluminal filament. Data 
presented as mean±SD, n=6 per group. P>0.05, 2-way ANOVA. 
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Figure 5-14A. The spatial distribution of acute ischaemic injury during ischaemia and following reperfusion in a vehicle treated SHRSP. The strain specific 
ADC threshold was applied to quantitative ADC maps to define the extent of injured tissue. Ischaemic injury is shown in white across 8 coronal slices within the territory 
of the MCA. 
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Figure 5-14B. The spatial distribution of ischaemic injury during ischaemia and following reperfusion in a low dose apocynin treated SHRSP. The strain 
specific ADC threshold was applied to quantitative ADC maps to define the extent of injured tissue. Ischaemic injury is shown in white across 8 coronal slices within the 
territory of the MCA. 
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5.3.3.7 Perfusion-Diffusion Mismatch 
 
Mismatch volume prior to reperfusion at 1 hour post-MCAO, was comparable between 
vehicle treated and apocynin treated rats. In the vehicle treated group, mismatch volume at 
1 hour post-MCAO was 32±17mm
3
, compared to a mismatch volume of 31±28mm
3
 in the 
apocynin treated group (P=0.91, unpaired t test, Figure 5-16A). The acute MRI data from 
all 6 vehicle treated rats were used to determine mismatch volume. However, in the 
apocynin treated group, mismatch data were acquired from 4/6 rats. This was because there 
were problems with the acquisition of perfusion weighted images on the days when 2/6 
animals were being scanned. In one rat, CBF images were only acquired for coronal slices 
3, 4 and 5 due to time restrictions and in the other rat, no perfusion data was acquired 
during ischaemia, as a result of technical difficulties.  
 
Across the 4 coronal slices, mismatch tissue was observed mainly on slice 3 and mismatch 
area decreased on the rostral slices. Mismatch tissue was identified mainly in the cerebral  
cortex in both groups, although mismatch was also observed sub-cortically to a lesser 
extent (Figure 5-16B). 
 
5.3.3.8 Functional Outcome 
 
Figure 5-17A shows the Bederson scores at 24 hours post-MCAO for all rats used in the 
study. There was no significant difference in score between the groups (P=0.49, Mann-
Whitney test). In the vehicle treated group, the median score at 24 hours was 4, which 
indicates severe impairment and no spontaneous activity. Three rats in the vehicle treated 
group scored 4 and two of these rats died before 48 hours and the other rat was euthanased 
at 48 hours due to its poor condition. The 2 rats which survived to 72 hours post-MCAO 
demonstrated less severe impairment and scored 2 at 24 hours, where reduced grip strength 
was observed without any circling behaviour. In the apocynin treated group, the median 
score at 24 hours was 5 as 4 rats out of 6 died before 24 hours post-MCAO. Of the two rats 
which survived to the 72 hours end point, one rat scored 2 and the other rat scored 0, 
indicating no observable neurological impairment.  
 
Over the 72 hours time course, the vehicle treated rats did not show any improvement in 
functional outcome, as assessed by the Bederson scale. One apocynin treated rat showed 
no evidence of neurological impairment at any time point and the other apocynin treated  
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Figure 5-15. Acute evolution of ischaemic injury in the rats which survived to 72h post-MCAO.  Row A shows the data from the vehicle treated rats and row B 
shows the data from the apocynin treated rats. Reperfusion was induced at 1h post-MCAO by withdrawal of the filament (dotted vertical line). Oedema-corrected infarct 
volume was defined at 24h post-MCAO by T2 weighted MRI and 72h by TTC staining. 
A 
B 
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Figure 5-16. Perfusion-diffusion mismatch at 1h post-MCAO in vehicle treated and low dose apocynin treated SHRSP rats. Mismatch area was calculated on 4 
coronal slices by superimposing the area of ADC derived ischaemic injury (shown in white) on to the perfusion deficit (shown in red) of the corresponding slice. The 
remaining perfusion deficit was measured on each slice to calculate mismatch volume. Mismatch volume was determined immediately before reperfusion in vehicle 
treated (n=6) and low dose apocynin treated (n=4) SHRSP rats (A). The MRI data shown are from a representative vehicle and apocynin treated rat (B). 
A B 
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rat demonstrated an increase in neurological impairment between 24 and 48 hours post-
MCAO, as the observed score increased from 2 to 4 (Figure 5-17B). 
 
Functional outcome was also assessed by an 18-point neurological score and by vibrissae-
evoked forelimb placement. Prior to surgery, all rats demonstrated successful placement of 
the right and left forelimbs and there was no evidence of limb preference or neurological 
impairment. Figure 5-18 presents the data for the rats in each treatment group which 
survived to 72 hours post-MCAO. In one vehicle treated rat, neurological function 
improved progressively, where neurological score increased from 11 at 24 hours to 14 at 
72 hours post-MCAO. However, the other vehicle treated rat displayed a decrease in 
neurological score (Figure 5-18A).  
 
In the apocynin treated group, one rat exhibited a decrease in neurological score from 8 at 
24 hours to 6 at 48 hours but outcome was improved by 72 hours post-MCAO as the score 
increased to 9. The other apocynin treated rat demonstrated no neurological impairment at 
any time point and achieved the maximum score of 18. This rat also showed no impairment 
in the vibrissae-evoked forelimb placement test and successfully placed the contralateral 
forelimb at every attempt. This rat demonstrated a smaller infarct than the rest of the rats 
which survived, where the infarct at 72 hours was 131mm
3 
which was less than 50% of 
infarct volume observed in the other 3 rats which survived to 72 hours post-MCAO. The 
infarct was located sub-cortically, whereas the other rats demonstrated infarcts which 
incorporated both the cortex and the sub-cortex. Both of the vehicle treated rats and the 
apocynin treated rat which demonstrated neurological impairment, showed gradual 
reduction in the ability to successfully place the contralateral forelimb. This was 
particularly evident between 24 and 48 hours post-MCAO. These observations conflict 
with the 18 point neurological score, where the functional outcome of these 3 rats 
improved over time. 
 
5.4 Discussion 
 
The results of the studies presented in this chapter characterise the effect of apocynin (an 
NADPH oxidase inhibitor) following both permanent and transient focal cerebral 
ischaemia and in the presence of stroke co-morbidities. We have provided further evidence 
that inhibition of NADPH oxidase with apocynin is neuroprotective following transient 
focal cerebral ischaemia, however no such effect was observed following permanent  
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Figure 5-17. Functional outcome in vehicle and apocynin treated rats up to 72h post-MCAO. Functional outcome was assessed by a modified Bederson scale. A 
score of 0=no observable deficit, 1=forelimb flexion, 2=reduced grip strength, 3=circling, 4=no spontaneous activity, 5=dead. The scores of all vehicle treated (n=6) and 
apocynin treated rats (n=6) at 24h post-MCAO are shown in figure A. The line denotes the median score. P=0.49, Mann-Whitney Test. Figure B shows the individual 
scores observed in the 2 rats in each treatment group which survived to 72h post-MCAO. 
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Figure 5-18. Functional outcome in vehicle and apocynin treated rats up to 72h post-MCAO. Functional outcome was assessed by an 18 point neurological score 
(A) and by the vibrissae-evoked forelimb placement test (B). In the 18 point assessment, a score of 18 indicates no observable deficit and a score of 3 indicates the 
most severe impairment. The forelimb placement test is scored on the number of successful placements of the contralateral forelimb out of 10 attempts. Therefore, a 
score of 10 depicts no impairment and a score of 0 indicates failure to place the forelimb. The individual scores of the 2 rats in each treatment group which survived to 
72h post-MCAO are shown.  
B A 
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cerebral ischaemia. In addition we have shown that the neuroprotective effect shown 
following transient cerebral ischaemia is only observed in normotensive rats since no such 
effect was observed in a rat model exhibiting genetic stroke risk factors (SHRSP).  
 
The precise mechanism involved in the neuroprotective action of apocynin is unclear at 
present. It has now been widely accepted that apocynin is a pro-drug which requires 
activation by myeloperoxidase to form diapocynin which is the metabolically active form 
of the drug (Simons et al, 1990; Ximenes et al, 2007). Since vascular cells do not express 
myeloperoxidase, it has been proposed that the neuroprotective action of apocynin is 
mediated by its antioxidant capacity, which may not require dimer formation, and not by 
the inhibition of vascular NADPH oxidase (Heumüller et al, 2008).  These authors 
demonstrated that apocynin failed to inhibit superoxide generation in HEK293 cells 
overexpressing NADPH oxidase isoforms (Nox1, Nox2, Nox4). However, when these cells 
were supplemented with myeloperoxidase, dimerization and activation of apocynin was 
observed with inhibition of NADPH oxidase activity. Furthermore, apocynin failed to 
inhibit NADPH oxidase activity and superoxide generation in endothelial and vascular 
smooth muscle cells which do not express myeloperoxidase. However, apocynin 
demonstrated antioxidant effects in vascular cells by inhibiting hydrogen peroxide activity 
and hydroxyl formation. Therefore, apocynin demonstrates free radical scavenging 
capability and it may be the antioxidant activity of apocynin which leads to the observed 
neuroprotective effects (Heumüller et al, 2008).   
 
However, the absence of myeloperoxidase in vascular cells may not prevent the oxidation 
of apocynin into it metabolically active form. Vascular cells may possess other peroxidases 
which can activate apocynin (Touyz, 2008). It has been previously demonstrated that 
horseradish peroxidase induces apocynin dimer formation with subsequent inhibition of 
NADPH oxidase activity (Vejražka et al, 2005). Despite horseradish peroxidase being an 
exogenous peroxidase, this study provides evidence that other peroxidases can influence 
apocynin activity.  
 
It has also been proposed that apocynin may inhibit vascular NADPH oxidase even if these 
cells do not express peroxidases which can activate the drug. It has been demonstrated in 
vivo, that neutrophils secrete myeloperoxidase which can be taken up by endothelial cells 
by the interaction of cytokeratin 1 on the endothelial cell surface (Astern et al, 2007). The 
internalised peroxidase can then activate apocynin leading to inhibition of vascular 
NADPH oxidase (Touyz, 2008, Figure 5-19).  
  
 
 
 
 
 
 
 
 
Figure 5-19. The potential effects of apocynin on phagocytic cells (neutrophil) and non-
phagocytic cells (vascular cell). In neutrophils, apocynin is oxidised by myeloperoxidase (MPO) 
to form metabolically active dimers and trimers. NADPH oxidase activity is dependent on the 
translocation of p47phox/p67phox/p40phox to the cell membrane where the cytosolic complex 
interacts with gp91phox and p22phox. Apocynin prevents translocation of the p47phox subunit and 
therefore inhibits superoxide generation mediated by NADPH oxidase. In vascular cells, which do 
not contain endogenous MPO, apocynin acts as an antioxidant, thereby reducing reactive oxygen 
species bioavailability, without inhibiting NADPH oxidase. It may be possible that vascular cells 
possess non-MPO peroxidases that could activate apocynin to dimers and trimers to inhibit 
vascular NADPH oxidase, which is composed of Nox2 or its homologues (Nox1, Nox4, or Nox5) as 
the catalytic subunit. In vivo studies suggest that apocynin in vascular cells could also be activated 
by MPO secreted from neutrophils. Dashed arrows indicate possible effects; →, stimulation; ⊥, 
inhibition. Reproduced from Touyz (2008).  
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The reduction in infarct volume observed following apocynin treatment in Sprague-
Dawley rats following ischaemia/reperfusion was comparable to that shown in other 
published studies (Tang et al, 2007). In the present study, infarct volume at 72 hours post-
MCAO was reduced by approximately 60% in apocynin treated rats, following 1 hour of 
ischaemia. Previously, reductions in infarct volume of up to 40% have been observed in 
normotensive rats following apocynin treatment. Tang and colleagues reported a 37% 
reduction in infarct volume in Sprague-Dawley rats following apocynin treatment 
administered at 1 hour post-MCAO (Tang et al, 2007). Similar observations have been 
reported following apocynin treatment in Wistar rats, where infarct volume was reduced by 
40%, when treatment was administered at 2 hours post-MCAO (Genovese et al, 2011). An 
improved outcome has also been reported with apocynin treatment in mouse transient 
ischaemia models. Reductions in infarct volume of up to 50% compared to control treated 
mice have been demonstrated. Chen and colleagues reported a 50% reduction in infarct 
volume when apocynin treatment was administered following 70 minutes of ischaemia 
(Chen et al, 2009) and a similar reduction in infarct volume was reported by Jackman et al 
(2009). However, these authors administered apocynin 30 minutes prior to the induction of 
ischaemia, which reduces the clinical relevance of these findings.  
 
In the permanent MCAO model, apocynin treatment had no significant effect on infarct 
volume or behavioural outcome in WKY rats at 24 hours post-MCAO. The vibrissae-
evoked forelimb scores observed across the 3 treatment groups were more severe than 
those previously described following permanent occlusion of the MCA in Sprague-Dawley 
rats, where 70-80% of contralateral placements were unsuccessful from 24 hours post-
MCAO (Schallert et al, 2000). This may be attributable to the larger infarct observed in 
WKY rats compared to Sprague-Dawley rats, as previously described (Chapter 3). In 
WKY rats, there is more extensive injury in both the striatum and the cortex and the 
forelimb placement test is sensitive to both cortical and striatal damage (Schallert et al, 
2000). 
 
In the present study, there was a trend (not statistically significant) towards improved 
functional outcome with low dose apocynin treatment in Sprague-Dawley rats following 
transient focal ischaemia which was associated with a significantly reduced infarct volume 
at 72 hours post-MCAO. The functional tests used in this study may not have been 
sensitive enough to detect subtle improvements in neurological function. The low dose 
apocynin treated rats exhibited normal feeding and grooming behaviours and their general 
appearance and condition was improved compared to vehicle and high dose apocynin 
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treated rats. However, the modified Bederson scale, the forelimb placement test and the 18 
point neurological score fail to detect these behaviours. It may therefore be advantageous 
for the benefit of future studies to develop a composite functional test which assesses 
feeding and grooming behaviours in addition to tests of general proprioceptive and 
sensorimotor capabilities.  
 
All previous studies examining the effects of apocynin in ischaemia-reperfusion models 
have assessed infarct volume at 24 hours post-MCAO. However, at this time point in 
transient ischaemia models, the infarct is still evolving, as demonstrated in the present 
study, where infarct volume increased between 24 and 72 hours (Figure 5-15). Neuronal 
injury following transient cerebral ischaemia is an evolving process which can continue for 
days following stroke (Williams et al, 2004). It has been previously demonstrated in rat 
transient ischaemia models that delayed reperfusion injury can contribute to the 
development of the infarct beyond 24 hours post-MCAO (Du et al, 1996; Li et al, 2000). 
Therefore, a limitation of the previously published studies with apocynin is that the effect 
on final infarct volume may have not been assessed accurately due to the use of the 24 
hour time point. 
 
In order to increase the likelihood of translation of neuroprotective drugs from bench to 
bedside, it is necessary to evaluate potential neuroprotective strategies in preclinical 
models with stroke risk factors, like increasing age and hypertension. The SHRSP is 
therefore a suitable rat model for assessing the neuroprotective efficacy of apocynin. It has 
also been demonstrated in this chapter, that apocynin had no protective effect in SHRSP 
rats following 1 hour of ischaemia. Treatment with 5mg/kg apocynin at 5 minutes post-
MCAO did not have any effect on perfusion-diffusion mismatch volume or the evolution 
of ischaemic injury in SHRSP rats during the critical acute phase following stroke. 
Mortality rates were high, with 67% of rats dying before the 72 hour end point. This 
prevented statistical analysis of infarct volume between groups since only 2 rats in each 
treatment group survived to 72 hours post-MCAO. Previously, it has been reported that 
apocynin treatment does not improve stroke outcome in aged rats despite an improvement 
in outcome being observed in young rats. Kelly and colleagues demonstrated that apocynin 
treatment worsened stroke outcome in aged rats, where the mortality rate was significantly 
higher in apocynin treated rats (36% mortality) compared to aged vehicle treated rats (14% 
mortality). Apocynin treatment also failed to improve functional outcome or reduce infarct 
volume at 24 hours post-MCAO compared to aged vehicle treated rats. Furthermore, 
oedema formation at 24 hours post-MCAO was significantly higher in aged apocynin 
 203 
treated rats, where the volume of the ipsilateral hemisphere increased by 20%, compared to 
a 6% increase in aged vehicle treated rats (Kelly et al, 2009). Aged rats demonstrate 
reduced levels of SOD, increased generation of reactive oxygen species and reduced 
antioxidant activity which supports the „free radical theory of aging‟ where increased 
levels of oxidative stress contribute to age-related diseases (Harman, 1994). Increased 
levels of oxidative stress have been reported in the SHRSP and contribute to the increased 
infarct volume observed following experimental stroke compared to the normotensive 
control strain, WKY (Kishi et al, 2004; Cheng et al, 2008; Dunn et al, 2008).  
 
The present studies demonstrate that inhibiting a component of the oxidative stress 
pathway with apocynin, improves stroke outcome in normotensive Sprague-Dawley rats 
but has no effect in SHRSP rats. Given the increased oxidative stress response in the 
SHRSP it was hypothesised that apocynin treatment may improve outcome by inhibiting 
the production of superoxide through NADPH oxidase inhibition.  The fact that we 
observed no effect in the SHRSP may be attributable to strain specific differences in the 
expression of NADPH oxidase isoforms. There is some debate regarding the contribution 
of specific isoforms to the generation of reactive oxygen species during ischaemia. It has 
been reported that Nox1 and Nox4 account for the generation of reactive oxygen species 
under physiological conditions (Miller et al, 2005; 2007) and upregulation of Nox2 occurs 
during ischaemia, making it the predominant source of reactive oxygen species (Kahles et 
al, 2007). Apocynin is believed to be selective for the Nox1 and Nox2 isoforms by 
preventing the translocation of p47phox from the cytosol to the Nox1/2 catalytic 
membrane domain (Stolk et al, 1994). Evidence for the Nox2 selectivity of apocynin was 
recently provided by Jackman and colleagues. This group of investigators demonstrated a 
significant neuroprotective effect of apocynin in wild type mice, where stroke outcome 
was improved and superoxide levels were reduced. However, no protective effect was 
observed in Nox2-deficient mice. These findings suggest that the neuroprotective effect of 
apocynin was mediated by inhibition of Nox2 containing NADPH oxidase and provide 
evidence for the importance of the Nox2 isoform during ischaemia (Jackman et al, 2009).  
However, Kleinschnitz and colleagues (Kleinschnitz et al, 2010) proposed that Nox4 is the 
most relevant source of reactive oxygen species under ischaemic conditions as it is the 
most abundant vascular isoform in cerebral vessels (Miller et al, 2005) and is upregulated 
in stroke (McCann et al, 2008). This study group reported that Nox4-deficient mice 
demonstrated an improved stroke outcome following permanent and transient ischaemia 
compared to wild-type mice. However, Nox1- and Nox2-deficient mice showed no 
improvement in stroke outcome (Kleinschnitz et al, 2010).  
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These findings may explain why apocynin treatment did not improve outcome in a model 
of permanent MCAO. If Nox4 is the principal isoform under ischaemic conditions, then 
inhibiting Nox2 with apocynin may not significantly reduce the generation of reactive 
oxygen species and its contribution to ischaemic injury. In addition, the free radical 
scavenging capabilities of apocynin may not be sufficient to reduce ischaemic damage. 
However, this does not explain the clear neuroprotective effects of apocynin demonstrated 
in transient focal ischaemia models. It may be the case that following reperfusion Nox2 
activity becomes the predominant source of reactive oxygen species and that apocynin 
mediates its neuroprotective actions by inhibiting Nox2 which may be upregulated 
following restoration of flow. However, this is highly speculative and the possible 
upregulation of NADPH oxidase isoforms following reperfusion has not yet been 
examined. It is interesting to note that all studies which report apocynin neuroprotection 
have employed ischaemia-reperfusion models of focal ischaemia. To date, there are no 
published reports on the effects of apocynin in stroke models of permanent MCAO. This 
may be because of negative findings which have not been published due to publication bias 
towards positive studies.  
 
The lack of a neuroprotective effect of apocynin specifically in SHRSP rats following 
transient focal ischaemia may be related to strain specific differences in NADPH oxidase 
isoform expression. It has been reported that SHRs demonstrate higher levels of Nox4 
mRNA compared to normotensive WKY rats and this is associated with enhanced 
cerebrovasodilatation in chronic hypertension (Paravicini et al, 2004). It is therefore not 
unreasonable to speculate that the SHRSP strain, derived by selective breeding from SHR, 
may also exhibit increased expression of Nox4. These data suggest that Nox4 may have a 
protective role in hypertension. However, as previously discussed Nox4 is upregulated 
during ischaemia and contributes to ischaemic injury (Kleinschnitz et al, 2010). In 
hypertensive animals, like the SHRSP, Nox4 may continue to be the principal source of 
reactive oxygen species following reperfusion. Therefore, apocynin treatment would not 
impact on the extent of ischaemic injury.  
 
Furthermore, apocynin treatment failed to prolong the lifespan of the ischaemic penumbra 
in SHRSP, as defined by perfusion-diffusion mismatch at 1 hour post-MCAO. This may be 
attributable, in part, to the small volumes of mismatch tissue detected in this strain. 
Previously, it has been reported that administration of the selective endothelin antagonist, 
SB 234551, successfully preserved mismatch defined penumbra in normotensive Sprague-
Dawley rats but failed to demonstrate a protective effect in SHR rats, where there was little 
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evidence of mismatch tissue at 1 hour post-MCAO (Legos et al, 2008). The lack of 
penumbral tissue in the SHR and SHRSP strains may therefore limit the potential for tissue 
salvage following stroke in models of genetic hypertension.  
 
It has been reported that increased generation of reactive oxygen species in hypertensive 
rats contributes to the development of arterial hypertension by inducing endothelial 
dysfunction (Alexander et al, 2000). Therefore, inhibition of NADPH oxidase with 
apocynin has been investigated as a potential anti-hypertensive strategy. However, 
apocynin has no effect on blood pressure in normotensive rats (Li et al, 2003) and there are 
conflicting reports on the ability of apocynin to lower blood pressure in hypertensive rats. 
Bäumer and colleagues reported that apocynin treatment lowered systolic blood pressure in 
SHRs as effectively as the calcium channel blocker, nifedipine. SHRs received daily 
administration of 33mg/kg apocynin or nifedipine (30mg/kg) for a period of 28 days. 
Within one week of treatment, apocynin significantly reduced systolic blood pressure from 
183±2mmHg to 164±12mmHg (P<0.05) and this treatment effect was maintained over the 
28 day observation period. The antihypertensive effect of apocynin was comparable to the 
effect of nifedipine treatment, where systolic BP had reduced to 166±27mmHg by day 2 
(Bäumer et al, 2007). The authors also observed that the anti-hypertensive effect of 
apocynin correlated with reduced vascular ROS levels, increased activity of eNOS and 
increased NO bioavailability, suggesting that the mechanism of action involves inhibition 
of vascular NADPH oxidase. However, these findings conflict with a previous study which 
reported that apocynin treatment over a 3 week period had no significant effect on blood 
pressure in SHR and WKY rats (Paliege et al, 2006). Similarly, Schlüter and colleagues 
also reported that apocynin treatment failed to reduce arterial pressure, which was 
measured via implanted radiotelemetric devices in SHR. Apocynin treatment was 
administered orally in the drinking water over a period of 5 weeks and arterial pressure 
continued to be assessed for a further 12 weeks. Apocynin treated SHR demonstrated 
virtually identical arterial pressures as untreated controls over the entire observation period 
(Schlüter et al, 2008). Furthermore, these authors assessed the vasodilator capacity of 
apocynin in vitro and observed that apocynin dilated arterial segments of SHRs in a dose-
dependent manner. However, the authors also examined aortic rings from p47phox 
knockout mice and reported an increased sensitivity to apocynin-induced vasodilatation, 
which was then prevented by Rho kinase inhibition. These authors therefore suggest that 
apocynin-mediated vasodilatation is not dependent on NADPH oxidase but involves Rho 
kinase activity. It has been reported previously that rho kinase activity contributes to 
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infarct volume following experimental stroke (Shin et al, 2007). These findings further 
complicate the already complex mechanism of action of apocynin.  
 
The dose of apocynin and the timing of administration appear to be critical to its 
neuroprotective effects in rodent stroke models. It has been reported that apocynin 
improves stroke outcome within a narrow dose range. Tang and colleagues reported that 
intravenous administration of 2.5mg/kg apocynin prior to reperfusion, significantly 
improved neurological outcome, reduced infarct volume and reduced the incidence of 
cerebral haemorrhage. However, when apocynin was administered at a dosage of 3.75 or 
5mg/kg, no improvement in stroke outcome was observed and there was an increased 
incidence of cerebral haemorrhage in both the ipsilateral and contralateral hemispheres 
compared to vehicle treated controls. Furthermore, mice treated with 5mg/kg apocynin 
demonstrated a higher mortality rate of 38%, compared to vehicle treated mice (25%), 
whereas mice treated with 2.5mg/kg apocynin had a lower mortality rate (13%).   
These findings are supported by other study groups, where mice pre-treated with 5mg/kg 
apocynin prior to ischaemia demonstrated a significantly higher mortality rate (41%) 
compared to vehicle treated mice (12%) and those treated with 2.5mg/kg apocynin (0%). 
Interestingly, mice pre-treated with 5mg/kg apocynin and then subjected to sham MCAO 
surgery did not die, suggesting that apocynin is only toxic at this dosage when cerebral 
ischaemia is induced (Jackman et al, 2009). The authors proposed that the higher dose of 
apocynin may compromise NADPH oxidase dependent cerebral vasodilatation by 
increased scavenging of H2O2. It has been shown previously that H2O2 mediates NADPH 
oxidase dependent vasodilatation in ischaemic brain regions (Paravicini et al, 2004; 2006).  
 
The dosage of apocynin is unlikely to account for the mortality rates observed in the 
present studies, as in normotensive rats the mortality rate was higher in vehicle treated 
animals than those treated with apocynin. These results are in conflict with the studies 
previously discussed. However, those studies examined the effects of apocynin in mice and 
there may be species differences in the dose of apocynin required to induce toxic effects. 
The high mortality rate (67%) observed in both vehicle treated and low dose apocynin 
treated SHRSP rats suggest that drug treatment had no influence on mortality rate. It is 
more likely that the high mortality rate was attributable to brain swelling following 
reperfusion. It has been reported that BBB dysfunction may contribute to ischaemic injury 
and extensive brain oedema in SHRSP rats (Yamagata et al, 1997; Lippoldt et al, 2000; 
Ishida et al, 2006).  
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In addition, the timing of administration appears to be important when evaluating the 
neuroprotective effects of apocynin. Jackman and colleagues reported that administration 
of apocynin 30 minutes prior to ischaemia had a neuroprotective effect. However, when 
apocynin treatment was administered 1 hour after reperfusion, following 30 minutes 
ischaemia, there was no improvement in stroke outcome. These findings therefore suggest 
that the therapeutic potential of apocynin may be limited. However, other study groups 
have reported the neuroprotective effect of apocynin when administered up to 2 hours post-
MCAO (Genovese et al, 2011), which is a more clinically relevant time point. In the 
present studies apocynin was administered at 5 minutes post-MCAO, however, the purpose 
of these experiments was to ascertain if apocynin demonstrated neuroprotective efficacy in 
a rat model of genetic hypertension and not to evaluate the potential therapeutic window, 
which would be the next logical step in this series of experiments.  
Another limitation of the studies presented in this chapter is that we did not measure 
oxidative stress levels in the either the vasculature or the brain to assess whether apocynin 
treatment reduced oxidative stress levels. This could have been achieved by assessing the 
levels of oxidative stress markers, such as 8-hydroxy-2‟-deoxyguanosine (8-OHdG) and 4-
hydroxy-2-nonenal (4-HNE), using immunohistochemistry.  
Furthermore, apocynin treatment was evaluated in SHRSP rats at a single dose of 5mg/kg. 
This dose may not have been optimal to confer neuroprotection in this strain despite 
demonstrating neuroprotective effects in normotensive Sprague-Dawley rats. In future 
studies, data on dose response should be generated to allow more accurate assessment of 
the effect of apocynin in SHRSP rats. 
 
When evaluating the effect of apocynin on stroke outcome, care must be taken when 
deciding on the solvent to dissolve the drug, and its concentration. Apocynin is highly 
soluble (i.e. to >1mol/L) in non-polar solvents such as dimethylsulphoxide (DMSO), 
chloroform and alcohols (Selemidis et al, 2008) and DMSO is commonly used as a solvent 
in studies examining the effects of apocynin on stroke outcome. However, DMSO 
demonstrates neuroprotective effects at concentrations ≥ 10%. For example, when 10% 
DMSO was used as a vehicle in mouse models of focal cerebral ischaemia, it demonstrated 
neuroprotective efficacy (Alyson Miller, personal communication, 2010). Furthermore, 
Bardutzky and colleagues (2005) evaluated the neuroprotective effects of DMSO in a 
rodent permanent stroke model and reported that administration of 33% DMSO at 60 
minutes post-MCAO prolonged the lifespan of the mismatch defined penumbra. This will 
impact on the findings of Genovese and colleagues, who recently reported an improvement 
in stroke outcome following apocynin treatment, where 10% DMSO was used as the 
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treatment vehicle. Therefore, the improvement in stroke outcome reported by this group 
may be attributable in part to the neuroprotection of DMSO. In the present studies, 0.1% 
DMSO was used as the vehicle to eliminate the possibility of neuroprotective efficacy. 
However, it may have been advantageous to include a saline treated control group to 
compare stroke outcome to the vehicle treated group.  
 
The results of these studies also highlight the need for functional testing in addition to 
measurement of brain injury, when assessing potential neuroprotective therapy. High dose 
apocynin treatment significantly reduced infarct volume following 1 hour of ischaemia in 
Sprague-Dawley rats but there was no improvement in functional outcome. The recovery 
of neurological function and improvement in quality of life are the outcomes which are 
important clinically, rather than a reduction in brain injury alone. On this basis, low dose 
apocynin shows greater potential for clinical efficacy. However, the failure of low dose 
apocynin treatment to prolong the lifespan of the mismatch defined penumbra in SHRSP 
rats, suggests that apocynin may be of limited clinical potential. These results highlight the 
need for studies examining the effects of potential neuroprotective strategies in stroke 
models with risk factors. The present study demonstrates that apocynin treatment improves 
stroke outcome in normotensive rats following transient ischaemia but has no effect when 
administered to rats with genetic hypertension. This finding is likely to explain in part the 
failure of successful neuroprotectants to translate to clinical trials, since most pre-clinical 
drug studies use young healthy animals, which have less relevance to the human condition.  
 
Summary 
In the present study we have shown that apocynin does not influence infarct volume or 
functional outcome when administered following permanent focal cerebral ischaemia in 
normotensive rats.  However, following transient cerebral ischaemia, apocynin reduced 
infarct volume and improve functional outcome when administered post-stroke.  In 
contrast, apocynin, when given at a dose that reduced infarct and improved recovery in 
normotensive rats, had no significant effect on the acute evolution of ischaemic damage or 
functional outcome in the hypertensive SHRSP rat.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. 
General Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 210 
In the crucial first hours of acute ischaemic stroke, identification and salvage of penumbral 
tissue is the ultimate goal of both clinicians and experimental stroke researchers. Positron 
emission tomography remains the „gold-standard‟ imaging modality for identifying the 
ischaemic penumbra in stroke research but its use is limited by the complex logistics 
associated with this technique. Consequently, MRI is now commonly used in clinical 
research to identify the penumbra as a result of its widespread availability and less 
complex logistics then PET. However, defining penumbra using the MRI perfusion-
diffusion mismatch technique presents its own difficulties. Penumbra may be 
overestimated by the inclusion of benign oligaemic tissue and may be underestimated by 
the assumption that the diffusion lesion represents irreversibly injured tissue, which is not 
necessarily the case as DWI lesion reversal has been demonstrated both in animal models 
and stroke patients (Minematsu et al, 1992; Hasegawa et al, 1994; Kidwell et al, 2000). In 
addition, few study groups have determined perfusion and diffusion thresholds to define 
penumbra and there is a lack of consensus on appropriate thresholds and the parameters 
used to define hypoperfused tissue. 
 
The findings in this thesis demonstrate that a single perfusion and diffusion threshold may 
not be appropriate for all rat strains since we have shown different values calculated in a 
rat model that displays stroke co-morbidities compared with normotensive rats. Strain 
differences in threshold values may lead to an over- or underestimation of penumbra. This 
will impact on preclinical drug studies, where salvage of the penumbra is used to evaluate 
drug efficacy across different rat strains. Therefore, it is important that perfusion and 
diffusion thresholds are defined in each rat strain used in preclinical stroke research. The 
calculated diffusion threshold for identifying ischaemically injured tissue was comparable 
in SHRSP and the normotensive control strain WKY. However, the absolute perfusion 
threshold was significantly higher in the hypertensive strain, which may indicate that the 
SHRSP is more sensitive to ischaemia than WKY. Therefore, it would be inappropriate to 
apply the same perfusion threshold to define the perfusion deficit across different rat 
strains, particularly those strains which exhibit stroke co-morbidities, like the SHRSP. The 
perfusion and diffusion thresholds determined in WKY and SHRSP in the present study 
also differ significantly from those previously defined in Sprague-Dawley rats using a 
similar method (Shen et al, 2003). In addition, the thresholds calculated in this thesis also 
differ from those defined in our laboratory in male and female Sprague-Dawley rats using 
the same method. In both male and female Sprague-Dawley rats a perfusion threshold of 
63% reduction from mean contralateral CBF defined the perfusion deficit (TA Baskerville, 
unpublished observations). These data differ from the perfusion thresholds determined in 
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SHRSP and WKY rats (70% and 81% reduction from mean contralateral CBF for SHRSP 
and WKY, respectively). The diffusion thresholds determined in male and female Sprague-
Dawley rats were comparable between the sexes, where a 27% and 30% reduction from 
mean contralateral ADC values defines the volume of ischaemic injury in male and female 
rats, respectively. However, these thresholds differ from the diffusion thresholds defined in 
SHRSP and WKY rats (23% and 21% reduction from mean contralateral ADC for SHRSP 
and WKY, respectively). This suggests that Sprague-Dawley rats may be less sensitive to 
reductions in ADC values and this may explain, in part, the smaller infarct volumes 
observed in this strain compared to SHRSP and WKY rats. These data further highlight the 
need for strain-specific thresholds of perfusion and diffusion abnormality.  
 
The studies presented within this thesis have also highlighted the importance of selecting 
the method used to define the penumbra using MRI. Despite criticism regarding the 
inclusion of benign oligaemic tissue and DWI lesion reversal on reperfusion, the MRI 
perfusion-diffusion mismatch model continues to be a useful tool for approximating the 
ischaemic penumbra in both clinical and preclinical stroke research. In the present study, 
the volumetric mismatch method consistently generated lower volumes of perfusion-
diffusion mismatch compared to spatially defined mismatch in both SHRSP and WKY 
rats, although this was not statistically significant. Although it is a simple arithmetic 
technique, the volumetric method does not provide any information on the extent and 
location of penumbral tissue, unlike the more precise spatial method, where mismatch 
tissue was assessed on each coronal slice. These findings are in agreement with previous 
reports, where volumetric and spatial mismatch methods were employed to define 
penumbra volume in stroke patients. It was demonstrated that simple arithmetic subtraction 
of the DWI lesion from the PWI defined perfusion deficit without any anatomical co-
registration, consistently underestimated penumbra volume by 40% compared to penumbra 
defined by co-registration of DWI and PWI (Ma et al, 2009). On the basis of these results 
and the findings presented in this thesis, it should be recommended that the volumetric 
method is not used to define the mismatch but rather spatial assessment of perfusion-
diffusion mismatch is carried out on each coronal slice. 
 
The studies presented in this thesis also demonstrate that the volumetric and spatial 
mismatch methods failed to detect any significant difference in mismatch volume between 
the SHRSP and WKY strains. Mismatch volume was comparable between the strains from 
1-4 hours post-MCAO and there was little evidence of mismatch defined penumbra from 
as early as 1 hours following stroke onset. This suggests that there may be a limited 
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potential for penumbra salvage in both strains. This is in conflict with previous reports 
from our laboratory, where mismatch was significantly reduced in SHRSP compared to 
WKY (McCabe et al, 2009). However, mismatch area was defined only on a single coronal 
slice within the MCA territory in this study. Other authors have also used the mismatch 
technique to define penumbra in rat models with stroke co-morbidities. There was no 
evidence of mismatch as early as 1 hour post-MCAO in SHR rats and administration of a 
selective ETA antagonist following stroke had no effect on final infarct volume at 24 hours 
(Legos et al, 2008). Letourneur and colleagues reported that mismatch volume was reduced 
in the SHR and renovascular hypertensive WKY rats (RH-WKY) compared to 
normotensive rats up to 4 hours post-MCAO (Letourneur et al, 2011). These results differ 
from the findings of the present study. It may be that the WKY rats used in the Letourneur 
study have a different genetic background to the WKY rats used in the studies described in 
this thesis. This could potentially influence the evolution of ischaemic injury and stroke 
outcome. Furthermore, the authors used the SHR strain which differs from the SHRSP 
strain used in the studies presented in this thesis. It has been demonstrated previously that 
both of the hypertensive strains demonstrate a significantly larger infarct volume than 
WKY rats following permanent MCAO and in addition, the SHRSP strain exhibits a larger 
infarct than the SHR strain (Duverger & MacKenzie, 1988). However, to date, there are no 
published studies in the literature which have compared mismatch volume in the SHR, 
SHRSP and WKY rat strains. 
 
Criticisms of the perfusion-diffusion mismatch model have led to the development of 
alternative techniques to define the penumbra in acute ischaemic stroke research. The 
oxygen challenge is a MRI technique which has recently been developed to overcome the 
limitations of the mismatch model, using oxygen as a metabolic biotracer in combination 
with T2* weighted imaging (Santosh et al, 2008). This novel technique should allow a 
more precise evaluation of penumbra on the basis of its metabolic activity and is based on 
the differing magnetic properties of deoxyhaemoglobin and oxyhaemoglobin and is 
currently being validated in preclinical and clinical research. Perfusion CT is another 
alternative imaging modality to detect the penumbra. This technique involves the 
intravenous injection of an iodinated contrast agent and the bolus is tracked through the 
cerebral circulation. However, the radiation dose is a significant issue which needs to be 
considered as the dose required for perfusion CT is higher than that needed for standard 
CT. Nevertheless, in clinical research perfusion CT may overtake perfusion-diffusion 
mismatch due to its cost-effectiveness and the wide availability of CT scanners in the 
clinical setting (Heiss & Sorensen, 2009). 
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The acute evolution of the penumbra was also evaluated retrospectively by assessing the 
growth of the ADC derived lesion. However as previously discussed in Chapter 4, this 
method is not suitable when examining the lifespan of the penumbra at acute time points as 
tissue must proceed to infarction to allow retrospective calculation of the penumbra. 
Nevertheless, this technique has been used in clinical research to provide a retrospective 
approximation of the penumbra to compare with a new MRI diagnostic technique for 
penumbra in patients where perfusion data was not available (Dani et al, 2010). However, 
these authors were aware of the limitations of this method. The findings of the present 
study demonstrate that ADC lesion growth was significantly larger in WKY compared to 
SHRSP at 30 minutes post-MCAO. This suggests that there is a reduced potential for 
penumbra salvage in the SHRSP strain within the first 30 minutes following stroke. 
However, by 1 hour post-MCAO there is no significant difference in ADC lesion growth 
between the strains. 
 
The studies presented in this thesis have also shown that the perfusion deficit increased 
significantly from 1-4 hours post-MCAO in both SHRSP and WKY rats. This is an 
interesting finding and may be indicative of a failure of collateral blood supply in both 
strains. Previously, our laboratory has demonstrated that the perfusion deficit increased 
significantly from 1-6 hours post-MCAO in SHRSP but not in WKY rats (McCabe et al, 
2009). One of the limitations of this previous study was that the perfusion deficit was only 
examined on a single coronal slice within the core territory of the MCA and therefore any 
changes in CBF within more rostral or caudal regions with different collateral supply will 
have been missed. It is not surprising that the perfusion deficit increased over time in the 
hypertensive strain, as it has been demonstrated that collateral flow is impaired in SHRSP 
rats (Coyle & Heistad, 1987) and this is likely to contribute to the significantly larger 
perfusion deficit observed in SHRSP compared to WKY in the studies presented in this 
thesis. However, the temporal increase in perfusion deficit observed in WKY was 
somewhat unexpected. This is unlikely to be attributable to changes in blood pressure as 
mean arterial blood pressure and arterial PCO2 and PO2 did not change significantly during 
surgery or the 4 hour MRI scanning period. This finding suggests that the normotensive 
control strain experiences some impairment of collateral blood supply following stroke. 
Our laboratory has also demonstrated a small temporal increase in perfusion deficit in 
Sprague-Dawley rats, although not statistically significant. It would be interesting to 
compare the collateral blood supply of the WKY to other normotensive rat strains, such as 
the Sprague-Dawley rat, to assess any potential strain differences. To date,
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Figure 6-1. Temporal evolution of ischaemic injury and perfusion deficit in SHRSP, WKY and Sprague-Dawley rats. The volume of ischaemic injury is significantly 
higher in SHRSP and WKY rats compared to male and female Sprague-Dawley rats (S-D) from 30min to 4h post-MCAO (A). The volume of perfusion deficit is significantly 
higher in SHRSP and WKY rats compared to male and female S-D rats. All data are presented as mean±SD. *p<0.001 (SHRSP vs male and female S-D), +p<0.05 (WKY 
vs male and female SD), 2-way ANOVA with Bonferroni’s post-test. WKY; n=12, SHRSP; n=15, Female S-D; n=10, Male S-D; n=9. 
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no such study has been undertaken. If indeed, the collateral vessels of the WKY rat differ 
in number, distribution, diameter or vasoreactivity compared to other normotensive strains, 
it may help to explain why, when exposed to the same ischaemic insult, the volume of 
ischaemic injury and perfusion deficit are significantly larger in WKY rats compared to 
Sprague-Dawley rats, as discussed previously in Chapter 3 (Figure 6-1). The experimental 
procedures and conditions within our laboratory were identical for the studies of both 
normotensive rat strains (although the data were produced by two investigators). The 
results demonstrated a greater extent of injury in WKY compared to Sprague-Dawley rats. 
The differences observed following focal cerebral ischaemia between normotensive rats 
strains warrants further investigation and it may be useful for further studies examining the 
SHRSP strain to also include the Sprague-Dawley rat as an additional control strain, as 
well as the WKY rat. 
 
Rats are commonly used in animal models of stroke due to similarities to man with respect 
to their cerebral anatomy and physiology. Furthermore, the use of specific and inbred 
strains improves homogeneity in outcome measures, the cost of purchasing and 
maintaining them is relatively low compared to larger mammals and there is a greater level 
of social acceptance in the use of rodents in preclinical research (Sicard & Fisher, 2009). 
However, there are disadvantages in using rats to model human neurological diseases. Rats 
have a small region of subcortical white matter which makes it difficult to study white 
matter and model lacunar infarction (Carmichael, 2005). In addition, rodents demonstrate 
rapid behavioural recovery following experimental stroke which is not relevant to the 
clinical situation and many neurological deficits are difficult to assess (Sicard & Fisher, 
2009). Furthermore, rodents possess small lissencephalic brains which are not directly 
comparable to the large gyrencephalic brains of humans. However, the use of larger 
species, like dogs, pigs and primates, is more relevant to the clinical situation as these 
species offer the advantage of having large gyrencephalic brains with proportions of grey 
and white matter which resemble that observed in humans (Howells et al, 2010, Figure 6-
2).  
 
Rodent stroke models have led to a better understanding of the mechanisms involved in the 
underlying pathophysiology of stroke and the identification of numerous targets for 
neuroprotective therapy (Mergenthaler et al, 2004). To date, the results of over 7,000 
studies examining the neuroprotective effects of over 1,000 therapeutic interventions have 
been published (O‟Collins et al, 2006) but unfortunately there has been a notable failure of 
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Figure 6-2. Brain size and gyral complexity in mammal species. Reproduced from Howells et 
al (2010).  
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translation from bench to bedside and thrombolytic therapy with recombinant tissue 
plasminogen activator remains the only successful pharmacological treatment in acute 
ischaemic stroke (NINDS, 1995). There are many factors which may explain why 
neuroprotective drugs demonstrate efficacy in experimental stroke models but fail to 
translate to human stroke patients. In some preclinical studies, therapy is administered 
prior to stroke onset and this does not reflect the clinical situation, where some stroke 
patients may not be diagnosed until many hours following stroke (Röther, 2008). In the 
study presented in this thesis, apocynin treatment was administered 5 minutes following 
stroke, which is not a particularly clinically relevant time point. However, the purpose of 
the studies was to assess if apocynin demonstrated a neuroprotective effect  
and the next logical step in this series of experiments would be to delay administration to 
determine the therapeutic time window. Unfortunately, time constraints did not permit 
such a study to be undertaken. 
 
Furthermore, there are significant anatomical, physiological and metabolic differences 
between humans and small rodents. Small rodents require higher drug doses on a mg/kg 
body weight basis compared to larger mammals and this means that effectivedoses cannot 
simply be translated from preclinical studies to clinical trial (Braeuninger & Kleinschnitz, 
2009). In addition, the ischaemic lesion induced in experimental models is highly 
reproducible but a heterogenous population of stroke patients with a wide range of stroke 
severity and etiology is included in clinical trials.  
 
Selecting the most appropriate stroke model is also important. Models which require a 
craniectomy, like the electrocoagulation method of distal middle cerebral artery occlusion 
(Tamura et al, 1981), are traumatic and do not mimic the clinical situation. Therefore, 
embolic and intraluminal thread models of middle cerebral artery occlusion may be more 
relevant to human stroke and also offer the significant advantage of permitting reperfusion 
(Braueninger & Kleinschnitz, 2009). However, the infarct produced by the intraluminal 
filament and the embolic model may be variable due to incomplete occlusion. In particular, 
infarcts produced by embolic models are generally less reproducible than those produced 
by the intraluminal filament and electrocoagulation models of MCAO due to variations in 
clot stability and the final lodgement of the embolus (DiNapoli et al, 2006). 
 
Poor study design may also contribute to the failure of translation of neuroprotective 
strategies from preclinical research to clinical trial. Only a minority of published studies 
reporting neuroprotection have reported randomised treatment allocation and blinding of 
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investigators (Worp et al, 2005). A previous meta-epidemiological study examined 13 
meta-analyses of experimental stroke studies and reported that those studies where 
induction of ischaemia was unblinded reported greater treatment effects than those studies 
which were blinded (Crossley et al, 2008). This demonstrates evidence of bias in 
preclinical stroke research when evaluating potential therapeutic strategies. In the studies 
presented in this thesis evaluating the potential neuroprotective effect of apocynin, the 
allocation of rats to treatment groups was carried out in a randomised manner using a 
random number generator, with the investigator performing the stroke surgery, drug 
administration and behavioural assessment (Emma Reid) completely blind to treatment 
group until completion of the experiments and data analysis. This limited any bias from the 
results presented in this thesis. Therefore, the improvements observed in stroke outcome 
following apocynin treatment in Sprague-Dawley rats following 1 hour of focal ischaemia, 
are likely to be true treatment effects. However, one source of bias in the studies presented 
in this thesis could not be removed. Although identical in general appearance, WKY rats 
are larger than age-matched SHRSP rats and this is a limitation which could not be 
controlled. Therefore the bias of knowing the strain of rat during stroke surgery could not 
be removed. 
 
The recommendations of the Stroke Therapy Academic Industry Roundtable (STAIR, 
1999) were taken into account when designing the studies to evaluate the neuroprotective 
efficacy of apocynin. Power calculations were performed to determine the group sizes 
necessary to detect a treatment effect. Apocynin efficacy was assessed following both 
permanent and transient ischaemia and rats with stroke co-morbidities (SHRSP) were used. 
In addition, treatment allocation was randomised and the investigator administering the 
drug and performing behavioural assessment was blind to treatment group. Furthermore, 
perfusion-diffusion mismatch was used as an outcome measure when evaluating the 
efficacy of apocynin in SHRSP rats.   
 
The results of Chapter 5 demonstrated that apocynin treatment had no effect on stroke 
outcome following permanent MCAO in WKY rats. However, both low and high dose 
apocynin treatment significantly reduced infarct volume by 60% in Sprague-Dawley rats 
following transient ischaemia of 1 hour duration. These findings are in agreement with 
previous reports of the neuroprotective effect of apocynin treatment in rat transient 
ischaemia models, where reductions in infarct volume of up to 40% have been 
demonstrated (Tang et al, 2007; Genovese et al, 2011). Furthermore, there was a trend 
towards improved functional outcome with low dose apocynin treatment, although this 
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improvement did not reach the level of statistical significance. However, the general 
condition of low dose apocynin treated rats was observed to be markedly improved 
compared to vehicle and high dose treated rats. Therefore, in future studies, it may be 
advantageous to develop a  test of functional outcome which incorporates feeding and 
grooming behaviours, in addition to the standard tests of sensorimotor function.  
 
Interestingly, when low dose apocynin treatment was evaluated in the SHRSP strain, it 
failed to confer neuroprotection and a mortality rate of over 60% was observed in both the 
vehicle treated and apocynin treated rats. This demonstrates that although apocynin 
improved stroke outcome in normotensive rats following 1 hour of focal ischaemia, it 
failed to confer neuroprotection under the same conditions in a rat model with genetic 
stroke risk factors. The STAIR guidelines recommend the use of perfusion-diffusion 
mismatch as an imaging biomarker to evaluate the efficacy of potential therapeutic 
strategies to improve the translation from preclinical to clinical trials (Fisher et al, 2009). 
The use of the mismatch model allowed the effect of apocynin on the acute evolution of 
ischaemic injury in SHRSP to be assessed. The failure of apocynin to confer 
neuroprotection in SHRSP rats may be attributable to the possibility that Nox4 is the 
predominant isoform of NADPH oxidase during ischaemia and reperfusion, rather than 
Nox2, which is inhibited by apocynin.  Furthermore, the lack of neuroprotective efficacy 
may also be attributable in part to the small volumes of mismatch tissue observed in the 
hypertensive strain. Therefore, there may be a limited potential for penumbra salvage in 
the SHRSP strain. The efficacy of potential therapeutic strategies may therefore be limited 
in preclinical models with stroke co-morbidities. Kelly and colleagues previously 
demonstrated that apocynin worsened stroke outcome in aged rats, compared to vehicle 
treated controls, where mortality rate was increased from 14% to 36% (Kelly et al, 2009). 
It may be that in aged rats, apocynin is not activated to the active dimer form as it has been 
reported that unactivated apocynin has pro-oxidant effects (Riganti et al, 2006) and this 
may have exacerbated ischaemic injury. The findings of Kelly and colleagues and the 
results reported in this may help to explain the failure of neuroprotective agents to translate 
to clinical trial. One of the major failings of preclinical research is the use of young healthy 
animals to assess the potential efficacy of therapeutic interventions. The majority of stroke 
patients recruited into clinical trials are elderly and may suffer from stroke co-morbidities 
such as hypertension, diabetes and atherosclerosis (Braeuninger & Kleinschnitz, 2009). It 
is therefore essential, that when evaluating the therapeutic strategies in preclinical research, 
that there should be increasing focus on aged animals and animals with stroke co-
morbidities, like the SHRSP strain. However, there are additional problems of increased 
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mortality when using aged animals and animals with stroke-comorbidities. Furthermore, 
there is an increased cost of housing, feeding and maintenance when using aged animals. 
 
Furthermore, preclinical studies to evaluate potential therapeutic strategies should routinely 
assess stroke outcome by functional testing, in addition to infarct volume. This step is vital 
for translation to clinical trial as a desirable outcome in human stroke patients is 
determined by the degree of disability and the improvement in quality of life, not solely by 
a reduction in brain injury, as this will not necessarily equate to an improved outcome for 
the patient. The need for combined assessment of brain injury and functional outcome is 
highlighted by the studies reported in this thesis, where low dose apocynin treatment 
significantly reduced infarct volume and improved functional outcome in Sprague-Dawley 
rats following 1 hour of ischaemia. However, high dose apocynin treatment failed to 
improve functional outcome despite reducing infarct volume by 60% compared to the 
vehicle treated group, although this may be related to the sensitivity of the behavioural 
tests. Furthermore, the design of the study could have been improved by increasing the 
number of rats in each group to increase the the likelihood of detecting differences in 
behavioural outcome between groups. However, on the basis of the results presented in this 
thesis, low dose apocynin treatment improves stroke outcome in terms of functionality and 
should be used in future studies rather than the higher dose of apocynin.  
 
In terms of future strategies to salvage brain tissue following stroke, combination therapy 
may be the way forward. The pathophysiological mechanisms are so highly complex that 
targeting a single component of the ischaemic cascade may have a limited effect on stroke 
outcome. There is an increasing focus on evaluating the combined effects of 
neuroprotective strategies and thrombolysis with rtPA (Fujiwara et al, 2009, Figure 6-3). 
Any new neuroprotective drug under test should be given in combination with rtPA or 
tested only in those patients not receiving treatment as it would be unethical to not to give 
eligible patients rtPA. 
 
 An alternative example of a potential combination therapy is magnesium treatment and 
hypothermia. The neuroprotective effects of hypothermia are well established and it is used 
clinically to limit brain ischaemia in comatose cardiac arrest patients (Hypothermia After 
Cardiac arrest Study Group, 2002). Magnesium therapy has also been demonstrated to be 
neuroprotective in animal models of cerebral ischaemia but failed to translate to clinical 
trial, with some evidence that magnesium may be beneficial in lacunar strokes (IMAGES 
Study Group, 2004).   
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Figure 6-3. Hypothetical scenarios for the progression of brain injury following ischaemic 
stroke. In the absence of any treatment the infarct will rapidly evolve leading to permanent injury 
(A). If a neuroprotective drug is administered but it does not alter the ischaemic environment then 
the infarct will progressively expand to reach its maximum volume although growth may be delayed 
by the action of the drug (B). The progression of infarction could be reduced by interventions which 
improve collateral blood flow to the penumbra or recanalise the ischaemic territory (C). 
Neuroprotective drugs may be useful in prolonging the time window for thrombolysis. Reproduced 
from Chavez et al (2009). 
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However, the mechanisms involved in the neuroprotective effects of hypothermia and 
magnesium therapy are poorly understood. It has been proposed that the neuroprotective 
action of magnesium is „unmasked‟ at low temperatures. Campbell and colleagues 
demonstrated that mild hypothermia and magnesium treatment had no significant effect on 
infarct volume following permanent focal cerebral ischaemia in rats but in combination a 
significant reduction in infarct volume of over 50% compared to vehicle treated groups 
(Campbell et al, 2008). This apparent synergistic effect of combination therapy may 
explain, in part, the failure of magnesium therapy to translate to clinical trial since patient 
management in the IMAGES trial did not involve the active induction of hypothermia 
(Meloni et al, 2009). In addition, in the majority of the preclinical studies reporting the 
neuroprotective effect of magnesium therapy, post-ischaemic body temperature was not 
reported. Therefore, it may be possible that spontaneous hypothermia induced the observed 
treatment effects (Meloni et al, 2009). In addition, magnesium and mild hypothermia 
treatment could potentially be administered in combination with thrombolytic therapy to 
extend the therapeutic time window in acute ischaemic stroke as magnesium and 
hypothermia treatment do not alter the enzymatic activity of tPA (Meloni et al, 2009).  
 
An alternative therapy could involve the combination of rtPA with hypothermia and 
apocynin.  The results presented in this thesis demonstrated that apocynin improved stroke 
outcome in normotensive rats in combination with reperfusion. Hypothermia may further 
improve stroke outcome. However, it would first have to be determined if apocynin has 
any detrimental effect on the enzymatic activity of rtPA before combining these 
treatments. Apocynin treatment could be administered simultaneously with rtPA and 
hypothermia could be induced concurrently by surface cooling.  
To conclude, perfusion-diffusion weighted MRI is an important imaging biomarker for 
identifying potentially salvageable penumbra in clinical and preclinical stroke research and 
in assessing the effect of potential neuroprotective strategies. However, the findings 
reported in this thesis demonstrate that care should be taken when applying thresholds to 
define hypoperfused and injured tissue, as the present study has shown variability between 
rat strains with and without stroke-comorbidities. The method used to determine penumbra 
should also be taken into consideration and on the basis of the results presented within this 
thesis, spatial co-registration of perfusion and diffusion lesions appears to be the most 
informative and precise method to define perfusion-diffusion mismatch. In addition, the 
work contained within this thesis has also reported that neuroprotective therapies may 
demonstrate efficacy in young, healthy rodent models of stroke but fail to confer 
neuroprotection in models with genetic stroke risk factors, like hypertension. These 
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findings highlight the need to evaluate potential therapeutic strategies in a range of animal 
models with stroke risk factors to improve the chance of successful translation to human 
stroke patients. 
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